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Abstract
Previous studies have shown that increased bone growth over massive prosthesis, promoted 
by hydroxyapatite (HA)-coated collars, can reduce aseptic loosening. Bone tissue engineering 
techniques using bone marrow stromal cells (BMSCs) may be able to further enhance bone 
growth and fixation o f implants to host bone. The hypothesis of this study was that BMSCs 
could enhance bone growth and bone-implant contact around bone tumour 
replacements.
Two sources o f bone marrow stem cells were firstly investigated, including those isolated 
directly from ovine bone marrow (BMSCs), and those isolated from ovine peripheral blood 
(peripheral blood-derived bone marrow stromal-like cells, or PBSCs). PBSCs were isolated 
after mobilisation via induced blood loss, or treatment with granulocyte-colony stimulating 
factor (G-CSF). BMSCs and PBSCs were characterised in v itro . A significant increase o f 
fibroblastic colony-forming units (CFU-F) post-G-CSF treatment was observed only after 
white blood cell counts returned to normal levels, suggesting a possible steady-state balance 
between haematopoietic stem cells and BMSCs.
Ovine BMSCs (oBMSCs), were found to survive and proliferate in fibrin glue or pressurised 
spray application.
An in vivo mid-shaft tibial replacement model was then used to test the effect o f autologous 
oBMSCs in fibrin  glue on bone growth and bone-implant contact, when sprayed onto the 
HA-coated collars, compared to non-treated implants. Radiography showed that the oBMSCs 
more than doubled the amount o f bone growth around the collars o f the implants after six 
months (p=0.017 in the M L view, and p=0.05 in the AP view). Using histological techniques
it was shown that bone area was significantly increased (p=0.02). Application o f oBMSCs 
also reduced the radiolucent lines present between the new bone and implants, and improved 
bone-implant contact. This study demonstrated the potential o f BMSCs to augment bone 
growth and bone-implant contact in conjunction with massive implants.
The second in vivo study investigated the effect o f BMSC cell dosage and use o f allogeneic 
cells on new bone formation and bone-implant contact in a tibial transcortical pin model in 
sheep. Partially-HA-coated screws were sprayed with varying concentrations o f autologous 
and allogeneic oBMSCs suspended in fibrin  glue, and implanted. After six weeks, no 
significant difference in bone formation around the pins was found between groups (p>0.05), 
although the untreated group with HA coating-only had a significant increase in bone 
formation (p=0.03) compared to the other groups.
In conclusion, this project has shown that ovine multipotent BMSCs and PBSCs can be 
isolated and expanded. When sprayed onto the HA-coated collars o f massive implants, 
BMSCs can augment bone formation and bone-implant contact. However, another model 
spraying oBMSCs onto trans-cortical pins did not produce a significant increase in bone 
growth or bone-implant contact. The findings presented may have important clinical 
applications in the use o f BMSCs to reduce aseptic loosening, which may improve the 
surv ival o f massive implants.
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CHAPTER ONE 
INTRODUCTION
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1.1 Aims o f Project
This main goal o f my thesis is to enhance the fixation of massive implants, using bone 
marrow stromal cells (BMSCs) in fibrin glue sprayed onto the surface of orthopaedic 
implants. In order to realise this goal, my work involved firstly the isolation, expansion, and 
characterisation o f ovine BMSCs, as well as an investigation into stromal-like cells obtained 
from ovine peripheral blood, w ith or without blood loss or administration o f a cytokine, 
granulocyte-colony stimulating factor (G-CSF). The viability and proliferation o f ovine 
BMSCs in fib rin  (sprayed and un-sprayed) was tested, as well as the ability o f this system to 
enhance bone growth in conjunction w ith orthopaedic implants to prevent aseptic loosening. 
The main hypothesis of this thesis is that viable BMSCs can be applied to orthopaedic 
implants using a fibrin glue-spray system, and increase bone formation adjacent to the 
implants and improve bone-implant contact.
This introduction w ill first discuss bone tumour replacements and their failure due to aseptic 
loosening. Secondly an introduction to stem cells w ill be presented and the advantages o f 
using bone marrow stromal cells (BMSCs), as well as the use o f alternative sources to 
BMSCs, w ill be discussed. Thirdly, tissue engineering w ill be reviewed, specifically with 
regard to bone regeneration.
1.2 Massive Endoprosthetic Replacements
The majority o f bone tumours are malignant, including osteosarcoma, Ewing’s sarcoma or 
chondrosarcoma (Grimer et al. 1999; Morris et al. 1995). The main sites o f bone tumour 
development include the humerus, scapula, radius, femur and tibia, w ith the majority o f cases
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occurring in the lower extremities (Cannon 1997). Giant cell tumours are often regarded as 
being benign, but can also potentially become malignant (Jewell and Bush 1964; Lewis et al. 
1985). In the past, recurrence was a major issue. However, since the 1970’s the survival rate 
o f patients has improved significantly, as a result o f early detection o f tumours, as well as the 
increased use o f chemotherapy, radiotherapy, and improved techniques o f resection o f the 
tumour surgically. (Capanna et al. 1994; Cannon 1997; Grimer et al. 1999; Horowitz et al. 
1993). Adjuvant chemotherapy (given post-operatively) has reduced the probability o f 
recurrence and/or metastases (Eckardt et al. 1991; Uchida et al. 1997).
Reconstruction o f the segmental defect created during tumour excision, in order to preserve 
the limb, can use a variety o f techniques; arthrodesis w ith auto/allograft; vascularized fibular 
graft, resection and reinsertion o f bone after sterilization; and arthroplasty using either 
auto allograft, synthetic graft or massive endoprostheses, including extendible prostheses for 
growing patients (Schindler et al. 1997; Unwin et al. 1996). Although reconstructions using 
autograft are preferable, it is frequently d ifficu lt to obtain sufficient amounts for bone tumour 
resection sites. Donor site morbidity can be an issue (Abudu, Carter and Grimer 1996a). 
Allografts suffer sim ilar problems in terms o f supply, disease transfer from donor to patient, 
graft failure and fracture, as well as issues with non-union o f the graft to the host bone 
(Gebhardt et al. 1991).
At present, the use o f endoprosthetic replacements in limb-salvage is the principal alternative 
to amputation (Cannon 1997). This technique attempts to preserve both the function and 
aesthetics o f the original limb, while allowing immediate post-operative weight bearing 
(Grimer et al. 1999). Studies have attempted to determine the long-term effects o f amputation 
and endoprosthetic replacement on tumour recurrence, functionality o f the limb post­
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treatment, and patient satisfaction. Results showed that limb-salvage procedures result in the 
same rate o f disease-free survival as amputations after 10 years, with no significant 
difference in patient satisfaction in most cases (Rougraff et al. 1994; Sugarbaker et al. 1982; 
Weddington et al. 1985). Some studies state a patient preference for limb salvage over 
amputation (Harris et al. 1990), and a study by Grimer et al. (1999) indicated that 
endoprosthetic reconstructions are more cost effective than amputation.
Massive implants for limb-salvage surgery are either custom-made or modular (Cannon 
1997) and generally use stems that are cemented into the intramedullary canals with 
polymethylmethacrylate (PMMA; see Figure 1.1).
Proximal
Stem
Knee
Joint
HA-coated
collar
Distal
Stem
Figure 1.1. Example o f a proximal tib ia l bone tumour replacement. The implant has 
proximal (top) and distal (bottom) cemented intramedullary stems (Cannon 1997).
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Uncemented stems are also used (Blunn et al. 2000; Capanna et al. 1994). An alternative to 
the use o f intramedullary stems is triplate fixation, where extracortical fixation can be used i f  
there has been a large resection, and an insufficient amount o f bone remains in which to 
cement an implant (Coathup et al. 2000; Cobb et al. 2005). Femoral or tibial endoprostheses 
can also include a knee jo in t replacement when the bone tumour has spread to the knee or 
there is possible contamination o f the jo in t or synovium, and en b loc  resection o f the jo in t is 
required (Sim 1979a; Walker et al. 1981). However, when compared with the success o f jo in t 
replacements, massive implants are not as successful (Blunn et al. 2000). The Swedish Hip 
Registry found that the survival rate o f total hip arthroplasties (THAs) over a ten-year period 
was 92.5°o (Malchau et al. 2005). By comparison, a ten-year follow up study o f massive 
implants w ith cemented intramedullary stems found that 93.8% o f proximal femoral, 67.4% 
o f distal femoral and 58°o o f proximal tib ial prostheses survived ten years (Unwin et al. 
1996). Scales et al. (1984) investigated the causes o f failure for Stanmore cemented massive 
implants in the 1980's and found that 5.4% o f all endoprosthetic reconstructions resulted in 
infection, 2.7% resulted in implant fracture, and 1.9% failed due to aseptic loosening. 
Infection was reported to be more common in primary massive endoprosthetic replacements 
than with conventional jo in t replacements (Malawer and Chou 1995). Capanna et al. (1994) 
found that the infection rate o f distal femoral replacements, using the Kotz modular femoral 
and tibial resection system (KMFTR) was highest when most or all o f the rectus and vasti 
muscles had been excised (Capanna et al. 1994). Infection has been a major concern for 
proximal tibial replacements. Bradish et al. (1987) reported a 7.5% infection rate in distal 
femoral replacements; whereas Roberts et al. (1991) found that, in 135 distal femoral 
replacements, 6.8% o f all implants suffered from infection, whereas 6% failed due to aseptic 
loosening. A study from the Royal Orthopaedic Hospital in Birmingham found that up to 
33.8% o f proximal tib ial reconstructions performed between 1977 and 1988 became infected
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within the first five years (Grimer et al. 1991). In 1995, Malawer and Chou (1995) reported a 
31% rate o f infection with proximal tibial replacements. Modem surgical techniques have 
reduced the overall infection rate suffered previously w ith this type o f procedure. For 
example, in proximal tibial replacements, retention or replacement o f lost musculature around 
the implant by use o f a medial gastrocnemius flap has reduced the above-mentioned infection 
rate from 33% to 12% (Grimer et al. 1999). Improved surgical techniques that reduce 
incidences o f infection and improved implant design have reduced the rate o f implant 
fracture, so that aseptic loosening is now considered to be the major cause o f failure o f 
cemented massive implants (Ward et al. 1991).
As a result o f  adjuvant chemotherapy, there has been an increase in the number o f young 
limb-salvage patients. This has affected the results o f more recent studies, as the methods that 
were developed for salvaging low-grade lesions in older patients are now routinely used in 
younger, more active patients with wider resections for larger, more aggressive tumours. A 
study looking at distal femoral replacements, found that between 1959-1980, the survival o f 
distal femoral replacements was 83 ± 8%, whereas from 1980-1991, the survival was reduced 
to 64 ±27%  (Cobb 2002).
A study by Unwin et al. (1996) studied the outcome o f 1001 patients with endoprosthetic 
replacement, mostly as a result o f osteosarcoma, osteoclastoma, and chondrosarcoma. This 
report showed that, over a ten-year period, although 93.8% o f proximal femoral replacements 
survived a ten-year period, only 67.4% o f distal femoral replacements and 54.8% o f proximal 
tibial implants survived. Seventy-one o f the 1001 patients (7%) required implant revisions for 
aseptic loosening. The study also found that patients under 20 years o f age with more than 
60% o f bone resected from the distal femur or proximal tibia had the worst prognosis for
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implant survival. The amount o f bone resected is also associated with failure in proximal 
tibial replacements (Unwin et al. 1996). The long-term study o f implant loosening by Unwin 
et al. (1996) looking at 493 distal femoral, 263 proximal femoral and 245 proximal tibial 
replacements, found a high incidence o f aseptic loosening.
Failure in the upper humeral prosthesis due to aseptic loosening is rare and is probably due to 
the lack o f heavy weight bearing in that limb (Cannon 1997). Uncemented implants, using 
the Kotz system, did not appear to show sim ilar levels o f aseptic loosening, although there 
were some cases o f implant fracture and infection (Capanna et al. 1994). Horowitz et al. 
(1993) reported a 25% failure o f distal femoral and proximal tib ial implants w ithin the first 
five-years post-operatively in sarcoma patients. Unwin et al. (1991) comparing survival data 
on 668 Stanmore femoral replacements (221 proximal and 447 distal femoral implants), 
found that the failure o f proximal femoral replacements over ten years was 92%, whereas 
surv ival o f distal femoral replacements was 72%. When loosening as the only mode o f failure 
was considered. Loosening in this study was defined as when an implant became unstable in 
the femur, whether it was due to infection, mechanical forces, or bone remodelling, in any 
replacement that required revision or resulted in amputation o f the limb (Unwin et al. 1991).
Diaphyseal femoral and tibial implants also have similar loosening rates. Abudu et al. 
(1996a) reported approximately one-third o f their diaphyseal implants failing due to 
“ symptomatic mechanical loosening” . One mode o f failure is thought to result from torsional 
forces caused by the use o f a fixed hinge knee component in certain massive implants 
(Roberts et al. 1991, Unwin et al. 1996). The use o f a rotating hinge has reduced the rate o f 
aseptic loosening (Unwin et al. 1996). However, this is not the only cause o f aseptic 
loosening responsible for implant failure.
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Studies by Blunn et al. (2000) and Unwin et al. (1996) have detailed a possible mechanism 
for aseptic loosening described. In the case o f massive implants, an offset exists between the 
tip o f the implant stem and the axis o f the femur from the femoral head to the centre o f the 
knee. This offset is thought to cause a bending moment w ithin the cemented fixation. Due to 
the line o f load, this offset is more pronounced proximally on the femur than distally and 
thus, stems that are cemented more proximally in the bone suffer from greater bending forces 
w ithin the cement mantle (Figure 1.2).
a b e
Axis of the
femur
Line of 
force
Decreasing
offset
Line of 
force
Line of 
force
Figure 1.2 a) Diagram demonstrating the line of force through the femur, which has a 
decreasing offset with the axis o f the femur as it moves distally; b) illustration of how 
this offset affects a proximal femoral replacement and c) a distal femoral replacement 
(adapted from Unwin et al. 1996, p 11).
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As distal femoral replacements have more proximal transection sites and subsequent 
cemented fixation than proximal femoral implants, they have a greater offset to the axis of 
the long bone. This is also the case with lengthier tumour resection, where the upper stem 
may be placed more proximally in the bone. The increased force from the bending caused by 
this offset eventually causes a deterioration o f the bone-cement interface, which slowly 
progresses from the transection site to the stem tip o f the implant (Unwin et al. 1996).
Loosening begins with osteolysis adjacent to the implant shoulder (Blunn and Wait 1991, 
Ward et al. 1997), which can occur within six months post-operatively. Over time, osteolysis 
is seen to progress along the bone-cement interface, and radiographically can be viewed as 
radiolucent lines (seen in Figure 1.3).
Radiolucent
lines
Proximal
stem
Collar
Figure 1.3 Radiograph of the proximal end of a massive implant, illustrating 
radiolucent lines that indicate aseptic loosening.
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Cobb (2002) reported a deterioration o f the interface between bone and cement, that was 
correlated with decreased function o f the implant. There was a steady deterioration o f the 
interface, and there was only a 56% probability o f a good interface eight years post- 
operatively. A study investigating telemetric data from a 42-year old patient with a distal 
femoral replacement compared the forces applied to the stem tip to those on the implant 
shaft. The data showed an increasing force at the stem tip over time, with an increase in the 
stem tip-to-shaft force ratio o f 25% to 63% over 23 months (Taylor et al. 1997). Supporting 
histological analysis o f growing patients w ith extendible prostheses shows bone remodelling 
adjacent to prostheses to porotic bone, and the growth o f fibrous tissue under the implant 
shoulder. However, it must also be noted that the authors mentioned a possible effect on 
remodelling by the blood supply, which is interrupted during surgery and implantation o f a 
cemented prosthesis. A subsequent ingrowth o f blood vessels into necrotic bone from the 
invading fibrous tissue at the transection site occurs (Blunn and Wait 1991). In addition, poor 
cement interdigitation, w hich is affected by the amount o f cancellous bone and shape o f the 
intramedullary canal into which the implant stem in inserted, could possibly affect the 
outcome o f these prostheses (Unwin et al. 1996). Nevertheless, various methods have been 
employed to promote load transfer to the shaft o f the prosthesis from the bone at the 
transection site in an attempt to prevent aseptic loosening. Especially at a time when the 
survival rate o f patients is increasing, the long-term fixation o f massive endoprostheses is o f 
even greater importance, and it is possible that bone marrow stromal cells (BMSCs) could 
play a role in biologically improving the fixation o f these implants.
Bone is dynamic, and responds to compressive and tensile forces by bone formation and 
resorption, respectively. W o lf f  s law, as first described by Julius W o lff in 1892, is the theory 
that mechanical stress determines bone structure, and that a change in stress can consequently
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result in changes in bone composition (W o lff 1892). Applying this theory to remodelling, in 
cases o f massive implants, means that bone adjacent to massive implants changes as a result 
o f the new compressive and tensile forces being applied. Thus certain trends in bone growth 
around these implants can be seen.
A common radiographic observation around massive implants, which may reflect the bending 
effect, is bone growth posteriorly and medially, whereas bone resorption is often seen 
anteriorly and laterally (Inglis et al. 1991; Unwin et al. 1996). Inglis et al. (1991) reported 
such a pattern o f bone growth around massive proximal femoral replacements. In this survey, 
which analyzed both lateral and anteroposterior radiographs, it was postulated that cortical 
thickening in the areas experiencing compressive forces would form a “ column”  o f bone, 
which would move down the implant with the pressure applied by adjacent muscles.
The metal from which massive implants are manufactured is significantly stiffer than bone. 
Titanium alloy, such as T i3 18, which is T i-6Al-4Va (also called T i), is a common alloy used 
which, in addition to being both strong and biocompatible, has a higher Young’s modulus 
than natural cortical bone (Table 1.1) (Dobbs and Scales 1983; Park 1995). Young’s modulus 
is a measure o f material stiffness, which is the ratio o f the rate o f change o f stress with strain, 
or the slope o f the curv e plotting stress versus strain.
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M ate ria l Young's M odulus (<■ l*a)
Stainless Steel (316L) 200
Tianium A lloy (Ti6A14V) 110
Hydroxyapatite 120
Cortical Bone (Long Axis) 17
Cortical Bone (Tangential) 12
Femoral Trabecular Bone 0.1
Table 1.1 Table outlining the Young’s Modulus (measure of material stiffness) of 
biocompatible metals used for massive implants, and cortical and trabecular bone 
(adapted from “Orthpaedic Prosthesis Fixation,” Park 1995, p 542). Note that titanium  
alloy has approximately 9 times the stiffness of cortical bone in the tangential aspect.
When prostheses are cemented, the consequence is that the host bone is under a decreased 
load and the strain is reduced, causing resorption. This phenomenon is known as “ stress 
shielding”  (Huiskes 1990). This change in load distribution to the metal implant and 
reduction o f load experienced by surrounding bone, causes strain adaptive remodelling to 
take place, according to W o lf f  s law (W o lff 1892).
In some patients, a pedicle o f bone grows from the transection site around massive metal 
implants, often with an intervening fibrous tissue layer between the implant and new' bone 
(Blunn and Wait 1991). Integration o f the implant into the host bone by ingrowth and 
attachment o f this new bone is thought to promote better load transfer to the shaft rather than 
the stem tip, preventing “ underloading”  (Inglis et al. 1991) o f the collar and overloading o f 
the cement mantle (Okada et al. 1988; Sim and Chao 1979). One method that promotes this is 
the use o f a collar on the implant shaft, at the transection site. These collars encourage bone 
to grow over and attach to the shaft o f the prosthesis. Modem implant coatings try to augment 
this “ bony bridge”  by using porous titanium beads, bone graft, grooves and/or a
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hydroxyapatite coating (Blunn et al. 2000; Chao and Sim 1985; Okada et al. 1988; Ward et 
al. 1993).
Hydroxyapatite (H A) is a biocompatible, resorbable, osteoconductive material that has been 
found to greatly enhance bone growth in both patients and animal models (Blunn et al. 2000; 
Coathup et al. 2000; D ’ Antonio et al. 1992; Geesink 1993). Osteoconductivity is the ability 
o f a scaffold to promote osteoblast attachment and bone formation. In comparison, an 
osteoinductive scaffold encourages osteoblast precursor cells, such as BMSCs, to attach and 
differentiate into active osteoblasts. Natural bone is an example o f an osteoinductive material 
(Datta et al. 2006). Another property o f  scaffolds, osteogenicity, refers to the presence o f 
osteoblasts or osteoblast precursor cells that deposit bone directly on the scaffold surface 
(Mizutani et al. 1990).
Synthetic hydroxyapatite is a calcium phosphate ceramic that shares a similar chemical and 
crystallographic structure to natural hydroxyapatite, which is the main mineral component o f 
bone (Engstrom and Zetterstrom 1951; Jarcho 1981). Although it has poor fatigue properties, 
which prevents it from being a useful structural implant material, HA can be applied to metal 
surfaces using a plasma-spray technique. This provides an implant with osteoconductive 
properties while maintaining the mechanical properties o f a metal implant (Geesink et al. 
1988). The bonding o f bone to HA-coated implants has been investigated previously in 
canines, and was found to be very strong, which was a result o f direct bonding o f the material 
to bone (Geesink et al. 1988). As the HA is resorbed, released calcium and phosphate ions 
may also promote the formation o f a biological apatite layer, and thus promote 
osteoinduction (Kurioka et al. 1999; Ozawa and Kasugai 1996). However, concerns do exist
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about the stability o f the metal implant-HA bond, in that it is non-permanent and may lead to 
wear particle production (Bloebaum et al. 1994).
The use o f grooved, porous, hydroxyapatite-coated collars has shown effective results in 
terms o f bone ingrowth to the implant collars (Blunn et al. 2000;
Figure 1.4). In the short-term follow-up reported by the authors (after more than 12 months), 
only one patient out o f forty-four showed any signs o f loosening, and a radiographic study 
showed no signs o f radiolucency around the implant. Chao et al. (2004) significantly 
improved extracortical bone growlh around massive implants in patients by using a porous- 
coated collar augmented with autologous bone graft. Only one out o f forty-three patients 
showed aseptic loosening after a mean o f 9.7 years follow-up. The use o f cementless fixation 
with proximal femoral components showed that the use o f HA coincided with a more even 
distribution o f bone growth around the implant when compared with control implants (Blunn 
et al. 2000).
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Figure 1.4 Photographs of hydroxyapatite (HA)-coated collars from a) a proximal tibial 
replacement and b) a massive implant with an HA-coated collar being implanted.
Compared to uncoated porous collars, hydroxyapatite-coated collars on distal femoral 
replacements appear to promote bone ingrowth in over 70% o f cases. This ingrowth is 
negatively correlated to the extent o f radiolucent lines on radiographs. Good bone formation 
into the HA-coated collars resulted in a decrease in the size and number o f radiolucent lines 
around the intramedullary stem (Cobb 2002; Unwin et al. 2005).
As this uncoupling o f load at the implant shoulder to the stem tip ultimately results in 
debonding and loosening o f the implant (Unwin et al. 1996), strategies to prevent this initial 
uncoupling have been considered. Ideally, the use o f a biocompatible material with an elastic
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modulus closer to that o f cortical bone would prevent overloading o f the stem tip. 
Unfortunately, studies that have investigated more flexible materials have shown them to 
promote higher proximal shear stresses between the stem/cement and bone interface. This 
could result in debonding, micro-motion, and eventual loosening o f the implant (Huiskes 
1990).
One strategy to reduce aseptic loosening has been to improve the fixation o f the implant to 
the bone by improving the osseous integration o f the implant. This is thought to prevent the 
uncoupling o f load from the implant shoulder through load transfer. This strategy has focused 
on promoting bone growth over the implant by developing implant collars at the transection 
site o f the implant. The resultant “ bony bridging”  is also thought to act as a “ purse string,”  
sealing the bone-implant interface, possibly preventing the migration o f wear particles to the 
site causing osteolysis. However, it should be noted that the existence o f these wear particles 
has not been proved empirically, unlike the polyethylene wear particles generated with 
traditional arthroplasty.
Another method by w hich fixation o f the implant could be improved is by using osteoblastic 
precursor cells such as bone marrow stromal cells (BMSCs) in combination with HA-coated 
collars, to further encourage greater bone growth and attachment into the implant collar. To 
augment this beneficial load transfer and reduce the aseptic loosening of massive 
implants using BMSCs is the goal of my thesis.
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1.3 Stem Cells
1.3.1 Definition
The term “ stem cell”  refers to an undifferentiated precursor cell that has “ the capacity for 
unlimited or prolonged self-renewal, that can produce at least one type o f highly 
differentiated descendant”  (Watt and Hogan 2000). These precursor cells can be induced to 
differentiate into another cell type, depending on the type o f stem cell and the cues given 
(Jaiswal et al. 1997). Between a fu lly  multipotent stem cell and a terminally differentiated 
cell type, there are thought to exist a series o f “ committed progenitors”  w ith a lower 
proliferative and differentiation potential. These can be referred to as “ transit amplifying 
cells”  (Watts and Hogan 2000).
There are many sources o f stem cells cited in the literature: the embryo, the adult bone 
marrow, umbilical cord blood, adipose tissue, as well as neuronal-derived cells (Bacou et al. 
2004; Lam et al. 2001; Zvaifler et al. 2000; Zandstra and Nagy 2001), all o f which have 
varying abilities to differentiate down numerous cell lineages. As promising as these cell 
sources may be, most past and current research concerns the first three types o f stem cell. It is 
becoming increasingly apparent, however, that adult stem cells isolated from the bone 
marrow have potential regenerative applications (Le Blanc and Pittenger 2005), such as the 
tissue engineering o f bone (Arinzeh et al. 2003; Lee et al. 2005).
1.3.2 Autologous, Allogeneic and Xenogenic Cells, and the Multipotency 
of Stem Cells: Definitions
In cases where the stem cells from a patient are re-implanted into the same individual, the
donor cells are referred to as being autologous. I f  donor cells are implanted into another 
individual o f the same species, the cells are termed allogeneic, and o f another species, 
xenogenic.
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A totipotent cell has the ability to differentiate into any type o f cell. Pluripotent cells can 
differentiate into almost all cell types, but not all. A cell that can only differentiate into a 
limited number o f cell types is termed multipotent (Zandstra and Nagy 2001).
1.3.3 Bone Marrow Stromal Cells (BMSCs)
Bone marrow stromal cells (BMSCs), are a population o f plastic-adherent cells derived from 
the bone marrow, that most often possess a fibroblastic morphology (Figure l .5). BMSCs, 
described as “ fibroblastic precursor cells,”  were first described by Friedenstein, Chailakhjan 
and Lalykina in 1970. A population o f  cells w ithin this heterogeneous population (Aubin 
1998) are commonly referred to as “ mesenchymal”  stem cells, referring to their multi- 
potentcy and/or ability to form mesodermal tissues such as bone (Haynesworth et al. 1992; 
Jaiswal et al. 1997), cartilage (Johnstone et al. 1998), adipose tissue (Ryden et al. 2003), and 
stroma (Majumdar et al. 2000). Friendenstein’s seminal works investigated the properties o f 
bone marrow stromal cells, in vitro, by observing their ability to mineralise after treatment 
with osteogenic supplements, and by their ability to form bony tissue in diffusion chambers 
in vivo (Friedenstein, Chailakhjan and Lalykina 1970; Friedenstein 1973; Friedenstein 1976). 
Bab et al., in 1986, also investigated BMSCs in diffusion chambers, and found that the tissues 
produced in these chambers originated from a small number o f originally implanted cells, 
with “ stem cell-like”  characteristics.
Friedenstein proposed a hypotheses leading from his work, that suggested that a single 
stromal cell could give rise to multiple lines o f cells (Friedenstein 1980). From their 
experimental data o f CFU-F derived from the bone marrow, Owen, Cave and Joyner (1987) 
produced a summarising flowr chart which indicated that stromal “ stem cells”  could
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differentiate into committed progenitors, which could then further differentiate into specific 
cell types such as fibroblasts, reticular cells, adipocytes, and osteoblasts.
Dahir et al., in 2000, isolated a “ precursor”  cell lines from mouse bone marrow, and was able 
to show, by labelling cells with the enzyme p-galactosidase (using a non-infections retrovirus 
containing the lacZ gene), that these cells not only had osteogenic characteristics in v itro , and 
were able to repopulate the bone marrow o f host mice, while maintaining their osteogenic 
capability.
Figure 1.5 Photo of human bone marrow stromal cells (BMSCs; from P. Kalia).
However, there is some controversy as to whether or not BMSCs are actually ‘stem cells,’ as 
they are only multi-potent or have restricted differentiation potential, as opposed to 
embryonic stem cells (ESCs) which have the capacity to differentiate into almost any cell 
type (Heins et al. 2004; Thomson et al. 1998). For this reason, the population of 
mononuclear, plastic-adherent, fibroblastic cells isolated from the bone marrow w ill be
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identified in this thesis as bone marrow stromal cells (BMSCs), a term that refers to the 
cells' origin and morphology.
In culture, these cells are selected from the marrow based on the following characteristics: 
their mononuclear phenotype, their capacity for adherence and growth on tissue-culture 
plastic and their ability to form fibroblastic colony units (colony-forming units-fibroblastic 
(CFU-F)). BMSCs populations can also be enriched for “ multipotent”  cells or “ stem cells,”  
by selecting cells based on their surface marker expression pattern using fluorescence- 
activated cell sorter (FACS) or magnetic-activated cell sorter (MACS) machines. Table 1.2 
lists a panel o f cell surface markers used in BMSC identification, some o f which are expected 
to be present and others absent.
BMSCs have great promise for tissue repair and regeneration, due to their ease o f isolation, 
high proliferative capacity and ability to retain their multi-potent capacity, as well as their 
ability to differentiate into various mesenchymal tissues. In addition, the immuno-modulatory 
effects o f BMSCs should also be considered as this may permit the use o f allogenic 
(unrelated cells o f the same species) cells in patients (see 1.3.3.3).
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Present Absent
CD29 CD14
CD44 34
CD54 45
CD71 68
CD90 HLA-DR
CD 120a
CD124
CD105 (Endoglin)
CD106 (V C A M -1)
CD 164 (Endolyn)
SH2
SH3
SH4
Stro-1
P-Zero Protein (PZR)
Table 1.2 Chart illustrating cells surface markers present and absent on human BMSCs 
(Baksh et al. 2003; Campagnoli et al. 2001; Pittenger et al. 1999; Watt 2006).
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1.3.3.1 Previous characterisation of BMSCs
In current practice, the positive identification o f BMSCs as multipotent precursor cells can be 
achieved through two methods: differentiation o f the cells down two or more lineages, and 
cell surface marker identification. Ideally, both methods should be utilised for complete 
characterisation.
Upon stimulation in culture w ith osteogenic reagents, BMSCs change morphology and begin 
to express osteoblastic characteristics temporally in the following order: cbfa-l/runx2 and 
osterix, transcription factors involved in osteoblast differentiation; alkaline phosphatase, 
which is expressed on the cell surface o f osteoblasts; osteonectin, which regulates mineral- 
collagen interactions and calcium binding; osteopontin, involved in calcium deposition; and 
osteocalcin, which regulates the later stages o f mineral deposition (Krishnan et al. 2003; 
Pittenger et al. 1999). When differentiated towards the chondrogenic lineage, BMSCs seem 
to upregulate the expression o f collagen II (basic matrix molecule o f articular cartilage), 
aggrecan, and sox-9, in addition to a chondrocytic phenotype (Lee et al. 2006; Mackay et al. 
1998). A fter treatment with adipogenic reagents, BMSCs appear to accumulate lip id vesicles, 
and are positive for the expression o f genes such as lipoprotein lipase (LPL) and nuclear 
peroxisome proliferators-activated receptor gamma (PPARy2) (Pittenger et al. 1999).
There has also been some evidence o f neural and hepatocytic (Kang et al. 2005; Lee et al.
2004) phenotypes being derived from BMSCs, although this has also been disputed (Bertani 
et al. 2005; Wang et al. 2003). Other groups have documented the differentiation o f BMSCs 
into cardiomyocytes and vascular cells (Nagaya et al. 2005). One group tracked cells in vivo 
and found that the implanted BMSCs, in addition to releasing mitogenic, angiogenic, and 
anti-apoptotic factors in v i t ro , were positive for many cardiac markers once implanted into 
myocardia in vivo.
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As mentioned above, human BMSCs (hBMSCs) can also be identified through the presence 
and absence o f a series o f cell surface markers, none o f which are specific to BMSCs (Baksh 
et al. 2003; Campagnoli et al. 2001; Pittenger et al. 1999). Recent research has identified the 
cell surface proteins CD164/endolyn and a specific isoform o f P zero-related (PZR) protein 
as being markers o f hBMSCs (Watt 2006), albeit they are not entirely specific. There has 
been some preliminary work looking at the gene expression o f BMSCs that seems to also 
indicate that the patterns o f gene expression o f BMSCs are unique (Djouad et al. 2005); 
however, this is not yet a commonly available tool for most laboratories. Whether or not all 
o f these markers are present or absent from the BMSCs derived from other species is 
unknown.
BMSCs from other species have been isolated and either partially or fu lly  characterised, such 
as from mice (Dennis and Charbord 2002; Phinney et al. 1999); rats (Lee et al. 2005); 
Okamoto et al. 2006), pigs (Bosch et al. 2006; Vacanti et al. 2005), cats (Martin et al. 2002), 
dogs (Kadiyala et al. 1997; Volk et al. 2005), goats (Kruyt et al. 2003), sheep (Kon et al. 
2000; Shang et al. 2001), cows (Troyer et al. 2003) and baboons (Bartholomew 2001).
Although Jiang et al. (2002a; 2002b) were able to isolate a special population o f cells from 
human, mouse and rat BMSCs, called multipotent adult progenitor cells (MAPCs) that 
appeared to have pluripotency similar to ESCs, some o f the FACS analysis for cells surface 
markers has been called into question (Verfaille and Jiang 2006; Jiang et al. 2007), 
challenging the valid ity o f group’s results (see general discussion).
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1.3.3.2 Proliferation rate of BMSCs
Human BMSCs have been documented as having a high proliferation rate and can undergo as 
many as 38 population doublings without loss o f their proliferative or osteogenic capacity 
(Bruder et al. 1997). This is almost twice the doubling capacity o f other human diploid cell 
types, such as adult lung fibroblasts, which have a doubling capacity o f 20 times (Hayflick 
1965). With such prolonged expansion o f BMSCs in culture, there are accompanying 
concerns regarding cell ageing and mutation. Unlike undifferentiated embryonic stem cells 
(ESCs; Heins et al. 2004), BMSCs do not express high levels o f telomerase, the enzyme that 
lengthens telomeres to prevent their shortening during cell division. As telomere shortening is 
directly related to cell ageing and senescence, there is a possibility that BMSCs expanded in 
culture could lose their characteristics and ability to proliferate and differentiate once re­
implanted in vivo (Baxter et al. 2004). Another factor is an accumulation o f mutations by the 
cells while in culture. It is well documented that not only immortalised tumour cell lines, but 
also BMSC cell lines could potentially mutate in artificial culture conditions (Devine et al. 
200lb). This may result in errors in cell division or DNA repair, which lead to translocations 
(movement o f one segment o f a chromosome to another) as well as aneuploidy (Wang et al. 
2005), which can be defined as having an abnormal number o f chromosomes. In addition, 
BMSC-like cells have been isolated from giant cell bone tumours (W ulling et al. 2003). The 
possibility o f accumulated cell damage and ageing should therefore be seriously considered 
when investigating BMSCs and thorough testing should be in place to ensure that such 
potentially tumourogenic mutations have not occurred before re-implantation or infusion o f 
cells.
1.3.3.3 Immunogenetic properties of BMSCs
Current research suggests that BMSCs have suppressive immunogenetic properties. The first 
evidence o f an immunosuppressive effect o f BMSCs was their ability to promote recovery
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and engraftment o f HSCs in high-dose chemotherapy patients receiving HSC infusions (Koc 
et al. 2000). A number o f in v itro  experiments have assayed the effects o f BMSCs on mixed 
lymphocyte cultures (Le Blanc et al. 2003; Tse et al. 2003). Le Blanc et al. (2003) added 
different concentrations o f both autologous and allogenic human BMSCs to mixed 
lymphocyte cultures in an attempt to measure immunoreactivity o f the BMSCs. Not only did 
the group observe a cell-dosage effect o f BMSCs on the proliferation o f lymphocytes and that 
BMSCs were able to prevent the formation o f activated T-lymphocytes, they also found that 
this effect was wholly independent o f the major histocompatibility complex (MHC). 
Rasmusson et al. (2003) obtained supporting results in a similar study.
Further work demonstrated that BMSCs retained their immuno-suppressive properties after in 
v itro  differentiation into osteogenic, chondrogenic, and adipogenic cells (Le Blanc et al. 
2003). What is the mechanism o f this immunomodulatory effect? BMSCs express MHC I 
and lymphocyte function-associated antigen (LFA)-3 antigens as well as MHC II and ICAM - 
1 antigens after stimulation with y-interferon treatment (Tse et al. 2003), but the observed 
effects are independent o f the MHC. Evidence by Aggarwal and Pittenger (2005) showed that 
prostaglandin E: (PGE:) plays a substantial role in mediating anti-inflammatory and 
immunomodulatory responses by showing a reversal o f the immunosuppression after 
treatment w ith a known PGE: inhibitor. It must be noted, however, that an earlier experiment 
by Tse et al. (2003) found that inhibiting PGE: had no such effect. The mechanism o f 
BMSC-modulated immunosuppression has not been conclusively studied as yet, however this 
property may explain the acceptance and effectiveness o f allogeneic cells in a few bone tissue 
engineering models (Arinzeh et al. 2003; De Kok et al. 2003; Tsuchida et al. 2003). In these 
models, allogeneic BMSCs have performed as well as autologous BMSCs in regenerating 
defects with new bone.
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1.3.4 Haematopoietic Stem Cells (HSCs)
HSCs are precursors o f the haematopoietic lineage, which are predominantly localised to the 
bone marrow in their undifferentiated state, and most often derived from this source. In 1980, 
T ill and McCulloch first documented the multipotency o f these bone marrow-derived cells 
after an injection o f HSCs into lethally irradiated mice resulted in the formation o f donor- 
derived haematopoietic colonies o f various lineages (T ill and McCulloch 1980). In 
comparison to BMSCs, HSCs are well documented in terms o f their differentiation pathways 
and mechanisms, localisation and attachment in the marrow, and the clinical results from 
transplanting these cells into human patients. Donor HSC infusions have been proved to be 
clin ically effective in the treatment o f  neutropenia (Reddy 2005). This often involves a 
selection o f cells expressing the cell surface marker CD34 using fluorescence-activated cell 
sorting (FACS) from a plasma-depleted blood donation, followed by infusion o f these cells 
into the patient. C linically, HSCs are often mobilised using granulocyte-colony stimulating 
factor (G-CSF) or granulocyte-macrophage-colony stimulating factor (GM-CSF). The 
mobilisation o f these cells is mediated via the binding o f HSCs to the bone marrow stroma. 
Upon stimulation, the HSC cell surface receptor CXCR4 dissociates from the cytokine 
stromal-cell derived factor-1 (SDF-1), a factor expressed by BMSCs and other cells o f the 
stromal lineage. A second mechanism involves the release o f the HSC adhesion molecule 
VLA-4 from vascular cell adhesion molecule-1 (V C A M -1), which is expressed on the surface 
o f BMSCs. In both cases, there is liberation o f proteases such as elastase, cathepsin G, and 
matrix metalloproteases (MMPs) such as MMP-9, which result in the degradation o f these 
molecules involved in adhesion as well as a subsequent remodelling o f the ECM 
microenvironment to promote release o f cells from the marrow (Lapidot and Petit 2002).
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1.3.5 Em bryonic Stem Cells (ESCs)
Embryonic stem cells (ESCs) are isolated from the inner cell mass o f pre-implantation 
blastocysts. ESCs were first isolated from mice by Martin Evans in 1981 (Evans and 
Kaufman 1981). Human embryonic stem cells were first successfully isolated and cultured 
into cell lines in 1998 (Thomson et al. 1998). A photograph o f a human embryonic stem cell 
colony can be seen in Figure 1.6. ESCs are pluripotent, as they can differentiate into almost 
any cell type, except a few extra-embryonic cell types such as the yolk sac visceral 
endoderm, parietal endoderm, and placental trophoblast (Zandstra and Nagy 2001).
Figure 1.6 Photograph showing a colony of H9 human embryonic stem cells (within 
circle; used w ith permission from Dr. M. Clements, University o f Westminster, 2006).
The advantage o f using ESCs is their ability to differentiate into any tissue derived from the 
three embryonic lineages (ectoderm, mesoderm, and endoderm) in two or three-dimensional 
culture. Also, ESCs may hold great promise in the pharaceutical industry, for drug discovery 
and toxicity testing. At present, there are insufficient sources o f specialised human cell types 
such as those derived from the liver or heart (hepatocytes or cardiomyocytes). By 
differentiating the highly proliferative, pluripotent ESCs into these cell types, a new reserve 
o f cells would be available for in vitro testing. In fact, as discussed by Ameen in 2007, these
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cells could even be used to derived cells that could activate and mobilise endogenous cells to 
organs or tissues in need o f repair or improved function.
The potential disadvantages o f using ESCs are numerous, and include the difficulties and 
expense associated with ESCs (Le Blanc and Pittenger 2005). It is impossible to use 
autologous ESCs, which are derived from embryos, as there are immunoreactivity issues to 
be considered in transplanting human leukocyte antigen (HLA)-mismatched cells into 
patients (Heng et al. 2005). When using BMSCs, it is possible to use autologous cells from 
the patient, expand those cells, and re-implant them without any donor-related risks. Another 
disadvantage is the d ifficu lty  in culturing ESCs. Although ESCs can be grown and expanded 
in v i t ro , i f  not maintained under strict control, the cells spontaneously differentiate into 
different cell types, some o f which may not be the desired type (Heng et al. 2005). For 
example, a study investigating ESCs administered in vivo in immuno-compromised mice 
(Tzukerman et al. 2003) showed that ESCs can give rise to teratomas and are tumourogenic. 
However, i f  ESCs were pre-differentiated into specific cell types before implantation, the 
probability o f tertartomic activity could decrease significantly (Ameen et al. 2007).
These factors have limited the potential o f ESCs for clinical application. The third, and
perhaps most controversial consideration in using ESCs, is the ethical and legal dilemma
posed by their potential use clinically. An important source o f human ESCs are embryos 
created through in v itro  fertilisation procedures. The moral idea that embryos have the
potential to become human beings and therefore should not be dissected for use in research,
and/or clinical practice, has made the use o f using human embryos both d ifficu lt practically 
and ethically controversial (Shenfield 2005; Young 2000). When mesenchymal tissues are 
regenerated in tissue engineering, adult stem cells such as BMSCs have been preferred as
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they are readily available, can be isolated from the patient who could be receiving therapy (as 
autologous cells), and have the potential to differentiate into the tissue o f interest.
1.3.6 Other sources of stem cells-Peripheral Blood Stromal-like Cells 
(PBSCs)
Until recently, the most common source o f osteoprogenitor cells has been the bone marrow. 
However, BMSCs are thought to comprise only 0.0001%-0.001% o f the bone marrow cell 
population (Pittenger et al. 1999). Therefore, other sources o f multipotent cells in the body 
that may require a less invasive procedure than a bone marrow aspirate in order to harvest 
cells have been considered, such as adipose tissue (Bacou et al. 2004; Rodriguez et al. 2004; 
Zuk et al. 2002), muscle (Asakura 2003; Sinanan et al. 2004), cord blood (Lam et al. 2001; 
Lee et al. 2004), and the peripheral blood (Fernandez et al. 1997; Kassis et al. 2006; Mansilla 
et al. 2006; Wan et al. 2006; Zvaifler et al. 2000). Stimuli that may promote cell mobilisation, 
such as induced blood loss, have also been investigated. Obtaining a greater number o f cells 
at the time o f isolation would expedite the process by which cells are cultured, and 
potentially used clinically.
In mice, CFU-F progenitors naturally circulate in the peripheral blood, and the possibility o f 
BMSC mobilisation in humans has been debated in the literature. The first published work 
indicating this possibility was by Fernandez et al. (1997), who isolated a population o f cells 
from the peripheral blood o f human patients. The resulting aphaeresis products were density 
separated and grown in culture. These cells were found to grow fibroblast-like colonies, 
similar to BMSCs, which were stained positively for the BMSC markers SH2 and SH3, and 
negative for CD 14 and CD34 (monocyte/macrophage and haematopoietic stem cell markers, 
respectively). Further work by Zvaifler et al. (2000) suggested the existence o f a mixed 
population o f cells w ithin the blood, including those with a mesenchymal precursor cell
phenotype, large cells, with adipocytic morphology, as well as those which were m ulti­
nucleated and stained positively for tartrate-resistant acid phosphatase, a characteristic o f 
osteoclasts. Purton et al. (1998) previously described such CD 14' fibroblastic cells as being 
monocytes, which achieve an osteoclastic phenotype follow ing high-density culture 
conditions. A similar fibroblastic, CD14’ population o f cells was termed “ fibrocytes”  by 
Bucala et al. (1994) due to their combined features o f both fibroblasts and leukocytes. More 
recently, other groups have obtained and characterised cells from the peripheral blood as 
having identical surface marker expression and multipotent ability as bone marrow-derived 
stromal cells (Mansilla et al. 2006, Wan et al. 2006). One o f these studies isolated a greater 
number o f PBSCs from patients w ith major bum injuries, suggesting that these cells are 
released from the bone marrow into the bloodstream as a natural response to injury (Mansilla 
et al. 2006). It may be possible to use these cells as an alternative to BMSCs in the tissue 
engineering or regeneration o f bone. A plentiful source o f cells can be obtained by taking a 
blood sample, rather than a painful bone marrow aspiration, which requires anaesthesia, and 
is more limited in volume.
1.4 Tissue Engineering
1.4.1 Introduction
Organ and tissue transplants have been used for some time in clinical practice, in many areas 
o f medicine, with varying levels o f success. Supply and demand, as well as 
immunocompatibility and disease transmission, are big issues in transplantation that often 
render them impossible or risky. Immunosuppressive drugs taken to accept these organ 
transplants can lead to tumour formation (Vacanti and Vacanti 2000). By creating tissues 
using the basic components o f cells, scaffolds, and bioactive factors, tissue engineering 
attempts to replace, re-construct, or repair tissues. There are two main approaches to this
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field, which are in v itro  (or ex vivo) and in vivo tissue engineering. In  v itro  tissue engineering 
strives to create tissue outside the body. This may require the use o f tissue culture techniques, 
in addition to bioreactors, bioactive factors, and specially designed scaffolds and 
biomatenals.
1.4.2 Scaffolds
One o f the important components o f tissues in the body, apart from the cells themselves, is 
the extracellular matrix (ECM) that they lay down. ECM serves a variety o f functions, from 
general structural support o f the tissue, to involvement in cell alignment and communication 
(Martins-Green 2000). This matrix is predominantly collagen-based, although other 
molecules such as hyaluronic acid, glycoproteins, elastins, fibronectin, vitronectin and 
laminin are also important components (Pearson et al. 2002). Embedded within the fibrils o f 
these matrix materials can be found various growth factors, cytokines, water molecules and 
enzymes such as elastases or metalloproteases (Martins-Green 2000). In tissue engineering, 
scaffolds attempt to simulate a native tissue environment with an artificial extracellular 
matrix. Ideally, the material should also be biodegradable (Pachence and Kohn 2000). Thus, 
popular scaffolds used include collagen I, alginate, poly-lactic acid (PLA), poly-glycolic acid 
(PGA), plasma, as well as fibronectin and fibrin (Andree et al. 2001; Gurevich et al. 2002; 
King et al. 2006; Kumar and Albala 2001; Pachence and Kohn 2000; Ting et al. 1998; Ye et 
al. 2000).
In bone tissue engineering, a mechanically supportive, osteoconductive, ceramic scaffold 
such as natural coral exoskeleton, synthetic hydroxyapatite, beta-calcium triphosphate or 
Bioglass * may be used (Chan et al. 2002; Oonishi et al. 1997), often in combination with one 
o f the above mentioned matrix materials. These scaffolds have inherent osteoinductive
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(Ripamonti 1996; Yuan et al. 1998) and/or osteoconductive properties (Geesink and 
Hoefnagels 1995). Newly developed biomaterials include silk-based scaffolds (Meinel et al. 
2005) and chitin-based scaffolds (D i Martino et al. 2005), which appear to be 
osteoconductive in vivo. BMSCs are generally combined with one or a combination o f these 
scaffolds with or without growth factors (see 1.4.5), for bone tissue engineering (Bruder and 
Caplan 2000).
Porosity and pore sizes have been investigated as to their effects on bone regeneration with 
scaffolds, with or without cells being added. Various works report that, overall, the minimum 
pore size o f a structure should be great than 300 pm, to allow for cell migration into the 
pores, nutrient migration, as well as to allow the invasion o f capillaries into the site, 
vasculogenesis being an important first step towards osteogenesis (Kuboki, Jin and Takita 
2001; Tsuruga et al. 1997; Gotz et al. 2004). While smaller pores can contribute to hypoxic 
conditions and the aggregation o f cells, resulting in osteochondral ossification, larger pores 
allow for direct osteogenesis. Although higher scaffold porosity encourages better bone 
ingrowth, increasing porosity often decreases the mechanical strength o f a scaffold, to the 
point where it is no longer o f withstanding the loads seen in orthopaedic applications 
(Karageorgiou and Kaplan 2005).
1.4.3 Fibrin Glue
Fibrin is a naturally occurring matrix, which has an important role in the final steps o f the 
coagulation cascade in wound healing (Kania et al. 1998), and has been used previously as a 
tissue engineering scaffold (Grant et al. 2002; Lee et al. 2005). In the body, fibrin is formed 
by the enzymatic cleavage o f the fibrin  zymogen fibrinogen by the serine protease thrombin. 
Fibrin then undergoes a polymerisation reaction with other fibrin molecules, as well as cross­
48
linking (facilitated through either Factor X III or endogenous trans-glutaminases) to itse lf and 
surrounding tissue, which lends it both haemostatic and adhesive properties (Marx and Mou
2002). Fibrinogen fragments as well as fibrin  degradation products are thought to promote 
the migration o f cells such as fibroblasts (Abiraman et al. 2002) and vascular smooth muscle 
cells to the healing site (Kodama et al. 2002). Fibrinogen-fibroblast interactions have not 
been thoroughly investigated (Gailit et al. 1997). Fibroblasts are thought to interact with 
fibrin by the interaction o f fibrinogen molecules with the integrins a vPi, a vp3, and anbPi 
(Hubbell 2000). Integrins are a large fam ily o f cell surface receptors involved in adhesion by 
binding to ligands found expressed in the ECM and by other cells (Gailit et al. 1997). 
Although there is evidence for direct fibroblast-fibrinogen interactions in cell adhesion, 
evidence shows that indirect interactions w ith fibronectin are required for cell spreading and 
migration into fibrin via the crucial integrin aiP.i binding to the sequence RGDS (Gailit et al. 
1997; Knox et al. 1986; Pierschbacher and Ruoslahti 1984).
Cells naturally express urokinase plasminogen activator and tissue plasminogen activator, 
serine proteases that activate the fibrin-degradation enzyme plasmin (Neuss et al. 2004), and 
this process, in addition to the action o f macrophages and multi-nucleated foreign body cells, 
naturally degrades fibrin over time.
Fibrin glue has been used for many years as a surgical haemostatic agent (Davidson et al. 
2000; Spotnitz et al. 1987), as well as other surgical uses, for example, preventing air leaks 
after pulmonary resection (Belboul et al. 2004). Figure 1.7 shows the components o f the 
commercially available Tisseel fibrin glue, as well as a reflection electron microscopy 
image o f fibrin at high magnification. Fibrin glue can also be sprayed (Figure 1.8). 
Commercially prepared fib rin  glue, such as Tissucol^ and Tisseel^ fibrin sealant (Figure 1.7),
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have two main components: human fibrinogen reconstituted in a bovine aprotinin solution, 
and a human thrombin-calcium chloride solution. The availability o f fibrin, in addition to its 
simple application system, makes it easy to obtain and use. Combinations o f fibrin and non- 
resorbable HA have been used throughout Europe for over a decade, in the reconstruction o f 
maxillofacial and dental defects (Bonucci et al. 1997). The fibrin phase has proved effective 
in moulding the ceramic scaffolds and holding the granules/powder in place as natural 
mineral deposition occurs.
■
Figure 1.7 a) Components of Tisseel fib rin  glue; b) Reflection electron microscopy 
(REM) image photograph of Tisseel fib rin  glue (scale 1:6000, used by permission from 
Baxter Biosurgery, USA).
At present, fibrin is a promising scaffold for cells for skin regeneration, and when combined 
with keratinocytes, can be sprayed onto wound sites (Grant et al. 2002). Fibrin has been 
shown to increase the level o f the angiogenic factor VEGF, which could enhance the healing 
effect o f fibrin scaffolds in skin tissue engineering (Flojo et al. 2003).
Figure 1.8 F ibrin glue sprayed using pressurised air (Baxter Biosurgery, USA. Used 
with permission).
The osteoconductive properties o f fibrin glue have been reported (Abiraman et al. 2002; 
Bosch et al. 1980; Kania et al. 1998; Yamada et al. 2003) and disputed (Greco et al. 1988; 
Lucht et al. 1986; Schwarz et al. 1993). An experiment by Abiraman et al. (2002) showed 
that fibrin glue had osteoconductive properties at an ectopic site; however, this was only 
observed when fibrin was combined with hydroxyapatite or bioglass. Similar work in a rat 
femoral defect model indicated a role for fibrin glue in osteogenesis, when implanted in an 
orthotopic site. In another study by Schwarz et al. (1993), fibrin glue did not promote 
osteoinduction at both ectopic and orthotopic locations in rats. Thus, no study has shown 
fibrin alone to possess osteoinductive properties.
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Fibrin may not induce differentiation o f osteoblastic precursors into osteoblasts, but may 
promote neo-vascularisation at the surgical site to promote faster healing and bone formation 
and organisation (Kania et al. 1998). In the osteoconductive experiments described above, 
control biomaterials such as bioglass and hydroxyapatite granules did not show reduced bone 
formation and bone ingrowth to materials when compared to those treated with fibrin, but 
also lacked neo-angiogenesis (Kania et al. 1998). A study by Abiraman et al. (2002) 
demonstrated that the ectopic implants coated in fibrin glue had noticeable neo- 
vascularisation and evidence o f intramembranous ossification when compared to controls, 
which were encapsulated in a thick fibrous layer.
Fibrin’s biocompatibility, commercial availability, in addition to its proven effectiveness in 
bone defects, makes it an ideal cell delivery vehicle in v ivo , for cells such as BMSCs, in 
tissue engineering applications.
1.4.4 The use of BMSCs in the tissue engineering of bone
The first evidence indicating the osteoinductive nature o f bone marrow cells was the ability
o f fresh bone marrow' to augment bone formation in orthopaedic surgery (Boyne and Yeager 
1969; Morris 1969). Following the seminal work o f Friedenstein et al. (1968) into the role o f 
BMSCs specifically in bone formation, they have become a major component o f bone tissue 
engineering strategies. One benefit o f using BMSCs as opposed to bone marrow is the lack o f 
erythrocytes, which may increase potassium to cytotoxic levels (Street et al. 2000). In vitro  
testing has frequently been used as a pre-indicator o f osteogenic capabilities o f 
osteoprogenitor cells and cell-scaffold constructs in vivo (Jaiswal et al. 1997, Rust 2004).
BMSCs have been shown to increase bone growth in vivo , in small and large animal models, 
at both orthotopic and ectopic locations (Bruder and Caplan 2000; Haynesworth et al. 1992;
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Kalia et al. 2006; Korda et al. 2006; Kruyt et al. 2003). Some o f the first experiments 
investigating the potential o f BMSCs in in v ivo , loaded cubes o f calcium phosphate ceramics 
with or without BMSCs, which were implanted subcutaneously in synergenic or immuno­
compromised rodents (Haynesworth et al. 1992). These studies found significantly increased 
bone growth into the cubes loaded with BMSCs when compared to the scaffolds alone. 
Further work by this group showed that this observation was applicable to cells from many 
mammalian species, such as goat, sheep, dog, rat, and human. Additionally, it was found that 
diluting the number BMSCs up to 50% with fibroblasts did not effect bone formation in vivo 
(Bruder and Caplan 2000). In addition to smaller animals such as mice, rats, and rabbits, 
larger animals, such as dogs, sheep, and goats, are often used for the in vivo testing o f bone 
tissue engineering strategies. The results o f in vivo investigations on the mechanical loading 
o f the hind limbs o f large animals indicate similar loading levels to those experienced by 
humans (Bergmann et al. 1984; Buma et al. 2004; Martini et al. 2001), suggesting that large 
animals may be a suitable model for the testing o f tissue engineering models with BMSCs.
A study investigating ectopic bone growth in a caprine model showed a significant effect o f 
BMSCs loaded seven days pre-operatively or per-operatively onto porous ceramic cubes, 
suspended in autologous plasma, and implanted into the bilateral paraspinal muscles o f goats 
(Kruyt et al. 2004). This biphasic calcium phosphate (BCP) scaffold has previously been 
shown to be osteoinductive, in that it promotes bone growth in an ectopic site, without the aid 
o f osteoinductive growth factors or osteoprogenitor cells (Yuan et al. 2002). In the 2004 
ectopic study by Kruyt et al. (2004), a comparison was made between cryopreserved and 
fresh cells to see i f  cells could be obtained in advance o f surgery and preserved for future use. 
These groups were also compared to control, untreated scaffolds as well as devitalised 
scaffolds. These are scaffolds which have cells grown onto them for seven days, after which
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the construct is devitalised to remove live cells, leaving behind an extracellular matrix 
coating. In this study, it was found that these ceramic blocks had significantly more bone 
growth when seeded pre-operatively or per-operatively with BMSCs compared to the 
scaffold only or a devitalised cell matrix/scaffold combination.
Kon et al. (2000) preceded their orthotopic, large animal work with a small animal study 
demonstrating the osteoinductive effects o f ovine BMSCs when loaded into fibrin-coated HA 
blocks, and implanted subcutaneously in nude mice. Interestingly, it has been suggested that 
an ectopic intramuscular site, which is extremely vascular, could be an effective in vivo 
bioreactor for bone tissue (Stevens et al. 2005; Wamke et al. 2006).
Bone tissue engineering can also be applied to cases where bone has been resected to treat 
tumours such as high-grade osteosarcomas, Ewing’s sarcoma, or malignant fibrous 
histiocytoma (Kenan et al. 1987). The patients are given pre-operative and post-operative 
chemotherapy to prevent the spread o f the tumour and the possibility o f metastases. One 
study demonstrated an improvement o f the five-year survival o f stage IIB  osteosarcoma 
patients from 32% without chemotherapy to 57% with this treatment (Eckardt et al. 1991). 
Lee et al. (2005) showed a negative effect o f a neoadjuvant chemotherapy regime on BMSCs 
proliferation on osteogenesis in v itro  and new bone formation in a rat osteotomy model, by 
using a combination o f doxorubicin and cisplatin. However, he was also able to demonstrate 
in a rat femoral defect model with external fixation, that the application o f fibrin glue and 
BMSCs to the defect site resulted in similar amounts o f bone formation, whether or not the 
rats had been given chemotherapy. These studies therefore both indicate a role for BMSCs in 
bone regeneration after chemotherapy, as well as the effectiveness o f BMSCs in combination 
with fibrin glue for augmenting new bone formation at an orthotopic site.
54
In 1998, Bruder et al. demonstrated the effectiveness o f autologous BMSCs in the healing o f 
canine segmental bone defects, when the cells were loaded onto a fibronectin-coated, p-TCP 
cylindrical construct. The femoral implants were supported by a lengthening plate and left in 
situ for 16 weeks (Bruder et al. 1998). In this case, the BMSCs resulted in a noticeable bony 
callus around the implant, as well as significantly more bone formation than the controls 
(untreated with fibronectin and cell-free). Untreated defects (with no implant or treatment) 
resulted in non-unions after sixteen weeks, and those ceramic implants that were not cell- 
loaded began to show signs o f cracking at twelve weeks, in contrast to the cell-loaded 
implants. This same group showed similar results after 16 weeks in the same canine defect 
model, but this time substituting allogeneic BMSCs that were dog leukocyte antigen (DLA, 
analogous to HLA)-mismatched as opposed to autologous cells (Arinzeh et al. 2003). Petite 
et al. (2000) attempted critical-sized defect bone regeneration, with the goal o f preventing 
non-union. As an alternative to autograft, the group created a BMSC-coral “ biohybrid,”  and 
compared bone formation and union o f the scaffold to host bone in an ovine model. The 
group first established the minimum length for non-union in sheep by creating a series o f 
metatarsal defects and observing their ability to achieve union, that is, ability to heal and 
form new bone to bridge the gap rather than become scarred (Petite et al. 2000). They then 
created a “ biohybrid”  to fit the critical-size defect and tested BMSC-loaded coral constructs 
and fresh bone marrow-loaded constructs to cell-free scaffold controls and untreated defects. 
They found that while the untreated defects did not heal after 16 weeks, cell-free scaffolds 
achieved some bone growth, although they did not integrate into the host bone. Those 
constructs containing fresh bone marrow were filled with fibrous tissue more akin to scar 
tissue than bone formation, whereas BMSC-loaded constructs demonstrated mostly new bone 
formation and union with the host bone (Petite et al. 2000).
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In another large animal model, a BMSC-loaded construct was implanted into critically sized 
defects o f sheep. BMSCs were loaded into HA cylinders by coating them with fibrin  and 
absorbing a cell solution into the fibrin-ceramic scaffold. This cell-loaded group had 
noticeably more bone growth into the construct, as well as greater callus formation around 
the implant, bridging it to the host bone (Kon et al. 2000). However, it must be noted that the 
group size was too small for meaningful statistical analysis.
Similarly for other types o f tissue engineering o f mesenchymal tissues, such as articular 
cartilage and craniofacial tissue (Frosch et al. 2006; Shang et al. 2001), ceramic or metal 
implants have been used as a scaffold for BMSCs, and tested in large animal models. In these 
cases it has been shown that BMSCs can be used to restore other tissues that provide 
important functional and or aesthetic roles.
1.4.5 Growth factors: Cytokines to target bone formation and
revascularisation
In an effort to stimulate natural molecular mechanisms that trigger bone formation, one can 
implant growth factors at a site where bone regeneration or formation is required, or 
incorporate them into a scaffold in the presence or absence o f osteoprogenitor or 
osteoinductive cells. These factors can be used to target the temporal mechanism o f bone 
growth. In this case, bone morphogenetic proteins such as BMP-2, BMP-4, BMP-7, or BMP- 
9, can be used to promote fracture healing, or healing o f critical-sized defects (Lin et al. 
2005; Mistry and Mikos 2005). Genes that also have been demonstrated to promote bone 
formation include sonic hedgehog (Edwards et al. 2005) and Runx2 (Byers et al. 2006). 
Vascularisation can be promoted by using growth factors such as VEGF, whether by direct 
protein or gene (DNA) injection into a site o f bone repair (Geiger et al. 2005; Huang et al.
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2005). There are, however, some disadvantages to using growth factors, such as their great 
expense, which makes their regular use exorbitant. For example, a study by Dimitriou et al. 
(2005) found that the average cost o f treating a fracture non-union with BMP-7 cost 
approximately £7,338. In an American study by the Washington State Department o f Labour 
and Industries (2003), treating a tibial non-union with BMP-2 cost approximately $12,468 
(about £6,764), which was about the same cost as treatment with autograft. Also, the 
effectiveness o f growth factors is not completely predictable, and in some cases is 
comparative to the use o f autograft (Friedlaender et al. 2001; Maniscalco et al. 2002). 
Autograft in this scenario refers to bone graft harvested from another site on the patient, such 
as the iliac crest (Burkus et al. 2003).
Similarly, osteoprogenitor cells or other cell types used for tissue engineering purposes can 
be genetically modified to express these growth factors. Use o f a temporary vector, such as 
replication-incompetent adenovirus, which w ill insert its DNA into host cells and express the 
protein for a limited period o f time, has its advantages (Lieberman et al. 1999; Tsuchida et al.
2003). These advantages include the targeted temporal expression o f the genes o f interest, as 
well as preventing over-expression o f the gene, and not using a virus prevents the risk o f 
adverse immune reactions or the formation o f recombination-competent virus. In some cases 
the adenoviral vector has been injected directly into a site o f repair (Kang et al. 2004). 
However, long-term expression o f growth factors by cells can be achieved by using retroviral 
vectors. Replication incompetent retroviruses have been used to insert genes into the host 
genome o f cells being implanted for use in bone tissue engineering (Breitbart et al. 1999; 
Mason et al. 2000).
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1.5 Goals
The main hypothesis of this thesis is that viable BMSCs can be applied to implants 
using a fibrin glue-spray system, and increase bone formation adjacent to the implants 
and improve bone-implant contact.
This work aimed to improve fixation o f orthopaedic implants to host bone in an attempt to 
reduce rates o f aseptic loosening, and can be divided into five aims:
1) To isolate, grow and characterise BMSCs from the bone marrow using standard 
tissue culture methods, as well as differentiating the cells down different 
mesenchymal lineages.
2) To investigate the behaviour of BMSCs in a fibrin glue scaffold, and determine if 
this therapy could potentially be applied as a spray by analysing the morphology 
of the cells using histological techniques, and measuring cell viability, 
metabolism, and proliferation using enzymatic and DNA-labelling assays.
3) To determine if bone marrow stromal-like cells (peripheral blood stromal cells- 
PBSCs) can be isolated and grown from the peripheral blood as an alternative to 
bone marrow aspirates, and measure the influences of blood loss or G-CSF on 
circulating PBSC number.
4) To test the system of sprayed, autologous BMSCs in fibrin in a large animal 
massive implant model, and measure the amount of bone growth around the 
implant when compared to an untreated implant, with the goal of improving 
fixation of the implant to reduce aseptic loosening, with the outcome determined 
in terms of radiological and histological measurements.
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5) To apply this same system in an in vivo model of implant loosening, and to 
compare the effects that different cell dosages have on new bone formation by 
assessing the amount of bone growth around the implant.
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CHAPTER TWO
THE ISOLATION, EXPANSION, AND 
CHARACTERISATION OF OVINE BONE MARROW 
STROMAL CELLS (OBMSCS)
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2.1 Introduction
First identified by Friedenstein as being “ fibroblast precursors”  in 1976 (Friedenstein et al. 
1976), bone marrow stromal cells (BMSCs) have been extensively studied, and their potential 
use in bone tissue engineering investigated. The primary characteristics o f BMSCs were 
originally identified by their adherence to tissue culture plastic, fibroblastic morphology and 
their ability to form colonies, derived from a single cell, called colony-forming units- 
fibroblastic (CFU-F). When the cells were transplanted in porous ceramic cubes into the 
backs o f nude mice, significantly more bone was produced than blocks alone, indicating the 
bone-forming potential o f these cells (Friedenstein et al. 1970; Castro-Malaspina et al. 1980; 
Owen et al. 1988). There arc two main methods used to characterise BMSCs. The first is to 
demonstrate the multipotency o f the BMSCs by differentiation down two or more lineages 
(Pittenger et al. 1999), the second is to use cell surface marker identification (Bruder et al. 
1997).
When cultured with dexamethasone, ascorbic acid, and P-glycerophosphate, or BMPs 
(Friedman, Long and Hankenson 2006; Chaudhary, Hofmeister and Hruska 2004) BMSCs 
have been observed to change morphology to a cuboidal. osteoblastic shape; express genes 
related to osteoblastic differentiation (Krishnan et al. 2003; Pittenger et al. 1999), and 
produce nodules that stain positively for calcium (Jaiswal et al. 1997; Gronthos et al. 1994). 
BMSCs have been stimulated to differentiate into other mesodermal cell types such as 
adipocytes, chondrocytes, and even neuronal cells.
In v itro  mineralisation can be tested by using a substitution reaction that allows visualisation 
o f the nodules with light microscopy (Von Kossa assay). This stain has been used for many
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years to indicate regions where calcium is deposited, which contain both phosphate and 
carbon salts. Following exposure to bright light, the Ag* ion in silver nitrate replaces the 
calcium ion in these salts and stains the calcium deposit brown-black. This stain has also 
been used to show osteogenic differentiation o f BMSCs (Schecroun and Delloye 2003; 
Gronthos et al. 1994).
Use o f energy dispersive analysis o f X-rays (EDAX) to identify and quantify the elemental 
composition o f these nodules can be used to identify the presence o f hydroxyapatite crystals 
(Best et al. 2004). Additionally, osteoblasts are known to express alkaline phosphatase (ALP) 
on their cell surface in order to create an alkaline environment in which bone mineral is laid 
down. An ALP assay determines the activity o f alkaline phosphatase (ALP) expressed by the 
differentiating cell. As stromal cells differentiate into osteoblasts, an increase in ALP has 
been observed in many studies (Rust PA 2005; Oreffo et al. 1998). In these studies, 
differentiated cells were compared to undifferentiated BMSCs that had not been exposed to 
the same chemical cues (dexamethasone, ascorbic acid and p-glycerophosphate). ALP 
cleaves the phosphate group found in p-nitrophenol phosphate to produce p-nitrophenol, 
which is alkaline, and can be spectroscopically detected at 405 nm. This increase in coloured 
product created by the enzymatic reaction is compared to the reaction time to produce a 
reaction rate, or enzyme activity rate. Oreffo et al. (1998) used this reading to indicate 
differentiation o f bone marrow osteoprogenitors into osteoblasts.
After culture with dexamethasone, indomethacin, l-methyl-3-isobutylxanthine, and insulin 
(Pittenger et al. 1999), BMSC-derived adipocytes collect lipids that can be detected using 
stains such as O il Red ‘O ’ and Sudan Black IV (Sotiropoulou et al. 2005). Oil Red O is a
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lipid-soluble dye used as a histochemical stain to indicate the presence o f neutral lipids, 
triglycerides, cholesterol esters, markers o f adipocytic cells (Preece 1972).
The second method used to identify BMSCs is to determine cell surface marker expression. A 
panel o f positive and negative reactions for various markers has been extensively used to 
isolate and identify BMSCs, and this expression is often used for fluorescence or magnetic- 
activated cell sorting techniques (FACS and MACS, respectively). Cells are subjected to such 
a panel o f markers in order to ensure positive identification. A number o f studies have 
identified both positive and negative markers for BMSCs; however, there is no single 
positive marker for these cells (due to their plasticity and often unpredictable reaction to 
these markers). Even Stro-1, a commonly-used hBMSC marker, reacts positively with some 
glycophorin-A-positive nucleated red cells and B-lymphocytes that are often isolated from 
the bone marrow along with hBMSCs (Gronthos 2003) - emphasising the need to test for 
multiple cell surface markers.
Previous work has attempted to characterise ovine BMSCs, however, these cells not been as 
well documented as the BMSCs from other species. In this chapter, a protocol for the 
isolation, expansion, and characterisation for ovine BMSCs is presented and discussed.
Hypothesis: Multipotential ovine BMSCs (oBMSCs) can be isolated from ovine bone 
marrow and expanded in culture, and differentiated down three different cell lineages: 
the osteoblastic, chondrogenic and adipogenic lineages.
The aims and objectives o f this chapter are to:
1. To isolate BMSCs from ovine bone marrow aspirates.
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2. To expand ovine BMSCs cells in culture using two-dimensional cell culture methods.
3. To differentiate oBMSCs down mesenchymal cell lineages: osteoblastic and 
adipogenic; using specific chemical cues for differentiation.
4. To confirm the differentiation o f oBMSCs down mesenchymal lineages using 
standard histological and immunohistochemical techniques.
2.2 Methods
2.2.1 Isolation, Culture, and Expansion of oBMSCs
English mule ewes were selected for use in this study. These animals were skeletally mature 
(two to five years in age), and weighed between 65-90 kg. A ll procedures were carried out 
according to the Home Office Animals Scientific Procedures Act o f 1986. Bone marrow 
aspirates were taken from sheep iliac crests using an aseptic technique, as follows.
2.2.1.1 Anaesthesia and Pre-Operative Preparation
Sheep were premedicated with an intramuscular (IM ) injection o f Xyalzine (O.l mg/kg, 
Rompun, Bayer Health Care, Newbury, Berkshire, UK), 10-30 minutes prior to induction o f 
anaesthesia. Sheep were then administered Ketamine (2 mg/kg, Ketaset, Fort Dodge Animal 
Health Ltd, Southampton, UK) and Midazolam (2.5 mg, Hypnovel, Roche Products Ltd., 
Welwyn Garden City, Hertfordshire, UK) intravenously (IV ) into the jugular vein to induce 
anaesthesia An endotracheal tube was then inserted and connected to an anaesthetic machine. 
Anaesthesia was maintained using a 2% halothane (Merial Animal Health Ltd., Harlow, 
Essex, UK) and oxygen mixture, which was adjusted as required. A stomach tube was 
inserted. A 10 cm2 area o f skin overlying the iliac crest was then prepared, first by shaving,
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then by treatment with Pevidine, a Povidone-iodine scrub and antiseptic solution (C-Vet, 
Bury St. Edmunds, UK). The area was then covered with a fenestrated drape.
2.2.1.2 Procedure for Bone Marrow Aspiration
A 0.5% w/v chlorohexidine gluconate solution in spirit (Adams Healthcare, Leeds, UK) was 
then applied to the skin as a sterilising agent, before a small incision directly positioned on 
top o f the iliac crest was made. A Jamshidi biopsy needle (R56780, Rocket Medical, 
Washington, UK) was used to penetrate into the intramedullary cavity o f the iliac crest. A 
minimum o f 8  mL o f bone marrow was aspirated, in 4 mL aliquots (Rust P et al 2004). 
Clotting was prevented by drawing up aspirates in syringes containing 0.5 mL heparin ( l 000 
units/mL) (Monoparin, CP Pharmaceuticals, Barnstable, UK). Post-operatively, animals were 
given 0.6 mg Buprenorphine as an analgesic (Vetergesic, Alstoe Animal Health, Melton, 
Mowbray, UK), as well as a long-acting antibiotic (15 mg/kg Am oxillicin, Betamox LA, 
Norbrook Laboratories (GB) Ltd., Great Corby, Carlisle, UK).
2.2.1.3 BMSC Isolation and Expansion
Manipulation o f aspirates and cells took place in a lamellar flow hood. Each 4 mL aliquot o f 
ovine bone marrow was carefully layered on top o f a 3 mL layer o f Ficoll-Paque™ PLUS 
sucrose gradient ( l 7 -1440-02, Amersham Biosciences, Chalfont St. Giles, UK). This gradient 
was used to separate the bone marrow components by density centrifugation. After layering, 
samples were spun in a refrigerated centrifuge at 1500 rpm, at 4°C, for 30 mins. After this 
time, layers became apparent in the sample, with a bottom layer that included an upper buffy 
layer, containing the mononuclear cells o f the bone marrow (Ficoll^ users guide). This buffy 
layer was carefully removed and washed with 10 mL o f DMEM media (DMEM+, or control
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media), supplemented with 10% fetal ca lf serum (FCS, First Link, UK) and 100 units/mL 
penicillin/streptomycin (P/S, 0082, Invitrogen, Paisley, UK). The cell suspension was then 
centrifuged for 5 minutes at 2000 rpm at room temperature. The supernatant was discarded 
and the remaining pellet resuspended in 1 mL DMEM+ using a 21 gauge needle and 1 mL 
syringe, before being transferred to a T25 polystyrene cell culture flask (Coming, Coming, 
NY, USA) with 4 mL o f media. This flask has a surface area o f 25 cm2 for cell expansion, 
and a treated surface for cell adhesion (Ramsey WS 1984, Amstein CF 1975).
Flasks were kept in a humidified incubator at 37°C, with 5% CCL. Within 7-14 days, colony- 
forming units (CFU-Fs) became apparent in the flask. Once these cells had expanded to cover 
70% o f the cell culture surface (70% confluent), cells were “ passaged,”  or expanded further 
(approximately 10-14 days).
DMEM+ in the cell culture flasks was removed and discarded, using a pipette. The cells were 
then washed with cold phosphate buffered saline (PBS), which was also discarded. The cell 
culture surface was incubated at 37°C for 5 minutes with a 0.5% trypsin- 5.3 mM EDTA 4Na 
solution (15400-054, Invitrogen, Paisley, UK), diluted from a lOx stock solution with PBS. 
After 5 minutes, the cells lifted o ff  the surface, and the trypsin was neutralised by adding a 
1:1 volume o f DMEM+. In order to determine cell viability, a 0.4% Trypan Blue solution 
(T8154, Sigma-Aldrich, Dorset, UK) was then used in a 1:1 ratio with a small quantity o f the 
cell suspension. A haemocytometer was used to quantify the concentration o f cells under a 
phase-contrast light microscope. Trypan Blue is a dye with two azo chromophores. The 
chromaphore is negatively charged, and thus only reacts with cells when the membrane is 
damaged. Thus it is assumed that the (blue) stained cells are dead and the unstained (clear) 
cells are alive (Biosource AlamarBlue™ manual). The cell suspension was then centrifuged
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for 5 minutes at 2000 rpm at room temperature, to obtain a cell pellet. The supernatant was 
discarded, and the cell pellet then resuspended in 1 mL o f DMEM+ (control media) using a 
21 gauge needle and syringe. Approximately 3,000 -  4,000 cells were seeded per cm2 o f cell 
culture area, and cells cultured in 0.1333 mL o f DMEM+ (control media) per cm2 o f surface 
area. DMEM+ (control media) media was changed every 3-5 days. This technique was used 
to expand cells when they reached 70-80% confluence on the cell culture flasks, until passage 
3-4, at which time they were used in in v itro  and in vivo experiments.
2.2.2 Characterisation of Ovine Bone Marrow Stromal Cells- 
Differentiation
2.2.2.1 Osteogenic Differentiation
Osteogenic Media (from Rust 2005 and Kostura et al. 2004):
Dulbecco’s Modified Eagle’s Medium (DM EM ) (4500 mg/L glucose, D6429, 
Sigma-Aldrich, Dorset, UK)
10% Fetal ca lf serum (FCS; First Link, UK)
1.0% Penicillin/streptomycin (P/S; 0082, Invitrogen, Paisley, UK)
1.0 x 10' M Dexamethasone, water-soluble (D2915, Sigma-Aldrich, Dorset, UK)
5.0 x 10-4 M Ascorbic Acid (255564, Sigma-Aldrich-Aldrich, Dorset UK)
1.0 x 10‘2 M p-glycerophosphate (G9891, Sigma-Aldrich, Dorset, UK)
For both the osteogenic and adipogenic supplemented media, FCS and P/S were added to the
DMEM. The differentiating reagents were dissolved in 10 mL o f this solution, then added 
back to the bottle o f DMEM using a 0.2 pm filter with a sterile 10 mL syringe.
Dexamethasone is a common glucocorticoid used in all o f the differentiation media. Used on 
its own as a cell culture media supplement, it has been shown to promote adipogenic and 
myogenic differentiation o f hBMSCs (Grigoriadis, Heersche and Aubin 1988; Yin, Li and 
Wang 2006) and has been suggested that it decreases the expression o f bone matrix protein
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mRNA transcripts (Cheng, Zhang and A v io li 1996), although a study by Igarashi et al. (2004) 
disputes this evidence.
oBMSCs were isolated, expanded, and trypsinised as described above. For histochemical 
staining (Von Kossa), 6  x 104 cells were plated out onto Thermanox* coverslips (Nalge Nunc 
International, Rochester, NY, USA), which had been placed at the bottom o f the wells o f 12- 
well plates (Coming, NY, USA). 1 mL o f supplemented osteogenic media was added to each 
well. Cells were grown in a standard humidified incubator, and media was changed every 3-5 
days. Cell morphology was observed every 5-7 days, up to 28 days after the initiation o f 
culture.
For the alkaline phosphatase (ALP) assay, 6.0 x 104 cells were plated into 6 -well plates 
(Nunc, NJ, USA) and grown for 7, 14, 21 and 28 days. For each cell line, there were two 
groups: cells grown in standard supplemented media, and cells grown in osteogenic media. 
Each group was repeated in triplicate for each time point.
2.1.2.2 Adipogenic Differentiation:
Adipogenic Media (from Rust 2005):
Dulbecco’s Modified Eagle’s Medium (DM EM ) (4500 mg/L glucose,
D6429, Sigma-Aldrich, Dorset, UK)
10% FCS (First Link, UK)
1.0% P/S (0082, Invitrogen, Paisley, UK)
1.0 x 10' 6 M Dexamethasone, water-soluble (D2915, Sigma-Aldrich, Dorset, UK)
200 pM Indomethacin (17378, Sigma-Aldrich, Dorset, UK)
500 pM l-methyl-3-isobutylxanthine (15879, Sigma-Aldrich, Dorset, UK)
10 pg/mL Insulin (10516, Sigma-Aldrich, Dorset, UK)
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For adipogenesis, 1x10^ cells were cultured per well in 12-well plates, on Thermanox 
coverslips. Cells were cultured in adipogenic media for 21 days, with media being changed 
every 3-5 days. After 21 days, cells were fixed in 10% neutral buffered saline (NBS).
2.2.2.3 oBMSC Passage Number
For adipogenic and chondrogenic differentiation, cells o f passage four were used. For 
osteogenesis, however, cells o f both passage 4 and passage 12 were used. As a direct 
comparison for sheep BMSCS, goat BMSCs were also differentiated as described above, and 
Von Kossa and ALP biochemical assays were performed.
2.2.2.4 Negative Controls
As negative controls, the HaCat (human transformed keratinocyte) and LG3 (human 
leukaemia monocytic) cell lines were used. HaCat cells are a transformed keratinocyte cell 
line, which means that they can continuously proliferate. The LG3 cell line is a lung 
fibroblast-derived cell line.
2.2.3 Histology-Osteogenesis
2.2.3.1 Von Kossa Assay
Cells were cultured on coverslips in osteogenic media for 28 days, after which the coverslips 
were washed with PBS after discarding the cell culture media. The coverslips were then fixed 
in methanol for 10 minutes. The coverslips were then gently washed with distilled water three 
times, after which they were incubated in 1.5% silver nitrate (762000, Hopkin &  Williams, 
UK) under a lamp for one hour. The light promotes the reduction o f Ca2‘ ions in the presence 
o f silver nitrate. A fter incubation, the silver nitrate was discarded and the coverslips were 
gently washed 3 times with distilled water. At this point, samples were covered with 2.5% 
thiosulphate (Fisions Scientific Apparatus, Loughborough, UK) for 5 minutes, after which
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samples were gently washed once with distilled water. Coverslips were counterstained for 5 
minutes with Neutral Red (x634, Sigma-Aldrich, Dorset, UK), which stains cell nuclei red, 
and afterwards rinsed gently in distilled water until clear. A negative control was prepared 
prior to staining by pretreating a coverslip with 5% acetic acid for 2 minutes. Photos were 
taken using an Olympus BH2 photographic microscope and a JVC KY F55B Colour Video 
Camera using Zeiss KS300 software (Imaging Associates, Thame, UK).
2.2.3.2 ALP quantitative biochemicai assay (Cobas Bio)
For the assay, a k it was used (AP307, Randox Laboratories, Antrim, UK). Pre-weighed p- 
nitrophenol powder was mixed with 10 mL o f diethanolamine buffer and pre-heated to 37°C 
to produce the working reagent. Cell culture samples, either treated with DMEM+ or 
osteogenic DMEM+, were washed in PBS, then cells were lysed by adding autoclaved, 
distilled water at 37°C (a hypotonic solution). Samples were frozen and thawed three times, 
then transferred to Eppendorf tubes and spun in an ultracentrifuge at 10,000 rpm for 10 
minutes. 50 pL o f the resultant supernatant was loaded into Cobas Bio * blue sample cups 
(AS Diagnostics, Blackpool, UK). 0.25 mL o f the p-nitrophenol phosphate working solution 
was used for each sample. The reagent and samples were loaded into the Cobas B io & analyser 
(Roche, Lewes, UK) to run the assay. ALP activity measurements were calculated as U/L.
To compare results w ithin groups, ALP activity readings were normalised for the number o f 
cells, by measuring the amount o f DNA in each sample. This was done using the fluorometric 
dye Floechst 33258, which binds specifically to the adenine-thymidine base pairs o f DNA 
(Rago, Mitchen and W ilding 1990, Rao and Otto 1992). For the assay, lysed samples were 
transferred from cell culture dishes to Eppendorf tubes, which were spun in an ultracentrifuge
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at 10,000 rpm for 10 minutes, and the supernatant transferred to fresh tubes. A standard curve 
was prepared in a Fluoronunc^ 96-well plate (Nunc, Rokskilde, Denmark), by diluting a 
stock, 1 mg/mL DNA standard (from ca lf thymus, D3664, Sigma-Aldrich, Dorset, UK) in 
saline sodium citrate (SSC) buffer, to 20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 pg/mL, and 
loading 100 pL o f the standards into the 96-well plate in triplicate. To prepare 500 mL o f a 
20x stock SSC buffer (20x the working concentration), 87.65 g o f sodium chloride and 44 .1 g 
o f trisodium citrate was dissolved in distilled water and the pH was adjusted to 7.0 with 1M 
HC1 or lM N aO H .
A map o f the 96-well plate was made to record the standard/sample order. 100 pL o f each 
sample was loaded into the plate in duplicate. The Hoerchst 33258 dye (B2883, Sigma- 
Aldrich, Dorset, UK) was diluted from 1.0 mg/mL to 1.0 pg/mL in SSC and 100 pL added to 
each standard or sample well in the Fluoronunc^ plate. Samples were run in a Fluoroskan 
Ascent' fluorimeter (Labsystems, Finland), using Genesis version 2.19 (Life Sciences UK 
Ltd.) and Ascent Research Edition version 1.1.1 software (Labsystems, Finland). The 
adenine-thymidine-Hoercht 33258-specific fluorescence was read at 460 nm. From the 
standard curve, the DNA concentrations could be calculated. For this, Microsoft Excel was 
used to plot the known concentration o f the standards versus their absorbance at 460 nm, and 
a linear equation fitted to the resulting line. Equations having a correlation coefficient o f 0.95 
or above were acceptable for calculating the DNA concentrations o f the samples.
ALP activity (U) per pg DNA was calculated as follows:
ALP activity (U /L) = fALP activity (U/mL) / 10001 
Sample DNA concentration x 0.05 mL (volume o f each sample used for ALP assay)
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2.2.3.3 Scanning Electron Microscopy (SEM)
Cells attached to coverslips were fixed in 1.5% gluteraldehyde (SEM grade, Agar Scientific, 
Stansted, UK) diluted in 0.1M sodium cacodylate (Na Cac, Agar Scientific, Stansted, UK) 
buffer for at least six hours. After this, samples were washed in 0.1M Na Cac buffer for 10 
minutes, then treated for two hours in 1% osmium tetroxide (Agar Scientific, Stansted, UK) 
in 0.1M Na Cac buffer. After this period o f time, samples were washed in 0.1M Na Cac 
buffer three times for five minutes. Samples were then covered with 1% tannic acid in 0.05M 
Na Cac buffer for one hour. After this, samples were washed for 5 minutes in 0.1M Na Cac 
buffer, then dehydrated with decreasing dilutions o f industrial methylated spirit (IMS) in 
distilled water, from 20% IMS to 96% IMS, for 5 minutes each. The samples were then 
dehydrated in 1 0 0 % ethanol dried w ith sodium sulphate for 1 0  minutes and 15 minutes. 
Samples were then treated with hexamethyldisalazane (H.M.D.S., H4875, Sigma-Aldrich, 
Dorset, UK) three times for 2 minutes each, then air-dried. Dried coverslips were then 
mounted onto titanium discs and sputter-coated using an Emitech K550 Sputter Coater 
(Emitech, Ashford, Kent, UK). Samples were then visualized using a Jeol JSM-5500LV 
Scanning Electron Microscope (SEM) using the corresponding Jeol User Interface version
4.04 (Jeol Technics, Welwyn Garden City, UK), at 5kV.
2.2.3.4 X-ray detection using Electron Dispersive Analysis of X-Rays (EDAX)
Electron probe X-ray microanalysis characterises elements present in a sample using x-ray 
detection. It has been used previously to determine a calcium-phosphate ratio in mineralised 
tissues, as would be found in bone containing hydroxyapatite (Caio(P0 4 )6(OH)2). This uses 
the SEM-prepared samples in the SEM machine, in combination with the EDAX PV9830 
Genesis X-Ray Microanalysis System (XMS), with EDAX Genesis^ software (EDAX UK, 
Cambs. UK) at 1500x magnification, and 15.0 kV. The percentage (%) weight o f calcium
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content o f samples was divided by the percentage weight o f phosphate to give a calcium to 
phosphate (Ca/P) ratio. The stoichiometric ratio o f calcium to phosphate naturally found in 
hydroxyapatite is 1.67 (Nayar et al. 2006).
2.2.3.5 Alamar Blue Activity Assay
To observe the effect o f osteogenic media on cell activity and viability, the AlamarBlue™ 
assay was used. AlamarBlue™ is a redox indicator; it changes colour from blue/non- 
fluorescent to red/fluorescent after being reduced from an oxidised state. This redox reaction 
is related to metabolic activity and cell growth, where a reductive environment indicates cell 
growth. It is reduced as a result o f acting as an intermediate in the electron transport chain o f 
the cells. This is in contrast to other assays, such as the MTT assay (Korda et al. 2006), which 
interrupt the flow o f electrons throughout the chain, causing a shutdown o f the electron 
transport chain and eventually cell death (AlamarBlue™ manual). For this assay, 6.0 x 104 
cells were plated out per well in a 12-well plate (Coming, Coming, NY, USA), 1 mL o f 
standard DMEM+ added, and cells incubated for 24 hours in standard conditions to permit 
cell attachment. The following day, the media was changed, so that ha lf o f the samples were 
cultured in DMEM+ and half cultured in DMEM+ with osteogenic supplements. A fter 24 
hours, AlamarBlue™ was diluted in PBS to make a 10% working solution. This solution (1 
mL) was added to each well and the plates incubated under standard conditions for 4 hours. 
After 4 hours, 100 pL from each AlamarBlue™-reacted sample was loaded in duplicate into a 
FlurorNunc™ white fluorometric 96-well plate, and absorbance read in a fluorometer. The 
excitation frequency was 560 nm and the absorbance frequency was 590 nm. Results are 
expressed as absorbance at each time point.
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2.2.3.6 Thymidine-H3 Cell Proliferation Assay
This assay measures the rate o f cell proliferation by measuring the rate o f DNA synthesis. 
Radioactive thymidine-H3 (thy-H3, GE Healthcare, Giles, Buckinghamshire, UK) is added to 
the culture media o f cells and incorporated into nascently synthesised DNA (Maurer 1981, 
M illipore 1991). For this assay, 1.0 xlO 5 cells were added to each well o f 3 6 -well plates 
(Orange Plastics, Triple Red Laboratory Technology, Long Crendon, Buckinghamshire, UK), 
covered with 2.0 mL o f standard DMEM+ and left overnight to allow cell attachment under 
standard conditions. Afterwards, the media was changed in all wells, half o f the wells 
receiving 2.0 mL o f standard media and half receiving 2.0 mL osteogenic media. A t this 
point, in one plate, 1.0 pL o f thy-H 3 was added for each 1.0 mL o f media, and placed in a 
designated standard humidified incubator for 24 hours. After this time, the media was 
removed and cells washed with PBS. Autoclaved, distilled water ( lm L ) was added to each 
well, and the cells left to lyse at 37°C for one hour, after which they were frozen at -20°C. 
The above steps were repeated between 24-48 and 48-72 hours after adding osteogenic 
supplements to cells. After the 72-hour period, all cell lysates were freeze-thawed 3 times. 
The samples were transferred to 1.0 mL Eppendorf tubes and centrifuged at 10,000 rpm for 
10 minutes. For the scintillation assay, 200 pL o f 20% trichloroacetic acid (TCA, T6399, 
Sigma-Aldrich, Dorset, UK), at 4°C was added to all the wells o f 96-well M illipore 
Multiscreen * filter plates (M illipore U.K. Ltd, Watford, UK). This TCA was aspirated o ff 
using a M illipore Multiscreen * vacuum manifold (M illipore, Watford, UK). 100 pL o f the 
cell lysate was then loaded into the wells o f these plates, a plate map being used to track 
samples. Following the samples, a further 100 pL o f 20% TCA at 4°C was added to all wells. 
The plates were incubated at 4°C for 30 minutes, on a shaker, after which the plates were 
aspirated again. Wells were washed with 200 pL 10% TCA, aspirating the wells after each 
wash. The plastic underside o f the plates were then removed and the filters left to dry
overnight at room temperature. The 96-well filters were then punched out into scintillation 
vials and 500 pL 0.01M potassium hydroxide were added to vials, which were then mixed on 
a R100/TW Rotatest shaker (Luckham, Burgess H ill, Susses, UK) for 2 hours. After this, 4.0 
mL o f scintillant (6013119, Ultima Gold™ XR, PerkinElmer, Boston, USA) was added to 
each vial. Vials were then capped, vortexed and read on a P-counter (Tri-Carb 2900TR 
Liquid Scintillation Analyzer, PerkinElmer, Boston, USA). Results were read using Quanta 
Smart 1.31 software (Packard Instrument Co.) for Windows NT.
1.3.7 Histology-Adipogenesis
O il  Red O ’ Stain
A stock Oil Red ‘O ’ solution was prepared by dissolving 0.5 g o f oil red O in 500 mL 
isopropanol and warming the bottle for 30-60 minutes at 56°C. A working solution was made 
by diluting 30 mL o f the stock solution in 20 mL distilled water. After 14 days in adipogenic 
media, cells were fixed in neutral buffered formalin for 1 0  minutes, after which they were 
washed with distilled water and then stained in O il Red ‘O ’ for 10 minutes. After staining, 
cells were washed in distilled water and then counterstained using Harris’ haematoxylin for 1 
minute.
2.2.4 Statistics
For the ALP biochemical assay, activity and proliferation assay results, normality was 
determined with the Kolmogorov-Smimov and Shapiro-Wilk tests, using SPSS 12. For non- 
parametric data, a comparison between groups was made using the Mann Whitney U test, 
where a p-value < 0.5 was considered a significant result.
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2.3 Results
2.3.1 oBMSCs-Observations
2.3.1.1 Colony-forming units-fibroblastic (CFU-Fs)
Within 5-7 days, fibroblastic colony-forming units (CFU-Fs) were observed in the cultures. 
These consist o f a colony o f fibroblastic-shaped cells originating from a single cell. After the 
first passage, cells took on a flat, fibroblastic morphology (Figure 2.1).
Figure 2.1 oMSCs after passage. Cells are flat, spindle-shaped in morphology, with 
large nuclei that have multiple, prominent nucleoli (see black arrows). The processes of 
some cells can be seen to be in contact (see white arrows).
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2.3.2 Osteogenesis
2.3.2.1 Von Kossa assay-Visual Observation and Qualitative Analysis
After 28 days, those oBMSCs treated with osteogenic media had a greater positive reaction 
than those oBMSCs grown in normal media, with black deposits indicating sites o f 
mineralisation. This included oBMSCs o f a low passage, and high passage oBMScs (Figure 
2.2c-f). Interestingly, the untreated oBMSCs also stained positively to the Von Kossa assay, 
although to a far lesser extent. As previously described with human BMSCs, over the 28 
days, a multilayer o f cells eventually formed three-dimensional folds, resulting in retraction 
o f cells on the plastic surface and thus empty pockets o f culture plastic became available for 
cell proliferation (Schecroun and Delloye 2003). There was no distinct change in cell 
morphology over the 28 days. Negative controls samples (Figure 2.2a-b) were low-passage 
BMSCs that were negative for the Von Kossa stain after treatment with 5% acetic acid. It 
should also be noted that the immortalised keratinocyte cell line (HaCats) also reacted 
positively to the Von Kossa stain when treated with osteogenic media for 28 days, with a 
minimal reaction when grown in normal media. Figure 2.2 shows photographs taken o f Von 
Kossa stain samples for the different cell lines.
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Figure 2.2 Results of Von Kossa staining (lOx magnification). Images d, f, and h are 
low-passage ovine BMSCs, high-passage ovine BMSCs and HaCats, respectively, that 
were fixed and stained after being grown in osteogenic culture media for 28 days. 
Figures c, e, and g are negative controls of low-passage BMSCs, high-passage BMSCs, 
and HaCats (respectively), grown in non-supplemented DMEM+ for 28 days. Images a 
and b are low-passage ovine BMSCs that were treated with 5% acetic acid before 
staining to create a negative calcium control. Nodules of calcium mineral are stained 
black with the Von Kossa stain, and are indicated with arrows.
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2.3.2.2 ALP Biochemical Assay
In all cultures, the levels o f ALP were significantly higher at day 14 when cultured in 
osteogenic media compared to standard supplemented media. With treatment in osteogenic 
media, ALP activity was highest in the low-passage oBMSC cultures at days 14 and 21 (1.42 
± 0.53 U/pg DNA, and 1.33 ± 0.10 U/pg DNA, respectively; see Figure 2.3). There was no 
significant difference within each group (normal and osteogenic) at each time point in the 
low-passage oBMSC group. The ALP activity in osteogenic cultures was higher than in 
oBMSC cultures grown in normal media at 14, 21 (p=0.05 at both days 14 and 21), whereas 
the activity in the higher-passage oBMSC cultures was highest at day 14 (2.84 x 102 U/pg 
DNA), and significantly different at day 21 (p=0.05). Between days 7 and 14, and 7 and 28 in 
the control group, and between 21-28 days and 7-28 days in the osteogenic group, there was a 
significant difference in the ALP activity.
HaCat cultures showed similar trends, w ith a high level o f ALP activity at all time points 
when treated with osteogenic media, and significantly different ALP activity when compared 
to normal oBMSC cultures at day 14 (p=0.05). Between time points in both the control and 
osteogenic groups, there was only a statistical significant difference between 7-14, 14-21, 21- 
28, 7-28, and 14-28 days in the osteogenic group. LG3-osteogenic supplemented cultures 
showed a significant difference in ALP activity at 7, 21, and 28 days (p=0.05 at all three time 
points). Looking at statistically significant differences between time points in LG3 cultures 
found a significant change in ALP activity between 21-28 days, 7-28 days, and 14-28 days in 
the control group, and between 7-14, 14-21, 7-21, 7-28, and 14-28 days in the osteogenic 
group.
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Figure 2.3 Graphs illustrating ALP biochemical assay results at 7, 14, 21, and 28 days 
after culture in osteogenic media. The cell lines tested include a) low-passage oBMSCs 
(P3); b) high-passage oBMSCs (P12); c) goat BMSCs (P4); d) HaCats (transformed 
keratinocvtes)and e) LG3 cell line (leukaemic monocytes).
2.3.2.3 SEM and EDAX o f nodules formed during osteogenesis o f oBMSCs 
and HaCats
When oBMSCs were treated with osteogenic supplements for 28 days, globular nodules 
developed on the surface o f the cell layer. These nodules, in addition to showing a positive 
Von Kossa reaction, also contained calcium and phosphate, with a mean Ca/P ratio o f 1.69. 
In contrast, the oBMSCs grown in standard DMEM+ did not show any sign o f calcium or 
phosphate deposition (see Figure 2.4).
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Figure 2.4 SEM photographs (1500x magnification) showing the area scanned for 
EDAX analysis, as well as the EDAX results presented in graphical form, showing 
peaks for all notable elements, such as carbon, oxygen, phosphate, and calcium. Ca/P 
ratios are also shown, although some samples did not show calcium or phosphate 
content. A) shows BMSCs grown in standard DMEM; b) are BMSCs grown in 
osteogenic media; c) are HaCats grown in standard DMEM+; and d) are HaCats grown 
in osteogenic media.
The HaCat cell line also demonstrated calcium and phosphate deposition when treated with 
osteogenic supplements for 28 days, with a mean Ca/P ratio o f 1.91 ± 0.70. HaCats were not 
positive for calcium or phosphate when grown in DMEM+. The low-level presence o f the 
inorganic metallic (gold, silver, palladium, yttrium, technetium) and rare earth elements 
(lathanthium), have resulted from sample processing and sputter coating prior to analysis. 
SEM images show oBMSCs and HaCats to have differences in their morphology and nodule 
formation, even after 28 days in culture with osteogenic supplements (Figure 2.5). BMSCs 
appeared to form distinct globular nodules, measuring 265 pm to 290 pm, and had a very 
organised structure, whereas smaller HaCats nodules, measuring 10 to 35 pm each, were 
sometimes clustered, appeared more evenly spread out over the surface and had prominent 
cell processes extending between cells (Figure 2.5c).
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Figure 2.5 SEM photographs of cell lines after 28 days in osteogenic media, a) and b) 
are oBMSCs at 230x and 600x magnification, respectively. HaCat cell lines are shown in 
c) and d), at 200x and lOOOx magnification, respectively.
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2.3.2.4 Cell Activity During Osteogenesis -  Alamar Blue Assay
Observations made using Alamar Blue™ absorbency as a measure o f cell activity showed a 
significant increase in cell activity after treatment with osteogenic supplements when 
compared to normal (DMEM+) oBMSC cultures, except at day 3 (p=0.01, p=0.01 and 
p=0.20 after 1, 2, and 3 days in culture, and p=0.000 at days 7, 10, 14, 21, and 28.)- The 
lowest Alamar Blue™ reading was made at day 1, with an absorbance o f 130.53 ± 4.23 and 
152.44 ± 4.46 for the DMEM+ and osteogenic medium groups, respectively. The highest 
values were observed after the cells had been growing for 28 days, when the absorbencies 
were 383.45 ± 6.89 and 581.26 ± 3.48 for the DMEM+ and osteogenic groups, respectively 
(Table 2.1 and Figure 2.6). Looking between all time points in each group (DMEM+ and 
osteogenic), there was a statistically significant differences in absorbency except between 3- 
7, 21-28, 10-21, and 10-28 days in the DMEM+ group, and between 10-21 days in the 
osteogenic group.
Day 1 130.53 ±4.23 152.44 ±4.46
Day 2 161.90 ±7.81 209.80 ± 12.81
Day 3 197.00 ± 13.72 301.70 ±26.42
Day 7 266.32 ± 13.36 414.98 ± 21.31
Day 10 350.39 ± 10.61 521.07 ±6.77
Day 14 354.91 ±8.55 576.54 ±7.31
Day 21 359.20 ± 11.46 530.37 ±4.87
Day 28 383.45 ±6.89 581.26 ±3.48
Table 2.1 a) Chart showing Alamar Blue™ absorbency over a 28-day period in oBMSCs 
grown in standard (DMEM+) and osteogenic medium. Cells grown in osteogenic 
medium had a higher cell activity than those grown in standard medium at all time 
points, p<0.05 at all time points except day 3.
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Figure 2.6 Chart showing Alamar Blue™ absorbency over a 28-day period in oBMSCs 
grown in standard (DMEM+) and osteogenic medium.
2.3.2.5 Cell Proliferation During Osteogenesis -  Thymidine-H3 Radioassay
There was no significant difference in the proliferation rate o f oBMSCs, with or without 
osteogenic supplements over the first 72-hour period (p>0.05). There was, however, a 
significant decrease in overall cell proliferation observed during the 48-72 hour period, after 
cells had been cultured in osteogenic media (47.20 ± 4.70 Bq/pg DNA»hour and 3.37 ± 0.95 
Bq/pg DNA«hour, respectively, p=0.01). Figure 2.7 illustrates the results o f this assay. In the 
osteogenic group, between 48-72 hours and between 24-72 hours there was a statistically 
significant decrease in proliferation in the osteogenic group (p=0.004). There was no 
statistical significance between time points in the control group.
24 Hours 48 Hours 
Time Point
72 Hours
■  Standard Media ■  Osteogenic Media
Figure 2.7 3H-thymidine inocorporation assay results, over 24, 48, and 72 hours. The 
two groups tested were cells grown in DMEM+, and cells grown in DMEM+ with 
osteogenic supplement, expressed in Bq/pg DNA.
2 . 3 . 3  A d i p o g e n e s i s
2.3.3.1 Oil R e d ‘O’ Stain
Over the 14 days, cells changed morphology, becoming less spindle-shaped and shorter with 
long extensions (Figure 2.8). The Oil Red ‘O’ stain indicated the increased presence o f lipids 
after oBMSCs were treated for 14 days in adipogenic media, when compared to those that 
were cultured in standard media. Although it must be noted that there were some cells 
staining positively for this lipid stain in the untreated oBMSCs cultures, it was to a much 
lesser extent than the ‘adipogenic’ cultures.
Figure 2.8 a) oBMSCs grown for 14 days in standard DMEM+ medium, fixed and 
stained with the Oil Red ‘O ’ for lipids and Harris’ Haemotoxylin (counterstain) (lOx 
magnification); b) oBMSCs grown for 14 days in osteogenic medium and similarly 
stained (20x magnification). Arrows point at the positively stained lipids (red).
2.4 Discussion
According to conventional BMSC differentiation, from the results observed in this chapter, 
the oBMSCs isolated here contain progenitor cells, capable o f differentitating down three 
different cell lineages. The oBMSCs were derived from the bone marrow, were plastic- 
adherent cells that formed characteristic CFU-Fs and had a fibroblastic morphology. When 
treated with osteogenic media for 28 days, these oBMSCs produced mineral-like nodules and 
had a significant increase in ALP activity. When differentiated down the adipocytic lineage 
for 21  days, lipids were detected using the conventional stain and when treated in a pellet 
with chondrogenic supplements, cells appeared to express markers o f hyaline (collagen II, 
GAGs) and fibrocartilage (collagen I, GAGs). Cells appeared to slow down their proliferation 
and increase their cellular activity, as found with the thymidine-H3 and Alamar Blue assays. 
However, by including a few cell controls, from lineages unrelated to oBMSCs, I have shown 
evidence that could be used to prove oBMSCs contain progenitor cells using these techniques 
is insufficient. It is possible that these assays may only be demonstrating cell plasticity, rather 
than BMSC identity.
Regarding osteogenic differentiation, it appears that transformed keratinocytes (HaCat cell 
line) as well as spontaneously transformed leukaemic monocytes (LG3 cells) seem to react 
very similarly. In the case o f HaCat cells, the increase in ALP activity after stimulation with 
osteogenic supplements is even higher than with oBMSCs and gBMSCs. Similar, unspecific 
ALP assay results were published by Almeida (2001), who found that after treatment with 
nacre water-soluble matrix and dexamethasone, a non-BMSC cell line (MRC-5 fibroblasts, 
derived from human fetal lung tissue), also expressed ALP similarly to BMSCs (Almeida 
2001).
It is possible that the ALP assay, first used by Oreffo et al. (1998) to show osteoblastic 
differentiation o f hBMSCs, is not specific enough. There exist a few different isoforms o f 
ALP, which are expressed in various tissues, such as the kidneys, liver and bone (Nakayama 
et al. 1998). ALP on osteoblasts is expressed on the cell membrane, whereas this assay looks 
at ALP activity o f a cell lysate. However, specific ALP antibodies have been used to show 
cell surface expression o f ALP (Rust 2004, Gronthos et al. 1994), although it has been 
suggested that the post-translational modifications to the carboyhydrate side chains o f the 
different ALP isoforms may not be easily detectable by commercially available antibodies 
(Nakayama et al. 1998). It would be useful to test i f  the ALP proteins expressed by the 
oBMSCs and HaCat cell lines were o f the same isoform, by either using more specific 
monoclonal antibodies that differentiate between isoforms (Martin et al. 1997, Masuhara et 
al. 1991) or affin ity chromatography (Nakayama et al. 1998). Additionally, to ensure that the 
observed positive osteogenic-like reaction o f the immortalised HaCat and LG3 cell lines is 
not due to changes in gene expression as a result o f transformation-related chromosomal or 
aneuploidic aberrations (Phillips et al. 2001), it would be useful to repeat this experiment in a
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primary, terminally differentiated and/or non-mesenchymal cell line, such as primary 
keratinocytes or epithelial cells.
Like other studies (Janssen et al. 2006; Gorustovich, Rosenbusch and Guglielmotti 2002), I 
was able to show calcium phosphate production in BMSCs undergoing osteogenic 
differentiation. However, the HaCat cell line also produces calcium and phosphate results. 
The non-cell-specific formation o f these nodules is a cause for concern, considering that it is 
widely used, although the nodules have a distinct morphology when grown from the oBMSC 
cell lines or the HaCat cell line. Positive Von Kossa staining has previously been encountered 
in cases o f acute phosphate nephropathy, where phosphate-based cathartic agents caused the 
formation o f calcium phosphate deposits in the kidney, w ith a calcium to phosphate ratio o f 
1.67, which is the ratio for pure hydroxyapatite (Desmeules, Bergeron and Isenring 2003). 
These results are in accordance with the positive Von Kossa stains.
Interestingly, some nodules could be detected in those samples cultured in standard media for 
the 28-day period. Although spontaneous differentiation o f the cells is a possibility, it has 
been suggested that phenol red, used as a pH indicator in normal cell culture media, may be 
responsible for this differentiation. Still et al, attempted to culture human BMSCs in phenol 
red-free medium, but did not see an osteogenic stimulatory effect o f the media on the cells 
until a significant concentration o f phenol red was present (Still, Reading and Scutt 2003).
The surfaces used to to culture the cells described in this chapter, and well as the surfaces 
used during differentiation, were slightly different in some cases. For example, Thermanox® 
coverslips were used to culture oBMSCs in osteogenic media to show mineralisation after 28 
days using the Von Kossa stain, whereas 6 -well plates were used to culture cells for the ALP
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assay, at 7, 14, 21 and 28 days. Each plastic surface is fabricated from different materials, and 
uses different techniques to treat the surface, whether it is by using an electrostatic charge, or 
etching methods (EMS Catalog 2007; Scholz 2007). This may, in turn have resulted in 
varying conditions and reactivity to the differentiating supplements.
In this chapter, all cell lines stained positively for Von Kossa (mineralisation) after 28 days. 
A study by Declercq et al. (2005) found that cell lines derived from the rat bone marrow, 
calvarial and early passage periosteal cells formed positively staining nodules after about 1 2  
days in osteogenic media containing dexamethasone and (3-glycerophosphate. In contrast, 
late-passage periosteal cells and the osteoblast-like cell line UMR-106 showed a much more 
diffuse pattern o f positive Von Kossa staining. These samples were tested using x-ray 
diffraction and Fourier transform infrared spectrometry to investigate the properties o f these 
crystals, and found that all samples had similar results (Declercq et al. 2005). In this chapter, 
a similar lack o f nodule formation was observed when HaCat cells were treated in osteogenic 
supplements, despite their positive Von Kossa results. In contrast, the oBMSC-derived 
nodules had an intricate, matrix-like structure. The nodule formation suggests a cell-mediated 
process o f mineralisation as opposed to a nucleation-type process (Schecroun and Delloye 
2003; Bellows et al. 1986). In future, one method that may be useful in the detection o f 
mineralised and non-mineralised nodules is the use o f the two-colour image analysis used by 
Purpura, Aubin and Zandstra (2003), where bone nodule number, size and type can be 
distinguished.
There were two oBMSC lines investigated in this chapter. It is possible that the difference in 
passage might have affected the reactivity o f the cells to differentiation medium. With 
increasing passage, the properties o f the cells may have changed (Devine et al. 2001b) such
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that they react differently with the osteogenic media. We did not perform karyotyping on the 
cells, so it is also possible that aneuploidy may have spontaneously occurred during cell 
division in my cell lines (Wang et al. 2005), affecting gene expressiona accordingly, thereby 
affecting the differentiation and growth o f the cells. This is one reason why the different 
passages o f the various cell lines used may have also influenced the results, as well as a 
potential change in cell phenoytpe as the cells were passaged and expanded in in v itro  culture 
(for example, low-passage oBMSCs were passage 3, whereas gBMSCs were passage 4).
It is possible that the reason for the HaCat and LG3 responses to osteogenic media are due to 
transdifferentiation, or cell plasticity. Transdifferentiation involves the “ conversion”  o f one 
cell type to another cell type (Burke and Tosh 2005). The gene for Core-binding factor A l 
(Cbfa-1) is the first transcription factor gene to be expressed after stimulation with osteogenic 
supplements. This gene is thought to be a “ master gene”  that instigates osteogenic 
differentiation o f cells by triggering a cascade o f gene expression that promotes osteogenesis, 
including binding o f the protein product, CBFP) to Runt-related gene 2 (Runx-2) (Mori et al. 
2006; Dennis and Charbord 2002). Osterix is another downstream transcription factor 
involved in activating a gene expression cascade including bone sialoprotein, osteocalcin, and 
collagen I (Mori et al. 2006). Wu et al. (2002) identified a molecular stimulator o f Cbfa-1, 
2,6,9-trisubstituted purine compound, purmorphamine, which upregulated members o f the 
hedgehog (Hh) signalling pathway such as G lil and Patched. It is possible that either this 
molecule, produced as a breakdown product o f osteogenic supplements, or the original 
chemical stimuli in osteogenic media, is responsible for a strong effect on the gene regulation 
o f many cell types, and that this Cbfa-1 activation may cause “ reprogramming”  o f the cell. 
Looking for these “ osteoblastic”  genes in the different cell lines after treatment with 
osteogenic supplements, using a quantitative method such as real-time polymerase chain
94
reaction (RT-PCR) would be useful in determining the specificity o f gene regulation in adult 
cell lines.
Another point regarding ALP expression after treatment with osteogenic media is that 
dexamethasone is a potent up regulator o f ALP expression in BMSCs (Yin, Li and Wang 
2006; Yang et al. 2003; Cheng, Zhang and A vio li 1996; Kim, Cheng and Kim  1999) or a rat 
calvarial cell line (Grigoriadis, Heersche and Aubin 1988). It may also be possible that ALP 
expression is elevated after BMSC treatment with other differentiating supplements. 
Diefenderfer et al. (2003) showed that dexamethasone triggered ALP expression in hBMSCs 
in v i t ro , whereas BMP-2, BMP-4, or BMP-7 failed to induce such an effect.
Few other groups have attempted characterisation o f oBMSCs, the purpose o f the tests 
having been mainly to validate the oBMSCs used in large animal orthopaedic models (Kon et 
al. 2000; Shang et al. 2000). One study detected ALP activity using a similar p-nitrophenol 
phosphate to p-nitrophenol assay, and found very low levels o f ALP in the ovine BMSCs 
when cells were grown in standard medium, when compared to human BMSCs (Kon et al. 
2000). This study also applied oBMSCs in fibrin glue into ceramic cubes to test the in vivo 
osteogenic capacity o f oBMSCs, and found that they had a much more significant bone 
growth into the ceramic cubes when compared to human BMSCs. Another study, by Shang et 
al. (2000), showed a significant difference in the ALP activity o f oBMSCs when compared to 
sheep dermal fibroblasts, with oBMSCs having ten times the activity o f the fibroblast 
cultures. In my experiment, I was able to show different levels o f ALP activity by different 
cell lines and from different species, such as sheep and goat BMSCs. The goat BMSCs were 
found to have approximately two-and-a-half times the ALP activity o f the low-passage sheep 
BMSCs. It may be possible that different species have different levels o f ALP or differences
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in ALP activity. Shang et al. (2000) also looked at osteocalcin expression using a 
radioimmunoassay over a 17-day period, and found that osteocalcin expression was much 
greater in those oBMSC samples treated with osteogenic supplements than those grown in 
standard culture medium. This paper also showed collagen I expression by the oBMSCs after 
four weeks and positive Von Kossa staining after 21 days, although no controls were shown 
for these stains. Work by Cheng et al. (1996) showed only positive Von Kossa staining for 
oBMSC osteogenesis and Sudan Black IV  for adipogenesis (Muraglia, Cancedda and Quarto 
2000). Appropriate controls are obviously critical determinants o f validity for these various 
stains and assays regarding differentiation. As yet, adipogenic and chondrogenic 
differentiation have not been attempted using the HaCat and LG3 cell lines. It is possible that 
with the normal differentiation supplements these cells may show signs o f “ differentiation”  
as well. Is this a sign o f transdifferentiation or are these assays any indication o f an oBMSC’s 
identity? In addition, BMSCs are often regarded as being a heterogeneous population o f cells, 
having varying degrees o f multipotency (Aubin 1998; Purpura, Aubin and Zandstra 2003). In 
order to determine the actual ‘multipotency’ o f the oBMSCs isolated in this chapter, that is, 
the ability o f the cells in the population to differentiate down all lineages, one would have to 
use a cell lines derived from a single cell (using serial dilutions), and test the ability o f these 
cells to differentiate down all three lineages, as well as testing the cell surface marker 
expression. The population I have reported on is heterogeneous, and therefore most probably 
contains cells with varying capacities for differentiation down different cel lineages or levels 
o f ‘multipotency,’ as suggested for human BMSCs by Jane Aubin in 1998. I have not shown 
that the entire population o f oBMSCs used in this chapter can differentiate down all three cell 
lineages, however I have been able to show that some cells in the population have the 
capacity to differentiate down at least one cell lineage.
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In future, other useful tests that could be used to characterise oBMSCs are a surface marker 
profile, as well as to look for mRNA expression o f genes involved in the different 
differentiation pathways, such as osteocalcin, osteopontin, ostrix, PPARy2, and collagen type 
II and X, and aggrecan (Lisignoli et al. 2006). One method that has been used to a smaller 
extent in the characterisation o f BMSCs is analysis o f many different genes using a gene chip 
(Bourne et al. 2004; Hishikawa et al. 2004). I previously attempted to react ovine BMSCs 
with the human Stro-1 marker, with negative results (not shown), as well as other human CD 
markers such as CD 105 and CD44. More surface marker profiling using oBMSCs is a very 
important task that should be carried out promptly, following from the results presented in 
this chapter.
There was no significant difference in the proliferation o f cells over a 72-hour period. 
However, these results conflict with other studies, which detected a significant decrease in 
thymidine-H3 incorporation after treatment with osteogenic media for as little as 24 hours 
(Kim, Cheng and Kim 1999). This may be in part due to the fact that 24 hours is too distant a 
time-point. Some cells may have already been undergoing S-phase when the tritiated 
thymidine was added to the cell culture media, so the results could reflect a combination o f 
proliferation that was already occurring before the thymidine was added, plus any 
proliferation that occurred afterwards. The same idea could be applied to the 48- and 72-hour 
time points.
Additionally, although the Alamar Blue* observations in this chapter have been attributable 
to metabolic activity, cell numbers were not accounted for in this assay. As the cells were 
proliferating during the time course o f the assay, the cell number would have changed, and 
this would have contributed to the rise in absorbency o f the samples at later time points. In
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future, the results o f this assay should be standardised to cell number, by either measuring 
DNA content using the Hoerscht assay, performing cell counts using Trypan Blue staining 
and a haemocytometer, or by treating the cells with a fluorescent stain, followed by flow 
cytometry for cell counting.
It has been suggested in the literature, that, although dexamethasone is required for the initial 
differentiation o f BMSCs, it may hinder the formation o f bone nodules (Schecroun and 
Delloye 2003; Chang et al. 1998), as cellular proliferation is reduced by cells exposed to 
dexamethasone, reducing collagen I expression, vital for the formation o f nodules. 
Additionally, it has been suggested that prolonged steroid intake in humans could be one 
probable cause o f osteonecrosis (Yin, L i and Wang 2006; Wang et al. 2003). It could be that 
steroids such as dexamethasone have detrimental effects on the mineralisation and nodule- 
forming activity o f osteoblasts.
There was no observable change in morphology o f the oBMSCs over the maximum o f 28 
days cells were cultured with osteogenic supplements. This is in contrast to many studies, 
which observe a marked change in cell morphology, from a fibroblastic shape to a cuboidal, 
round cell shape (Jaiswal et al. 1997, Grigoriadis, Heersche and Aubin 1988).
It is unknown as to whether or not the anaesthetic regime used during bone marrow aspiration 
affected the isolation, viability, or phenotype o f the BMSC isolated from sheep. Halothane 
does not immediately clear out o f the body, staying dissolved in fat and other tissues for up to 
x to x hours after the cessation o f the anaesthetic regime. Also, the bone marrow was treated 
with 500 IU o f heparin per sample, in order to prevent clotting. The effects o f heparin on 
BMSCs or bone marrow cells has not been extensively reported in the literature, although it
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has been suggested that heparin-binding domains found in various elements o f the extra­
cellular matrix and the cell surface composition might affect cells signalling (Beauvais and 
Rapraeger 2004; Lopes, Dietrich and Nader 2006). Also, the animals were under general 
anaesthesia with an inhaled anaesthetic (halothane) while bone marrow aspirates were taken. 
Bone marrow contains fatty tissue, which can accumulate hydrophobic halothane molecules 
(Martin 2004), which may in turn affect the BMSCs. However, studies show that the first 
tissues to be exposed to halothane are those that receive a high fraction o f cardiac output. The 
bone marrow is well vascularised, so a certain percentage o f halothane probably did reach 
those cavities in the short term, even though the animals were not under anaesthetic for 
extended periods o f time (time ranging from 10-45 minutes). Halothane has been shown to be 
carcinogenic in vitro, although one report did describe an increase in cancer cases in 
anaestheticians who had been repeatedly exposed to waste anaesthetic gas, as well as a rise in 
congentital abnormalities and spontaneous abortion (Martin 2004). It is therefore possibile 
that halothane could cause mutagenesis in the BMSCs, or be accumulated in liposomes or 
any other lipid-containing structure in the cell for some length o f time, before breaking down 
into its metabolic derivatives.
In conclusion, the results presented in this chapter suggest that standard histochemical and 
enzymatic detection o f cell type after osteogenic differentiation o f BMSCs may not be 
specific to BMSCs. Thus, a thorough characterisation o f oBMSCs would be the most 
conclusive identification o f a multipotent bone marrow stromal cell. This could be done using 
cell surface marker identification, using FACS or MACS and via the detection o f mRNA 
transcripts o f osteoblastic genes, in addition to the standard histochemical tests. Also, in vivo 
tests o f BMSCs, showing their differentiation into osteoblasts after seeding onto ceramic 
cubes and implanting ectopically would be useful, and may show species-specific differences
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in the osteopotential o f BMSCs. In the case o f human BMSC-derived osteoblasts, the 
expression o f osteoblastic mRNA transcripts such as cbfal, c-fos, osterix, osteocalcin, and 
osteopontin (Marom et al. 2005, Igarashi et al. 2004, Jaiswal et al. 1997) are tested and 
should be repeated with oBMSCs. Gene analysis using microarrays may also differentiate 
cell types, for example, work by Brendel et al. (2005) which showed unique gene expression 
between BMSCs and skin fibroblasts when compared in over 9600 genes. The presence o f 
chondrocyte and adipocyte differentiation-related mRNA transcripts should also be tested 
with BMSC-derived chondrocytes and adipocytes. This future work w ill be very important in 
determining the effectiveness o f in v itro  tests in proving BMSC identity.
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CHAPTER THREE
THE EFFECTS OF GRANULOCYTE-COLONY 
STIMULATING FACTOR (G-CSF) AND BLOOD LOSS 
ON THE ISOLATION OF PERIPHERAL 
BLOOD-DERIVED STROMAL-LIKE CELLS
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3.1 Introduction
Bone marrow stromal cells (BMSCs) are a heterogeneous population o f non-haematopoietic 
cells derived from the adult bone marrow. The stroma, from which these cells are derived, is 
the connective tissue o f the bone marrow that supports haematopoiesis via the expression o f 
cytokines and cell-cell interactions. Much o f the recent literature supports evidence that 
MSC-like cells are present in many other tissues in the body, such as fat, skin, muscle, and 
umbilical cord blood. Many o f these cell lines, derived from these other sources, have been 
shown to demonstrate a similar multipotency to BMSCs (Kern et al. 2006; Lee et al. 2004; 
Bartsch et al. 2005). One recent source o f BMSCs that was previously debated in the 
literature is the peripheral blood. Kucia et al. (2004) showed the presence o f muscle, neural 
and liver stem cells in the bone marrow that responded to a stromal-derived factor-1 (SDF-1) 
gradient and were mobilised to the peripheral blood after tissue injury and stress.
In terms o f bone tissue engineering, it would be advantageous to have an alternative source o f 
BMSCs other than the bone marrow, which requires a painful aspiration step and provides 
varied results in terms o f isolated cell number. Over the past five years, evidence has been 
growing that BMSC-like cells have the capacity to migrate or “ home”  to adult bone and bone 
marrow when infused into the bloodstream (Devine et al. 2001), with or without stimulus. 
These stimuli include chronic hypoxia in rats (Rochefort et al. 2006) and G-CSF 
administration following breast cancer treatment in humans (Fernandez et al. 1997). This 
paper reported that peripheral blood-derived stromal-like cells (PBSCs) were isolated from 
eleven out o f fourteen patients tested. It has also been demonstrated that BMSCs have the 
capacity for engraftment and site-specific differentiation in sheep when implanted in utero 
(Liechty et al. 2000). Another study has isolated peripheral blood-derived stromal-like cells 
(PBSCs) using fibrin microbeads. Paget, in 1854, described matrix-producing cells in the
peripheral circulation. Kuznetsov et al. (2001) were able to consistently isolate peripheral 
blood from normal individuals as well as small animals such as mice, rabbits and guinea pigs. 
Wan, He and L i (2006) were also able to isolate peripheral blood stromal-like cells in one out 
o f two human cases.
High levels o f haematopoietic stem cell (HSC) mobilisation from the bone marrow to the 
circulating bloodstream occurs during leukocyte recovery following chemotherapy, and can 
also be induced using granulocyte colony stimulating cytokines. The harvest, purification and 
transplantation o f these cells back into patients undergoing high-dose cytotoxic 
chemotherapy to repopulate their bone marrow are successful procedures.
The very late antigen 4 (VLA4) adhesion molecule expressed by HSCs, binds in the marrow 
compartment to VCAM-1, expressed by stromal cells, endothelial cells, and BMSCs. 
Additionally, the molecule stromal-derived factor (SDF-1/CXCL12), expressed by BMSCs 
and stromal cells, attracts and localises HSCs by interacting with the receptor CXCR4. These 
interactions may be interrupted when HSC release from the bone marrow is required, or 
stimulated by mobilising factors such as G-CSF. Cleavage o f VCAM-1 and the degradation 
o f SDF-1 by proteases, neutrophil elastases and cathepsin G are implicated in this mechanism 
and are released upon G-CSF administration (Levesque et al. 2001; Levesque et al. 2003; 
Velders and Fibbe 2005; Kronenwett, Martin and Haas 2000). Cell-specific splice variants o f 
the mucin receptor CD 164, also with varying glycosylation patterns, have also been 
implicated in HSC-endothelial cell/BMSC interactions (Zannettino et al. 1998; Watt et al. 
1998).
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The matrix metalloprotease (MMP)-7 has been implicated in the remodelling o f the bone 
marrow microenvironment by degrading extracellular matrix interactions and structure. 
MMP-7 is increased upon G-CSF administration and is also known as type V I collagenase 
(Sugimoto et al. 2001). Collagen IV  is another molecule thought to be involved in HSC- 
BMSC interactions in the bone marrow, and G-CSF has been shown to modulate collagen IV  
expression in BMSCs (Fernandez et al. 1997).
Possible multipotent stromal cell mobilisation into the peripheral blood system concurrent to 
HSC mobilisation has been debated (Fernandez et al. 1997; Lazarus et al. 1997; Purton, 
Mielcarek and Torok-Storb 1997). However an in v itro  study in 2003 by Baksh, Davies and 
Zandstra proposed that the increased BMSC growth observed when co-cultured with CD45 + 
haematopoietic was due to positive interactions between the two cell types in terms o f 
survival and proliferation, and a possible steady-state balance. This group was able to show 
the sustained growth o f HSCs in the presence o f BMSCs, in a non-adherent culture system, 
without growth factors normally required to propagate HSC growth and proliferation in vitro. 
One HSC transplantation study also showed an increase in successful haematopoiesis with 
the co-infusion o f HSCs with cultured BMSCs (Koc et al. 2000). I postulated that it may be 
possible that a smaller volume o f blood loss, such as that experienced in blood donation, may 
induce stromal cell release into the peripheral blood, and that mobilised cells from the bone 
marrow may contain BMSC-like precursor cells. In my thesis, I investigated this possibility 
in an ovine animal model by quantifying the number o f fibroblastic colony-forming units 
isolated from blood and bone marrow after blood loss or cytokine therapy. The peripheral 
blood could be an alternative source to bone marrow for multipotent stromal-like cells, which 
unlike the latter two sources, would be simpler to obtain and could follow a similar protocol 
to the current practice for mobilised HSC therapy (Reddy 2005).
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The first hypothesis is that peripheral blood-derived stromal-like cells (PBSCs) could be 
isolated from an ovine model, expanded and characterised to be multipotent.
The second hypothesis is that induced stress, such as blood loss or cytokine-induced 
mobilisation of HSCs, would also result in the co-mobilisation of PBSCs into the 
peripheral blood in greater numbers and that these mobilised cells would have the same 
multipotent identity as those isolated from untreated peripheral blood.
The aims and objectives o f this chapter were to:
1. Show that the isolated ovine PBSCs have the same multipotent characteristics as 
BMSCs.
2. Demonstrate that induced blood loss (7 and 15% blood loss) would increase PBSC 
release into the bloodstream alongside HSC release in both the marrow and the blood 
in an ovine model.
3. Test i f  cytokine stimulation using G-CSF (Filgrastim) would increase PBSC 
circulation in an ovine model.
4. Investigate i f  there exists a change in the number o f PBSCs isolated from the blood in 
relation to the amount o f time post-G-CSF administration.
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3.2 Materials and Methods
3.2.1 Part I: Induced Blood Loss
3.2.1.1 Experimental Layout
To determine baseline levels o f CFU-F forming stromal cells in the bone marrow and blood, 
iliac crest bone marrow aspirates (two 4 ml samples) and venous blood samples (two 5 ml 
samples) were taken from 8  Mule ewes for haematological analysis and cell culture. Bone
{'c'1marrow was aspirated from the iliac crest and processed on Ficoll for BMSC culture as 
described in Chapter 2.
Those sheep that did not have normal haematological results were not used any further for 
this investigation (2 sheep), leaving 6  sheep in total that were used for the experiment. Blood 
cell counts (concentrations o f white blood cells, neutrophils, lymphocytes, monocytes, 
eosinophils, basophils, red blood cells and platelets) from these initial samples were taken as 
being the “ baseline”  result for cells from the blood and marrow, with which all other results 
were compared. Seven sheep samples were used to create the baseline mean CFU-F counts 
and three sheep underwent 7% bleeding, and 15% bleeding one month afterwards. Blood and 
bone marrow samples were then taken, and respective CFU-Fs counted.
The estimated blood volume o f each sheep was calculated using the assumption that each 
animal’s total blood volume was approximately 70 ml/kg body mass. A ll sheep used in this 
study ranged in mass from 80-87 kg and therefore 7% o f the blood volume (5 ml/kg) ranged 
from 392 -  426 ml.
Seven days post-aspiration, 7.0% o f each sheep’s blood was removed from the internal 
jugular vein, using a syringe and canula. O f this blood, 10 ml was taken back to the
106
laboratory for cell culture. Further aspirates (two 4 ml samples) and small blood samples (two 
5 ml samples, one for culture and one for haematology) were taken seven days after bleeding 
for haematological analysis and cell culture. Animals were then allowed to recover for a 
period o f three weeks.
After the three week recovery period, 15% o f the animals’ blood volume (10.5 ml/kg) was 
then taken over two days from the internal jugular vein. On the second day, 10 ml o f blood 
was taken for cell culture and counting. A week after the 15% bleeding, aspirates (two 4 ml 
samples) and small blood samples were taken (two 5 ml samples, one for culture and one for 
haematology). Figure 3.1
Figure 3.1 illustrates the experimental layout using a flowchart.
Blood samples 
(culture and 
haematology) 7 days
Bone marrow aspirate
t
6  s h e e p
Blood sample 
(culture)
7% Blood Loss
Blood samples 
(culture and 
haematology)
7 days
Blood samples 
(culture and 
haematology)
Bone marrow aspirate
7 days 1
7 days
Blood sample 
(culture)
Bone marrow aspirate 15% Blood Loss
Figure 3.1 Flowchart depicting the experimental layout testing the effects of induced 
blood loss (7% and 15%) on the mobilisation of BMSCs into the peripheral blood. The 
experiment consisted of pre-bleeding blood and bone marrow samples being taken, 
followed by either 7% or 15% blood loss one week later. One week post-blood loss, 
further blood and bone marrow samples were taken, for cell culture and haematological 
analysis.
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3.2.1.2 Anticoagulants
For aspirates and blood being used for cell culture, 500 units/5 ml o f heparin was used for 
each sample. For those samples used for haematological analysis, 15% EDTA was used as an 
anticoagulant.
3.2.2 Plating Cells For Counting CFU-Fs
After being processed on Ficoll and the buffy layer removed, washed and pelleted (see 
Chapter 2), cells were resuspended in 5 ml o f DMEM+. 2 ml o f this suspension was diluted 
in 15 ml o f media, and counted using a haemocytometer. Cells were plated in triplicate at 4.0 
x 10' cells/cm2, on either T25 flasks (Coming, Coming, N.Y., USA), or 12-well plates 
(Orange Plastics, Triple Red Laboratory Technology, Long Crendon, Buckinghamshire, UK). 
The remaining cell suspension was plated into a T25 flask for cell culture. Media was 
changed after seven days post-plating and cells were grown in DMEM+ under standard tissue 
culture conditions.
The number o f adherent cells was counted for each sample at 5 days. Fibroblastic colony 
forming units (CFU-Fs) were counted at 7, 11, and 14 days, after being plated out using a 
light microscope. As each clonal colony is derived from a single cell (Friedenstein AJ 1976), 
CFU-F counting gave an approximate number o f BMSC-like cells in the initial cell culture. 
Counts were expressed as CFU-F/cm2, from both the blood and bone marrow.
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3.2.3 Statistics
Non-parametric data from all three groups was compared using Friedman’s ANOVA. Data 
from the first two groups (Pre-treatment and 7% blood loss) were tested using the Wilcoxon 
test for related samples.
3.2.4 Part II: Effects of G-CSF Treatment
3.2.4.1 Experimental Layout
Eight Mule ewes had l ml venous blood samples taken for haematological analysis, as 
described above. Six o f these sheep, which displayed “ normal”  results, were used in this 
study. Sheep were estimated to be approximately 4-5 years old, as identified from coloured 
ear tags demarcating year o f birth.
Before G-CSF treatment, two 20 ml blood samples were taken from the internal jugular vein 
o f one sheep with 0.5 units o f heparin / 10 ml, for pre-G-CSF cell culture.
Filgrastim^ (G-CSF) was given to sheep subcutaneously at the same time each day, at a daily 
dose o f 5 pg/kg, for five days. This is based on a protocol for human administration o f G- 
CSF described by Cottler-Fox et al. (2003). Sheep were observed for any sign o f side effects 
during this time.
After G-CSF treatment, 16 ml o f blood was taken as described above, 4, 12, and 24 hours 
after the last G-CSF dose was given, for cell culture. For three sheep, 16 ml blood samples 
were taken 14 days post-G-CSF treatment. A t each o f these time points, 1 ml o f blood was 
taken for haematological analysis. Figure 3.2 is a diagram depicting the experimental design.
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Figure 3.2 Flowchart illustrating the experimental design to test the effects of G-CSF on 
BMSC release into the bloodstream. Firstly, blood samples were taken for 
haematological analysis. Sheep with normal “ within range”  results were then 
administered G-CSF at 5 pg/kg, for five days. Blood samples were then taken 4, 12, 24 
and 336 hours after G-CSF treatment, and cultured for CFU-F counting.
3 . 2 . 5  P l a t i n g  f o r  C F U - F  C o u n t i n g  a n d  C u l t u r e
Cells were processed as described in 7.2.1.2, except that for cell counting, red blood cells 
were first burst using 2.5% acetic acid. Nucleated cells were then counted using Trypan blue 
(to exclude dead cells from counting) and a haemocytometer and plated out in vented T25 
culture flasks (Coming cellBIND4, Coming, Coming, N.Y., U.S.A.) at a cell density o f 4.0 x 
104 nucleated cells/cm2, and cultured according to standard cell culture methods (see Chapter 
2) in 4 ml o f DMEM with 20% FCS (First Link, UK) and 1% penicillin/streptomycin (0082, 
Invitrogen, Paisley, UK). Media was changed seven days afterwards.
CFU-F were counted 7 and 14 days after initial culture under a phase-contrast light 
microscope and expressed as CFU-F/cm2. Cell morphology and behaviour was also observed. 
Photographs were also taken using an Olympus Camedia C2020Z digital camera (Olympus 
UK Ltd, London, UK), and Olympus 1x70 microscope (Olympus UK Ltd, Middlesex, UK).
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3.2.6 Characterisation of PBSCs
For osteogenic and adipogenic histochemical stains, ovine PBSCs obtained post-bleeding 
(see 3.2.2) were plated out at 4.0 x 104 cells/Thermonox^ coverslip, onto six coverslips, and 
grown in osteogenic media for 28 days or adipogenic media for 14 days, using the defined 
media outlined in Chapter 2. Following osteogenic differentiation, the Von Kossa stain, SEM 
and energy dispersive analysis o f X-rays (EDAX) was performed as described in Chapter 2. 
For adipogenic differentiation, the O il Red ‘O ’ stain was performed as described in Chapter
2. Chondrogenic differentiation is outlined below. Samples were compared to oBMSC and 
HACAT cell lines, as differentiated in Chapter 2.
3.2.6.1 Chondrogenic differentiation:
Chondrogenic Media (modified from Rust 2005):
High-glucose DMEM (4500 mg/L, D6429, Sigma-Aldrich, Dorset, 
UK)
1.0% P/S (0082, Invitrogen, Paisley, UK))
1.0 x 10 ' M Dexamethasone, water-soluble (D2915, Sigma-Aldrich, Dorset, UK)
50 ng/mL Ascorbic Acid (A4544, Sigma-Aldrich, Dorset, UK)
1.0 nM Sodium Pyruvate (P5280, Sigma-Aldrich, Dorset, UK)
10 ng/mL Recombinant Human TGF-p^ (#100-36, PeproTech EC Ltd., London,
UK)
A control media was prepared as above, but without TGF-p^. For differentiation into 
chondrocytes, oBMSCs were isolated, expanded, and trypsinised as described above, and 
counted using a haemocytometer. Approximately 5.0 x lO* oBMSCs were transferred to 
universal containers, where they were then centrifuged at 2000 rpm for 5 mins. These pellets 
were left at the bottom o f the universal containers, and 10 mL chondrogenic media added. 
The lids o f the containers were left loosely screwed onto the containers to permit gas 
exchange. The pellets were cultured in a standard humidified incubator, at 37°C with 5% CO2 
(Nuaire DH Autoflow, Triple Red Laboratory Technologies, Long Crendon,
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Buckinghamshire, UK). After 24 hours, the pellets rounded up into small spheroid-shaped 
pellets. These pellets were cultured for 21 days, with media changes every 3-5 days, using 
supplemented chondrogenic media. Both control and chondrogenic pellets were 3-
(R^dimensional (3D). After this time, the pellets were frozen in Tissue Tek OCT compound 
(Sakura Finetek, Zoeterwoude, Netherlands), and stored at -20°C. 10 pm Cryosections were 
made o f the pellets, using a cryosectioning machine (Bright Instrument Company, 
Huntingdon, UK) at -20°C, and mounted onto 1.0 - 1.5 mm thick glass slides (BDH, UK) and 
stored at -20°C.
3.2.6.2 Alician Blue and Sirius Red Histochemistry
To prepare the Alcian Blue stain. 1 g o f Alcian Blue powder was dissolved in 100 mL o f 3% 
acetic acid, and the solution filtered. The Sirius Red stain was prepared by dissolving 0.5 g o f 
Sirius red F3B in 45 mL o f distilled water. Absolute ethanol (50 mL) was then added, 
followed by 1.0 mL 1% sodium hydroxide. The solution was mixed vigorously, adding 4.0 
mL o f 20% sodium chloride, and the solution left to stand overnight before being filtered. 
Slide-mounted cryosectioned samples were fixed with methanol, after which they were 
washed in distilled water. They were then incubated with the Alcian Blue stain for 5 minutes, 
washed with distilled water, and then incubated in the Sirius Red stain for 1 hour.
3.2.7 Statistics
SPSS 11.0 for Mac was used for all statistical tests. Normality was calculated using the 
Kolmogorov-Smimov test. Non-parametric data comparing pre- and post-G-CSF treatment 
groups, at 7 and 14 days, was calculated using the Friedman for multiple, related groups. 
Bivariate correlation co-efficients were calculated with Pearson’s correlation co-efficient, and
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partial correlation co-efficients were also calculated. FACS data was analysed as described in 
Chapter 2.
3.3 Results
3 . 3 . 1  P a r t  I :  T h e  E f f e c t  o f  I n d u c e d  B l o o d  L o s s  o n  P B S C  M o b i l i s a t i o n  a n d  
I s o l a t i o n
3.3.1.1 Formation o f CFU-F
CFU-Fs were obtained from all pre-bleeding, and post-7% bleeding bone marrow aspirate 
samples, and from some o f the post-7% and 15% bleeding venous blood samples. CFU-Fs 
from both sources had a similar morphology: spindle or fibroblastic-shaped cells growing 
outwards in a circular colony (Figure 3.3).
Figure 3.3 Photo of CFU-F after 14 days of culture, isolated after 7% blood loss (4x 
magnification).
3.2.1.2 CFU-F Counts In B lood A nd  Bone Marrow Aspirate Samples
No PBSC/CFU-F were isolated from the blood before 7 and 15% bleeding (i.e. initial
samples and samples taken at time o f bleeding). After 7% blood loss, 0.0150 ± 0.015 CFU- 
F/cm2 were counted at 7 days, 0.0300 ± 0.02058 CFU-F/cm2 at 11 days, and 0.1211 ± 0.1063 
CFU-F/cm2 at 14 days. Using Friedman’s ANOVA, differences were not found to be 
significant (p = 0.368, p = 0.135, and p = 0.135 at 7, 11, and 14 days). After 15% blood loss,
113
0.0078 ± 0.005490 i H  -I- cm" were counted at 7 days (Table 3.1). Out o f  three sheep, 
PBSCs were isolated from two sheep after 7% bleeding hgure  3.4 and Table 3.1 graphically 
illustrate these results. In the pre-bleeding group, there was a statically significant increase in 
the number o f CFU-Fs between 14 days, 7-11 days, and 11-14 days. There were no 
significant differences observed between time points in the other groups.
0.25  ■
n=6
p=0.135
0 .2  -
0.15  -
n=6
p=0.135
n=6
p=£l,368
7 Days 11 Days 14 Days
Time
—H — P re-T rea tm en t B y Blood Loss —• — 15%  Blood Loss
Figure 3.4 Graph illustra ting  results o f CFU-F counting o f cells isolated from  the 
peripheral blood under normal conditions (pre-treatment), and after 7% and 15% 
blood loss. CFU-F counts at 7, I I ,  and 14 days are shown.
Looking at bone marrow samples, after 7% blood loss, there was a significant increase in the 
number of' ( I t  -1 s. Pre-treatment, there were <»,% I I - n. 09035 CFU-F/cm2, 0.3425 ± 0. 
t 1 U -1 Lin and t>.42% • o. 14 %  i M -1 cm2 counted at 7, 11, and 14 days; whereas after 7% 
blood loss, 04)044 L U2M.U c o.%13 ( l l -I cm2, and 1 %1 * n . o f U  C M  -I cm2
were counted at 7, 11 arid 14 days respectively (see Figure 3.5 and  fable 3.1). Using
Friedman’s A N O V A  at 7 days, this difference is significant (p = 0.023). Using W ilcoxon ’s 
test at 11 and 14 days, comparing the pre-treatment and post-7%~hlood loss groups, the 
difference was also significant »p - u ,u l2  and p = 0.012, respectively). Once again, only a
fraction o f these initial, adherent cells grew into CFU-F. There were no staticically significant 
differences in the CFU-F counts between time points in the two groups.
7 Days (CFU-F/cm 2) 11 Days (CFU-F/cm2) 14 Days (CFU-F/cm 2)
Blood
Pre-Treatment 0 0 0
7%  Loss 0.0150 ±0.0150 0.0300 ± 0.02058 0.1211 ±0.1063
15% Loss 0 0.0078 ± 0.005490 0
Marrow
Pre-Treatment 0.2711 ±0.09035 0.3425 ±0.1075 0.4259 ±0.1479
7%  Loss 0.9644 ±0.2183 1.653 ±0.3913 1.851 ±0.6193
15% Loss 0.3178 ±0.1040 - -
Table 3.1 Chart with results o f CFU-F counts of cells isolated from the peripheral blood 
and bone marrow, before and after blood loss.
I Pre-Treatment ■  7% Blood Loss 15% Blood Loss
p = 0 . 0 1 2
p = 0 . 0 1 2
2
7 Days 11 Days 14 Days
Time
Figure 3.5 Means o f CFU-F counts o f cells isolated from the bone marrow before blood 
loss, 7 days post-7% blood loss, and 7 days post-15% blood loss.
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3.3.2 Part II: The Effects of G-CSF Treatment on the Isolation and 
Mobilisation of PBSCs
3.3.2.1 CFU-F and Cell Morphology
At seven days, a noticeably heterogeneous population was observed in the G-CSF treated cell 
cultures. Spindle-shaped, fibroblastic cells formed CFU-F in a circular pattern (Figure 3.6a is 
an early CFU-F, Figure 3.6b after 10 days) in addition to macrophage colony forming units 
(CFU-M) and dendritic colony forming units (CFU-D), were noted. CFU-M consisted o f 
highly reflective, round cells that were in association with bipolar cells with a pinched 
appearance, in addition to polygonal-shaped cells (Figure 3.6d, Figure 3.6e). CFU-D 
consisted o f colonies o f cells with spiked protoplasmic processes. Distributed throughout all 
cultures were small, round, adherent cells, akin to lymphocytic cells, which did not form 
colonies or appear to proliferate in v itro  (Figure 3.6d, Figure 3.6e). In control cultures, large, 
multi-nucleated, senescent-looking cells were seen, nearby to the small, round, cells 
described above (Figure 3.6d, Figure 3.6e). These cells did not proliferate.
Cells were grown until they covered the entire culture dish (100% confluence, Figure 3.6c). 
These cultures were also observed to be heterogeneous in morphology. Although most cells 
were fibroblastic in morphology, some cells were more cuboidal in nature (Figure 3.6f).
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Figure 3.6 Photos of cells isolated from the peripheral blood after G-CSF treatment, a) 
shows a typical CFU-F observed after 5 days of culture (20x magnification); b) a CFU-F 
after 7 days of cell culture (20x magnification); c) shows cells at 95% confluence, (20x 
magnification). D) is a photo of adherent cells that are not fibroblastic in morphology 
and did not proliferate in CFU-F. These cells appeared spread out and senescent (see 
arrows, 40x magnification). E) shows non-proliferative, small adherent cells round in 
morphology (40x magnification); f) is a photograph of proliferative, cuboidal cells that 
grew to confluence and had a less circular organisation to the observed typical-looking 
CFU-F (40x magnification).
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3.3.3 CFU-F Formation At 7 and 14 Days
A ll blood samples taken before G-CSF therapy did not show any signs o f CFU-F formation 
(0 CFU-F), after both 7 and 14 days in vitro. However, after G-CSF treatment, CFU-Fs were 
observed in blood samples taken 4 and 12 hours, and 2 weeks after treatment. The CFU-F 
count was highest at 7 days o f culture, in the blood samples taken 12 hours post-G-CSF 
treatment (0.1467 ± 0.1388 CFU-F/cm2), and lowest 4 hours post-G-CSF (0.02668 ± 0.01978 
CFU-F/cm2).
After 14 days in culture, CFU-F counts were highest in the blood samples obtained 2 weeks 
post-G-CSF administration (1.027 ± 30.1353 CFU-F/cm2), compared to the lowest count 
which was at 12 hours post-G-CSF treatment (0.064 ± 0.064 CFU-F/cm2). Table 3.2 is a chart 
containing the quantitative observations, and Figure 3.7 is a graphical representation o f the 
results.
m m
Pre-G-CSF (n = l) 0 0
4 Hours Post-G-CSF 0.02668 ±0.01978 0.09332 ± 0.05992
12 Hours Post-G-CSF 0.1467 ±0.1388 0.064 ± 0.0064
2 Weeks Post-G-CSF 0.04 ±0.02310 1.027 ± 0.1353
Table 3.2 Chart displaying CFU-F counts of cells isolated from peripheral blood 
samples, 7 and 14 days after the initiation of culture.
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p=0.11
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p=CL79-
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p=0.47
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♦  7 Days »  14 Days
Figure 3.7 L ine graph illustrating the num ber o f C F U -F  grown from  peripheral blood 
samples before G -C S F  treatm ent, and 4, 12, and 336 hours (2 weeks) after G -C S f  
treatm ent.
Haematology results showed an increase in white blood cell, neutrophil, and monocyte 
counts over the two week period after G-CSF administration. After five days o f G-CSF 
administration, the white blood cell (WBC) count increased from 7.610 ± 0.7988 x 109 
cells/L to 26.90 ± 1.909 x 109 cells/L. This count remained out o f range 12 and 24 hours after 
the last dose o f G-CSF (29.25 ± 2.501 x 109 cells/L and 27.70 ± 1.381 x 109 cells/L, 
respectively), and returned to normal levels after two weeks (10.57 ± 0.4065 x 109 cells/L). 
These changes in WBC levels were significant (compared to pre-G-CSF values) over all time 
points (p = 0.031). This trend was also seen with neutrophils (1.828 ± 0.2220 x 109 cells/L, 
14.81 ± 1.322 x 109 cells/L, 22.11 ± 2.098 x 109 cells/L, 17.15 ± 1.657 x 109 cells/L, and 
2.413 ± 0.1519 x 109 cells/L pre-G-CSF, 4, 12, 24 hours post-G-CSF, and 2 weeks post-G- 
CSF, respectively; p = 0.038). Also there were significant differences observed in 
lymphocyte counts in pre- and post-G-CSF blood samples (5.100 ± 0.7179 x 109 cells/L,
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8.388 ± 1.635 x 109 cells/L, 3.650 ± 0.7765 x 109 cells/L, 8.833 ± 1.630 x 109 cells/L, and 
6.950 ± 0.3614 x 109 cells/L pre-G-CSF, 4, 12, 24 hours post-G-CSF, and 2 weeks post-G- 
CSF; p = 0.022). Haematology results also showed a significant increase in monocytes from 
the pre-G-CSF levels (0.3383 ± 0.0680 x 109 cells/L) and at 4, 12 and 24 hours post-G-CSF 
(2.470 ± 0.4329 x 109 cells/L, 2.373 + 0.5205 x 109 cells/L, 0.9783 ± 0.1606 x 109 cells/L) 
This was followed by a return to normal values after 2 weeks post-G-CSF-treatment (0.1067 
± 0.06064 x 109 cells/L, see Table 3.3). There was no significant difference in all other values 
measured (p > 0.05).
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W B ^ lO T U 4.0-12 7.610 ± 
0.7988
26.90 1  
1.909
29.25 1  
2.501
27.70 1  
1.381
10.571
0.4065
Neutrophils
(lO’ /L)
0.7-6.0 1.828 ± 
0 . 2 2 2 0
14.81 1  
1.322
2 2 . 1 1  1  
2.098
17.151
1.657
2.4131
0.1519
Lymphocytes
(lO’ /L)
2.0-9.0 5.1001
0.7179
8.3881
1.635
3.6501
0.7765
8.833 1  
1.630
6.950 1  
0.3614
Monocytes
(lO’ /L)
0-1.5 0.3383 1  
0.0680
2.470 1  
0.4329
2.373 1  
0.5205
0.9783 1  
0.1606
0.10671
0.06064
Eosinophils
( ioVl )
0 - 1 .0 0.2683 1  
0.0788
0.7760 1  
0.2607
0.5400 1  
0.2474
0.6033 1  
0.09790
1.0631
0.1617
Basophils
(109/L)
0-0.4 0.0467 1  
0.03461
0.06601 
0.06600
0.14001
0.1038
0.0483 1  
0.0483
0.13331
0.08452
RBC (10l2/L) 8.0-16 12.031
0.5149
11.851
0.6915
12.501
0.6792
11.481
0.5491
1 1 . 0 0 1
0.6110
HGB (g/dL) 8.0-16 12.801
0.4412
12.541
0.4946
13.271
0.5420
12.381
0.4110
11.731
0.5239
RDW (%) - 2 2 . 0 0  1  
0.5177
2 2 . 6 8  1  
0.4984
24.181
0.7696
' 21.701 
0.7563
21.671
0.7356
PLT (109/L) 200-800 396.01
92.66
603.8 1  
84.98
537.3 1  
140.0
352.21
40.55
502.0 1  
72.75
Table 3.3 Results of haematological analysis, o f blood samples taken p re -G -C S F  (n=6); 
4 hours post-G -CSF (n=6); 12 hours post-G -C SF (n=6); 24 hours post-G -CSF (n=6) and 
2 weeks post-G -CSF (n=3). Results were compared to norm al “ range” values, and 
abnorm al results are highlighted (yellow). Blood was also processed for PBSC culture. 
Abbreviations: W B C  =  white blood cells; R B C  =  red blood cells; H G B  =  haemoglobin; 
R D W  = P L T  =  platelets.
It was at two weeks post-G-CSF, when WBC, neutrophil, lymphocyte, and monocyte counts 
reduced to normal values, that the highest number o f CFU-F/cm2 were observed after 14 days 
o f cell culture (Figure 3.8). When WBC numbers were correlated with CFU-F counts, the 
Pearson’s correlation co-efficient, the co-efficient was -0.523, which was significant 
(p=0.023), indicating that 27.4% o f the WBC counts were inversely related to CFU-F counts 
and vice versa. However, once the time variable was accounted for and controlled using the
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test for partial correlation coefficients, the correlation co-efficient was found to be -0.0063, 
and was not significant (p=0.492).
30
25
20
0 4 12 336
Tim e Post G-CSF Treatm ent (Hours)
—♦—White Blood Cells x 10e9 cells/L - • —CFU-F/cm squared
Figure 3.8 G raph  com paring the W B C  levels to C F U -F  counts over 336 hours post-G- 
C S F treatm ent. As W B C  levels dropped back to norm al values, the C F U -F  counts 
significantly increased. W hen tim e, W B C  levels and C F U -F  counts were correlated, this 
w as found not to be significant (p>0.05).
3 . 3 . 4  C h a r a c t e r i s a t i o n  o f  C u l t u r e - E x p a n d e d  P B S C s
3.3.4.1 Osteogenesis
After 28 days in culture, cells were stained for mineralisation using the Von Kossa method. 
PBSCs (cultured from peripheral blood CFU-Fs) treated with osteogenic supplements stained 
positively, with large regions 50 pm in width and 100 pm in length showing evidence o f 
mineralisation. PBSCs grown in normal DMEM+, showed small flecks (5-20 pm2) that 
stained positively for the Von Kossa stain, but to a much smaller extent to the osteogenic 
cells (Figure 3.9). The morphology o f cells treated with osteogenic supplements was not 
observed to change and remained fibroblastic in appearance.
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Figure 3.9 Photos of cells stained using the Von Kossa method after 28 days in culture  
in D M E M + , w ith or w ithout osteogenic supplements (b and a, respectively). Examples  
of mineralised areas are indicated w ith  arrows.
EDAX results showed positive calcium and phosphate detection, in both samples that had 
been treated with osteogenic supplements and those which had been grown in DMEM+ only. 
In the SEM photos, nodules can be seen in the sample treated with osteogenic supplements. 
These were positive for calcium and phosphate using EDAX. In terms o f calcium phosphate 
ratios, the untreated sample had a Ca/P ratio o f 1.96 ± 0.037, whereas the sample treated with 
osteogenic supplements had a ratio o f 2.14 ± 0.072, slightly higher than the untreated sample 
ratio.
Figure 3.10 shows the SEM photos and EDAX peak graphs for the two groups. Like the 
samples in Chapter 2, there were peaks for other elements that were present as a result o f 
processing and sputter coating. Also, these samples were run alongside HaCat cell lines, 
which produced calcium and phosphate nodules upon culture with osteogenic supplements, 
as described in Chapter 2. However, the PBSCs produced nodules with a different Ca/P ratio 
(the HaCat ratio was 1.92 with osteogenic supplements) with or without osteogenic medium 
and did not require supplements in order to produce these nodules.
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Ca/P = 1.99 ±0.035
1 .0 0 1.00 3 .7 0 4 .6 0 5 .5 0 6 .4 0 7 .3 0 0 .2 0
Ca/P = 2.14 ±0.072
1 .0 0  2 .0 0  3 .0 0  4 .0 0  5 .0 0  6 .0 0  7 .0 0  0 .0 0  9 .0 0  1 0 .0 0  11 .0 0
Figure 3.10 SEM images of PBSCs after 28 days in culture with or without osteogenic 
supplements (b and a, respectively). Nodules can be seen in the osteogenic culture; 
however, both samples tested positive for the presence of calcium and phosphate. This 
can be seen in the peak graphs alongside the SEM images. The Ca/P ratios differed 
between the two groups and have been noted.
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3.3.4.2 Adipogenesis
PBSCs were observed to change morphology after 14 days o f culture in adipogenic media 
from a compact, fibroblastic shape to that which was wider in appearance, and less densely 
populated than the controls that had been cultured in DMEM+ (Figure 3.11). The Oil Red ‘O’ 
stain, which indicates the presence o f lipids, produced a bright red stain around certain 
clusters o f cells (see arrows).
Figure 3.11 Photos showing results o f O il Red fcO ’ staining. PBSCs were e ither cu ltured  
in D M E M +  (a) or D M E M +  w ith  adipogenic supplements (b ) fo r 14 days, a fte r which  
they were stained. A  positive reaction, showing the presence o f lip id  vacuoles, can be 
seen in b), and is identified  by a b lack a rro w . A  sm all positive reaction can be seen in a), 
indicated by a b lack a rro w .
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3.3.4.3 Chondrogenesis
After 21 days in chondrogenic media, PBSC pellets showed positive staining with Sirius Red 
and Alcian Blue (see Figure 3.12). Both stained more noticeably at the periphery o f the 
pellet, although the Sirius Red stain was seen to stain a larger area around the pellet. The 
inside o f the pellet was not as well stained and look necrotic under light microscopy. There 
were not enough cells available to run a negative control o f PBSCs grown in a pellet, in 
normal DMEM+.
Figure 3.12 PBSC pellet after 21 days of culture in chondrogenic media, stained with 
Sirius Red (for collagen, red) and Alcian Blue (for GAG expression, blue). GAG- 
positive cells can be seen at the periphery of the pellet (see black arrows), as well as 
Sirius Red staining, which has penetrated deeper into the pellet (see white arrow).
1 2 6
3.4 Discussion
Due to injury (bone marrow aspiration), the results from the first part o f this study may have 
been affected, in addition to the effects o f blood loss. Future experiments require a group o f 
animals that only have induced blood loss, with no bone marrow aspirates. However, studies 
analysing the amount o f time required for the bone marrow to regenerate after bone marrow 
donation found that, in two patients, the turnover o f CD34+ ranged between 20-25% per day 
(Sinclair et al. 2000). However, from the bone marrow CFU-F counts, a significant difference 
was found between periods o f blood loss. The aspiration taken after 15% bleeding had much 
lower CFU-F than the previous aspirate, which had been taken 3-4 weeks previously. 
Although, according to bone marrow regeneration studies, the HSC population may have 
recovered (Sinclair et al. 2000), it is possible that the BMSC population has not as yet 
repopulated the marrow.
A 1% blood loss is akin to Class I, or minor haemorrhagic shock, and 15% blood loss can 
result in symptoms o f Class II shock (Wilson and Baskett 1992). Haemorrhagic shock can 
result in hypoxic metabolism. Rochefort et al. (2006) were able to show a 15-fold increase in 
the number o f CFU-F isolated from the peripheral blood after exposure to hypoxia conditions 
(50 kPa as opposed to normoxic conditions o f 101 kPa) for three weeks in a rat model. 
However, differences between this study and the one reported in this chapter are the different 
species used and the method o f inducing hypoxia, as well as the amount o f time before blood 
and bone marrow was retrieved. Interestingly, this increase in PBSCs did not relate to a 
change in the number CFU-Fs obtained from the bone marrow. Also, this change did not 
affect HSC levels in the bloodstream, as measured by counting the colony-forming units o f 
granulocyte-macrophages (GM), macrophages (M), erythroid (E), mixed (M ix) and burst- 
forming units-erythroid (BFU-E). In this chapter, bone marrow aspirates showed a significant
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decrease in CFU-F number after the different levels o f blood loss. This may be due to 
repeated aspirations (as mentioned above), whereas in the rat study by Rochefort et al. (2006) 
bone marrow was taken from femurs retrieved after sacrifice.
In one sample post-15% blood loss, CFU-F were observed after 7 days o f culture. However, 
at 14 days, these cells ceased proliferation and the display o f CFU-F-like characteristics, 
disputing the identity o f this CFU-F as a true stromal population. In future studies, it would 
be useful to retain these cells and characterise their cell surface marker expression to see i f  
they may be terminal cells o f the mesenchymal lineage.
The differentiation o f these cells down the osteogenic, adipogenic, and chondrogenic lineages 
suggests that these cells are multipotent. However, results from Chapter 2 showing a similar 
response o f HaCat (transformed keratinocytes) after stimulation with osteogenic 
supplements, brings into light questions regarding the effectiveness o f these methods for 
proving BMSC identity. The Ca/P ratio obtained in this chapter with the PBSCs was 2.14, 
whereas the normal ratio for hydroxyapatite is 1.67. This ratio is based on the formula for 
pure hydroxyapatite, Caio(PC)4)6(OH )2 (Posner 1969). Variations in the hydroxyaptite that 
was present, as well as the formulation o f different molecules such as calcium phosphates, 
could have altered the standard ratio, increasing it to 2.14. This could be investigated further, 
in future, by using techniques such as X-ray diffraction, in order to approximate the material 
structure (Posner 1969, Calafiori et al. 2007).
With regards to the adipogenic and chondrogenic differentiation, although some positive 
staining was seen (Oil Red ‘O ’ in the case o f adipogenesis, and Sirius Red/Alcian Blue in the 
case o f Chondrogenesis), it was not completely widespread or evenly distributed in the
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samples. Therefore only some o f the cells differentiated can be said to be phenoytpically 
adipocytic or chondrogenic. Use o f techniques such as RT-PCR for genes involved in BMSC 
differentiation, as well as cell surface marker analysis, may prove to be more useful and/or 
specific tools for confirming BMSC/PBSC identity. It should also be noted that no proper 
negative or positive controls were run alongside the PBSCs, unlike in Chapter 2, in order to 
check the efficacy o f staining for the osteogenic, adipogenic, and chondrogenic cell lines. 
This would be important for future work, in order to confirm the identity o f the differentiated 
cell lines.
Blood loss from the peripheral blood circulation did not appear to have as dramatic an effect 
on the numbers o f CFU-F obtained from the blood, as with the use o f G-CSF. It is possible 
that the repetitive aspirations in part I o f this study may have confounded the results, being an 
invasive procedure removing bone marrow from the animal. However, only one iliac crest 
was aspirated in the animals, which is only one source o f bone marrow out o f many. The 
hypothesis therefore has proved to be false. The theory behind this experiment was that 
physically removing blood from the circulation would cause mobilisation o f HSCs from the 
bone marrow to repopulate the blood cell population (via cell signalling due to blood loss 
and/or a change in oxygen pressure in the systemic environment (Antoniou et al. 2004)), and 
the remodelling o f the bone marrow microenvironment involving such proteins involved in 
HSC mobilisation, such as MMP-9 and elastases, might result in a drive to restore a HSC- 
MSC equilibrium, and subsequent BMSC mobilisation (Levesque et al. 2001; Sugimoto et al. 
2001; Baksh, Davies and Zandstra 2003). The fact that BMSCs can increase erythrocyte 
formation also provokes a look at the HSC-BMSC balance (DeGowin and Gibson 1981). 
This experiment took blood samples seven days post-bleeding, when in Part II o f this 
experiment, a large increase in CFU-F counts took place at 10 and 14 days post-G-CSF
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treatment, after haematological results had returned to pre-G-CSF values. It is possible that 
BMSCs were only released from the bone marrow or detectable at a later time point than was 
investigated.
Regarding G-CSF-induced bone marrow cell mobilisation, the rise in WBC, neutrophil, 
lymphocyte, and monocyte counts (HSCs and cell types originating from CD34+ HSCs) after 
the 5 days o f G-CSF treatment has been observed in many studies (Fischmeister and Gadner 
2000; Takeyama and Ohto 2004). A fter two weeks, the levels o f these cell counts returned to 
normal. In 3/3 animals, this return to normal levels coincided with a significant increase in 
CFU-F counts and the growth o f PBSCs with a fibroblastic morphology. A  significant 
bivariate correlation between WBC levels and CFU-F counts was demonstrated, which was 
not significant when time was a constant. The results for two weeks post-G-CSF have a lower 
number o f samples in the group. Therefore, it is important to repeat this experiment to 
increase the sample size to comparable levels (a minimum o f N =  6). This may result in the 
partial correlation becoming significant. Clincally, blood is collected for HSC donation 4 
hours after the fu ll G-CSF treatment (Watts et al. 1998), however the number o f PBSCs 
isolated did not appear highest at this time.
It is possible that, after mobilisation o f HSCs into the peripheral bloodstream, the 
remodelling o f the extracellular matrix associated with G-CSF-mobilised HSC release 
eventually caused a shedding o f the bone marrow stroma, and subsequent release o f BMSC- 
like cells. Interestingly, it has been shown that constant treatment with G-CSF can cause 
osteopenia in patients w ith congenital neutropenia (Sekhar et al. 2001). In a mouse model o f 
sustained HSC mobilisation for 3 weeks, mice showed a significantly increased 
osteoclast/endosteum ratio. In these cases, an increase in osteoclast activity due to the release
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o f monocytes into the peripheral blood has been indicated as a possible mechanism. 
However, work by Semerad et al. (2005) showed that upon constant G-CSF stimulation, mice 
with a mutation in their G-CSF receptor displayed a reduction in CXCL12/SDF-1 expression 
after treatment with G-CSF for 5 days, which was related to a decrease in osteoblast number, 
rather than a decrease in CXCL12 expression. G-CSF was administered at a much higher 
concentration than used in this study (100-250 pg/kg per day, or a 20-50 times the dose given 
clinically). This corresponded with histomorphometry and osteocalcin results, which 
indicated a noticeable reduction in osteoblasts lining the endosteum 3 to 4 hours after the last 
dose o f G-CSF. Osteoblasts are considered to be a critical factor in the bone marrow 
microenvironment (Calvi et al. 2003; Taichman and Emerson 1998). These authors suggested 
that through an indirect mechanism, osteoblast activity and/or CXCL12 expression is 
downregulated following G-CSF administration, which in turn would promote HSC release.
It is possible that, with constant HSC mobilisation, a readjustment in the HSC-BMSC 
equilibrium in the bone marrow causes a release o f BMSCs that no longer interact w ith HSCs 
via adhesion molecules and growth factors. There is experimental evidence to suggest that 
HSCs influence BMSC growth in v i t ro , and that cross talk exists between the two cell types 
(Baksh, Davies and Zandstra 2003). BMSCs could possibly be attracted out o f the bone 
marrow into the circulation via interactions with HSCs, or shed as a result o f the lack o f 
interactions with HSCs. Future work should further investigate the relationship between HSC 
and BMSC release into the peripheral blood, by looking at cell levels at different time points, 
as well as their proliferative and differentiation potential. Another interesting point o f 
investigation could be to try to reverse this mobilisation process, for example, to observe any 
changes in the HSC-BMSC steady-state balance after an intravenous infusion o f BMSCs or 
HSCs, by quantifying the numbers o f these cells over time, from the peripheral blood or bone 
marrow. This could possibly answer questions as to whether or not it is the presence o f HSCs
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in the bone marrow, or the process o f bone marrow remodelling, or both events, that are 
responsible for the delayed detection o f PBSCs after HSC mobilisation. Investigating the 
microenvironment o f the bone marrow after G-CSF treatment compared to untreated sheep, 
looking at the morphology, and HSC and BMSC levels may also give some insight.
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CHAPTER FOUR
THE SURVIVAL AND PROLIFERATION OF BMSCS 
IN FIBRIN GLUE AND THE USE OF A SPRAY 
SYSTEM FOR THE APPLICATION OF CELLS TO
IMPLANT SURFACES
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4.1 Introduction
In Chapters 2 and 3 o f my thesis, ovine bone marrow stromal cells (oBMSCs) and peripheral- 
blood derived stromal-like cells (PBSCs) were isolated, expanded, and characterised, w ith the 
purpose o f using these cells to augment bone growth around orthopaedic implants. For 
effective application o f these cells to an implant surface, a sprayable, biodegradable matrix 
would be best.
As introduced in Chapter l,  fibrin glue is a natural scaffold that is derived from human 
plasma and is biodegradable, with a half-life o f 2 1 days (Baxter Healthcare Corporation
(R)2006). Baxter’s Tisseel is a fibrin matrix that has been previously applied in combination 
with stem cells in a femoral defect model in rats undergoing chemotherapy (Lee et al. 2005). 
In this study, filling  the defect with only fibrin using a cannula promoted less bone growth 
than a combination o f BMSCs and fibrin. Another application in orthopaedics would be to 
spray cells within fibrin directly onto implant surfaces. Sprayed fibrin is used routinely, 
without cells, in surgery adjunct to haemostasis or in other surgical situations where sutures 
or cautery should not be used. A previous study using keratinocytes sprayed in cell culture 
medium found no negative effects on cell viability following spraying (Grant et al. 2002). 
The effect o f spraying BMSCs in fibrin on viability, proliferation and metabolic activity has 
not previously been determined. Additionally, although human BMSC activity has been 
previously shown to vary according to different thrombin and fibrinogen concentrations 
(Bensaid et al. 2003), this has not been tested with oBMSCs. This is an essential first step 
before oBMSCs can be used in a fibrin glue spray for bone tissue engineering in a large 
animal model.
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There are a variety o f assays that can be used to test the viability, metabolic activity and 
proliferation o f cells after suspension in fibrin glue or after spraying in fibrin glue. To test 
viability in a gel scaffold, the most appropriate method to use is the fluorescent Live/Dead 
stain with confocal microscopy, which can be used to quantify the number o f live and dead 
cells in fibrin glue after spraying. Confocal microscopy allows the visualisation throughout 
many optical sections, in contrast to normal microscopy. This feature makes it suitable for 
scanning three-dimensional samples.
The Live/Dead assay uses two molecules, calcein AM  and ethidium homodimer. These two 
dyes stain live or dead cells, respectively (Molecular Probes 2001). Calcein A M  is a 
nonfluorescent, cell-permeable molecule, which is metabolised by live cells to the fluorescent 
molecule calcein, visible in the FITC range (excitation wavelength 495 nm; emission 
wavelength 515 nm). Ethidium homodimer can enter cells with damaged membranes, 
whereas it cannot enter live cells w ith undamaged plasma membranes, and can bind to 
nucleic acids within the cell, where its fluorescence is then enhanced forty times (excitation 
wavelength 495 nm; emission wavelength 635 nm, Molecular Probes 2001; L3224, 
Invitrogen, Paisley, UK). These stains can also be visualised in three-dimensional (3D) 
constructs using confocal microscopy (Kauth and Kapperich 2005).
To measure cell metabolism, a “ redox”  indicator, such as Alamar Blue™, can be used. 
Alamar Blue™ changes colour from blue/non-fluorescent to red/fluorescent after being 
reduced from an oxidised state (Fields and Lancaster 1993). This “ redox”  reaction is related 
to metabolic activity and cell growth, where a reductive environment indicates cell growth. It 
is reduced as a result o f it acting as an intermediate in the electron transport chain (ETC) o f 
the cells. This is in contrast to other assays, such as the MTT assay (Korda et al. 2006), which
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interrupts the flow o f electrons through the chain, resulting in a shutdown o f the ETC and 
eventually, cell death (Biosource™ International Inc.).
To test for differences in cell proliferation, measuring the rate o f new DNA synthesis can be 
accomplished by quantifying the rate o f radioactive thymidine incorporation in a certain 
period o f time (Lee et al. 2005). Radioactive thymidine-H3 is added to the culture media o f 
cells, and incorporated into nacently synthesised DNA (Maurer 1981) during the S phase o f 
the eukaryotic cell cycle (Voet and Voet 1995).
The hypothesis of this study is that oBMSCs would still be viable and retain the ability 
to proliferate following suspension in Tisseel® fibrin glue, and after application by 
cannula or by spraying.
The aims and objectives o f this chapter are to:
1) To observe the viability, metabolic activity, proliferation, and morphology o f 
oBMSCs in fibrin glue when applied using a cannula or a pressurised spray, using in 
vitro  assays.
2) To determine the best pressure at which to spray oBMSCs in fibrin glue onto surfaces 
by making observations on the ability o f fibrin to coat surfaces, and by measuring the 
survival o f cells with the Live/Dead assay.
3) To investigate the effects o f different thrombin concentrations (500 IU2, 250 IU 2, and 
100 IU 2) on oBMSC metabolic activity, when suspended in fibrin glue, using the in 
vitro  Alamar Blue™ assay.
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4.2 Methods and Materials
4.2.1 Suspension of oBMSCs in fibrin glue
Ovine BMSCs were isolated and expanded in culture as previously described in Chapter 2. 
To test the proliferation o f the cells in fibrin, cells were trypsinised o ff tissue culture plastic 
after three passages (P3), centrifuged to form a pellet and were resuspended in the thrombin 
component o f fibrin glue at a concentration o f 1.0 x 106 cells/mL.
The fibrin glue used in this study was Tisseel® fibrin glue (Baxter Health Care Ltd., 
Newbury, Berkshire, UK). This glue consisted o f four components in their commercial 
concentrations: a vapour-heated Tisseel^ powder component (100-130 mg protein, o f which 
approximately 75-115 mg is human fibrinogen); a bovine aprotinin solution; a vapour-heated 
human thrombin powder (45-55 mg protein containing about 500 IU 2 active bovine 
thrombin); a calcium chloride solution. The Tisseel® fibrinogen component was reconstituted 
in the aprotinin solution after a 10-minute incubation at 37°C in a device specifically created 
to heat fibrin components (Fibrinotherm , Baxter Health Care Ltd., Newbury, Berkshire, 
UK). Ovine BMSCs were put in a universal container and spun in a centrifuge at 2000 rpm 
for 5 minutes. The supernatant was then discarded and the pellet at the bottom o f the 
universal resuspended in the 1.0 mL o f reconstituted thrombin. Each component was then 
loaded into a 1.0 -  2.0 mL syringe (included in the Tisseel package) and snapped into a 
dual-syringe holder with attached plunger device.
To make plugs, a cannula was fixed to the end o f the dual-syringe system and the oBMSC- 
fibrin combination ejected to produce 0.1 mL plugs o f fibrin. These were transferred to 12- 
well plates (Coming, Coming, N.Y., USA), covered with 1 mL o f standard DMEM+ and 
cultured using standard tissue culture techniques.
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4.2.2 Spraying oBMSCs in fib rin  glue and fib rin -ce ll plug form ation
To spray the fibrin glue using this system, a Duploject (Baxter Health Care Ltd., Newbury, 
Berkshire, UK) spray set was used, which consisted o f sterile plastic tubing which connected 
to the a dual-syringe tip, which allowed air to come into contact with the fibrin components 
as they came out o f the syringe. The other end o f the tubing was connected to a Fibrijet® 
(Micromedics, Inc., St. Paul, Minnesota, USA) pressure gauge, which was connected to a 
pressure pump (Figure 4.1). The Fibrijet was set to 0.5, 1.0, or 1.5 Atm, and the plungers o f 
the fibrin system pressed to allow release o f sprayed fibrin onto the dry tissue culture surface 
(6 -well plates; Orange Plastics, Triple Red Laboratory Technology, Long Crendon, 
Buckinghamshire, UK), without any tissue culture media present. The area o f each well was
9.03 cm2. 2 ml o f DMEM+ (control media) was added to each well afterwards.
n/off switch
. Foot pedal for
pressure qauqe
Figure 4.1 Equipment used for spraying fibrin , including an air compressor and a 
pressure gauge, which is controlled by a foot pedal (see arrows).
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4.2.3 The effect of fibrin glue on oBMSC viability, metabolism, 
proliferation, and morphology when applied using a spray or 
cannula
4.2.3.1 Viability
To assess the viability or death o f cells after spraying the Live/Dead assay was used. For this 
experiment, 2.0 x 106 cells/mL were suspended in thrombin and combined with fibrinogen, as 
described above, and 0.05 mL o f each component was applied using a cannula, or with a 
pressurised spray, onto the tissue culture surface o f 6 -well plates (6 -well plates (Orange 
Plastics, Triple Red Laboratory Technology, Long Crendon, Buckinghamshire, UK),. Cells 
were then incubated with DMEM+ with l .0 pM calcein and ethidium homodimer each, for 
one hour. After this time, samples were rinsed in PBS and viewed under a confocal 
microscope (Leica SP2 AOBS system, Leica Microsystems UK Ltd., M ilton Keyes, 
Buckinghamshire, UK), using Leica Confocal Software (LCS version 2.61, Leica 
Microsystems UK Ltd., M ilton Keyes, Buckinghamshire, UK) in 200 pm-thick sections, and 
were reconstructed in a 3D overlay using LCS Lite (version 2.61, Leica Microsystems UK 
Ltd., M ilton Keyes, Buckinghamshire, UK) software. Six samples were analysed per group. 
The four groups were: 1) oBMSCs suspended in fibrin glue, applied with a cannula; 2) 
oBMSCs suspended in fibrin glue, which was sprayed at 0.5 Atm; 3) oBMSCs sprayed in 
fibrin glue at 1 Atm; and 4) oBMSCs in fibrin glue, sprayed at 1.5 Atm. The percentage o f 
live cells was calculated by dividing the number o f live (calcein AM  positive) cells by the 
total number o f live and dead (ethidium homodimer-positive) cells. Results were compared to 
oBMSCs in itia lly  plated at the same concentration, but on tissue culture plastic and without 
fibrin glue.
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4.2.3.2 Metabolic Activity
To observe the effect o f fibrin glue on the cells’ metabolic activity, the Alamar Blue™ assay 
was used on oBMSCs in fibrin glue applied with a cannula or sprayed at 0.5, 1.0 or 1.5 Atm 
o f pressure. After 4 hours o f sample incubation with Alamar Blue™, 100 pL from each 
Alamar Blue™-reacted sample was used and analysed as described in 2.2.3.5. These results 
were compared to oBMSCs applied at the same concentration without fibrin glue.
4.2.3.3 Proliferation
A thymidine-H3 incorporation assay was used to determine the proliferation o f oBMSCs in 
fibrin glue when applied via a cannula or sprayed at different pressures. For this assay, either 
0.1 mL o f fibrin was cannulated onto the surface or sprayed at 1 Atm onto the well surface o f 
6-well plates (Orange Plastics, Triple Red Laboratory Technology, Long Crendon, 
Buckinghamshire, UK), and covered with 2 mL o f standard DMEM+. Proliferation was 
measured from 0-24 hours, 24-48 hours and 48-72 hours. For the 0 - 2 4  hours group, 1.0 pL 
o f thymidine-H3 (GE Healthcare, Giles, Buckinghamshire, UK) was added for each 1.0 mL 
o f media, and placed in a designated standard humidified incubator for 24 hours. The assay 
was repeated in triplicate for each treatment and results were compared to oBMSCs seeded at 
the same cell numbers as the cells suspended in fibrin, but cultured without fibrin glue.
After each 24-hour time point, cells were lysed and processed as outlined in 2.2.3.6, with an 
additional step: to break down the fibrin, samples were then freeze-dried overnight, 
resuspended in 0.5 mL o f 1% papain in PBS and incubated at room temperature overnight on 
a gentle shaker.
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4.2.3.4 Morphology and distribution of oBMSCs in fibrin glue plugs
To observe the morphology and distribution o f oBMSCs in fibrin glue, six plugs were formed 
using the commercial concentrations o f thrombin and fibrinogen (see 4.2.1) and cultured for 
2 weeks, then fixed for wax histology in 10% formal saline. Samples were dehydrated in 
increasing concentrations o f industrial methylated spirit (IMS), from 30% to 100% IMS, 
cleared in xylene, infiltrated with paraffin wax and embedded. Wax-embedded samples were 
mounted on a sledge microtome and thin (4-5 pm) sections cut, which were then mounted 
onto glass slides. Specimens were de-waxed in xylene and stained with haematoxylin (a 
nuclear stain) and eosin (counterstain).
4.2.4 The effect of thrombin concentration on oBMSC activity
Different concentrations o f thrombin were tested for their effects on cell proliferation. 
Thrombin was either used undiluted (500 IU 2- Tisseel^’s commercially available 
concentration) diluted with phosphate buffered saline (PBS) to ha lf (250 IU2) and one-fifth 
the original concentration o f thrombin (100 IU 2). Ovine BMSCs were isolated and expanded 
in culture as previously described in Chapter 1. For this assay, 2.0 x 106 oBMSCs/mL were 
suspended in thrombin. Using the cannula-ended dual syringe, 0.05 mL o f each component 
was ejected to produce 0.1 mL plugs o f fibrin glue. These plugs were cultured in 12-well 
tissue culture plates with 1.0 mL o f DMEM+. An Alamar Blue assay was carried out at 1,3, 
and 9 days to assess cell activity. For each time point and each concentration o f thrombin, six 
samples were tested.
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4.2.5 Data analysis
Raw data was entered into SPSS 11 for statistical analysis. Data normality was determined 
with the Kolmogorov-Smirnov test. Parametric data for two groups was tested with the 
student t-test and non-parametric data from two groups were compared using the Mann- 
Whitney U test for independent samples. The one-way analysis o f variance (ANO VA) test 
was used to compare parametric results from more than 2 independent groups. Results were 
considered significant when P<0.05.
4.3 Results
Fibrin application at 1.0 and 1.5 Atm was visibly easier, smoother and more evenly 
distributed when compared to spraying fibrin at 0.5 Atm, where the fibrin did not have 
enough pressure to properly form an aerosol.
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4.3.1 The effect of fibrin glue on oBMSC viability, metabolism , 
proliferation and m orphology when applied using a spray or 
cannula
4.3.1.1 Viability
There was no significant difference in the viability o f cells after spraying at 0.5 Atm, 1.0 
Atm, or 1.5 Atm in fibrin glue. Calcein was spread intracellularly, while the ethidium was 
visualised in the nucleus/nucleolar region o f the cell. In all samples, some cells were seen to 
stain positively for both calcein A M  and ethidium homodimer, suggesting plasma membrane 
damage that allowed ethidium penetration or cell death w ithin minutes after spraying (Figure 
4.2). The mean percentage o f live cells in the groups sprayed at 1.5 Atm was 52.26 ± 5.08 %, 
while for the cells applied by a cannula, the mean percentage o f live cells was 59.82 ± 13.36 
% (Figure 4.3, Table 4.1). There was no significant difference between all groups (p > 0.05 in 
all comparisons).
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Figure 4.2 An example o f the sectional images obtained fo r the live/dead stain using 
confocal microscopy (20x magnification). In  this example, all o f the optical sections have 
been layered so that all cells in the fib r in  gel can be visualised. The green cells are those 
stained positively w ith calcein A M  (live), and is spread throughout the cell cytoplasm. 
Red cells are those stained w ith ethidium  homodimer (red), which intercalates w ith 
nucleic acids and therefore is mostly visualised in the cell nuclei. A double labelled-cell 
is noted w ith arrows.
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Figure 4.3 Chart indicating the percentage of live (Calcein AM  positive) oBMSCs in 
fib rin  glue after being ejected from a cannula or using a spray, at 0.5 Atm, 1.0 Atm, and 
1.5 Atm. The total number of cells was calculated by dividing the number o f live cells by 
the total number of live and dead (ethidium homodimer positive) cells.
Cannula 59.82 ± 13.36
0.5 Atm Spray 56.89 ±5.37
1.0 Atm Spray 55.91 ±5.05
1.5 Atm Spray 52.26 ±5.08
Table 4.1 Table showing the mean percentage and standard error of live cells in each 
group.
All groups: n=6
Canula 0.5 atm Spray 1.0 atm Spray 1.5 atm Spray
Group
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4.3.1.2 Cell metabolism
The lowest cell metabolism (indicated by the absorption o f the reduced Alamar Blue™ 
product) was observed just after cannulating or spraying the samples (14.54 ± 0.58 and 14.40 
± 0.27, respectively, see Figure 4.4 and Table 4.2). There was no significant difference 
between the three groups (oBMSCs fibrin applied using a cannula, or spray at 1.0 Atm) at all 
time points 0, 2, 4, and 7 days after spraying the oBMSCs in fibrin glue (p=1.00, 0.87, 0.15, 
and 0.55, respectively), although there was a significant difference after 1 day post-spraying 
(p=0.00). Cells were observed to migrate out o f the fibrin glue gel onto the tissue culture 
plastic in all groups. A ll differences in absorbency between time points in each group were 
significant (p<0.03) except between days 2-4, 4-7, and 1-7 in the canula group, and between 
2-4, 4-7, 1-4, 1-7 and 2-7 in the 1.0 atm spray group, where p>0.05.
p=0.87
p=0.15
p=0.55
p=0.00
n=6
p=1.00
Day 4
I Canula 1.0 Atm
Figure 4.4 G raph  illustrating results of A lam ar Blue™ assay, when oB M SC s in fib rin  
were either applied w ith a cannula or spray at 1 A tm . This assay, which is an indicator 
of cell activity, was tested just a fter application (D ay 0), and at days 1, 2, 4, and 7 after 
application.
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Cannula 14.54 ±0.58 16.39 ±0.41 21.61 ± 1.43 19.63 ± 1.38 19.13 ±2.25
1.0 Atm 14.40 ±0.27 20.06 ± 0.39 21.96 ±0.56 21.32 ± 1.13 20.44 ±0.71
Table 4.2 Table showing Alamar Blue™ absorption measurements over the seven days. 
4.3.1.3 Proliferation
Samples grown without fibrin glue (oBMSCs only) appeared to have less proliferation than 
those samples in fibrin glue applied with a cannula at 24 and 48 hours (35.95 ± 4.74 Bq/pg 
DNA/hour and 36.20 ± 11.06 Bq/pg DNA/hour in the oBMSC-only group; 79.33 ± 8.61 
Bq/pg DNA/hour and 70.66 ± 7.73 Bq/pg DNA/hour in the cannula group). Cell proliferation 
was reduced after 24 hours in samples that had been sprayed, compared to cannula-applied 
controls (63.93 ± 6.00 Bq/pg DNA/hour at 24 hours, 6.61 ± 0.90 Bq/pg DNA/hour at 48 
hours and 7.56 ±1.81 Bq/pg DNA/hour at 72 hours; see Figure 4.5, Table 4.3, and Table 
4.4). The difference in values were significant at 24 and 48 hours between the oBMSC-only 
and cannula groups (p = 0.01, p=0.03 at 24 and 48 hours, respectively), at 24 hours between 
the oBMSC-only and spray groups (p=0.02), and at 48 hours between the cannula and spray 
groups (p=0.03). Cell proliferation was reduced in all samples at 72 hours (19.32 ± 11.89 
Bq/pg DNA/hour; 3.78 ± 0.66 Bq/pg DNA/hour; and 7.56 ±1.81 Bq/pg DNA/hour, in the 
oBMSC-only (control, cannula and spray groups, respectively). There was no significant 
difference between groups at this time point (p > 0.05 for all group comparisons). A 
significant difference in proliferation between 48-72 hours in the canula group (p=0.02) and 
between 24-72 hours in the spray group (p<0.01) was observed.
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Figure 4.5 Bar graph comparing 3H-thymidine incorporation (indicative of 
proliferation) between oBMSCs grown on tissue culture plastic, oBMSCs suspended in 
fib rin  glue, and oBMSCs sprayed in fib rin  glue, at 0-24 hours (24 hours), 24-48 hours 
(48 hours) and 48-72 hours (72 hours) after the intitia tion of culture.
oBMSC-only 35.95 ±4.74 36.20 ± 11.06 19.32 ± 11.89
Cannula 79.33 ±8.61 70.66 ± 7.73 3.78 ±0.66
Spray 63.93 ± 6.00 6.61 ±0.90 7.56 ± 1.81
Table 4.3 Table showing oBMSC proliferation for all groups at the three time points.
oBMSC-only-Cannula 0.01 0.03 0.48
oBMSC-only-Spray 0.02 0.22 0.66
Cannula-Spray 0.22 0.03 0.14
Table 4.4 Table of P-values between all three groups at each time point.
148
4 . 3 . 2  M o r p h o l o g y  a n d  d i s t r i b u t i o n  o f  o B M S C s  i n  f i b r i n  g l u e
Wax-embedded sections o f samples that were fixed after 2 weeks o f culture, and stained with 
H&E, showed small numbers o f cells clustered in the middle o f the plugs, with elongated 
cells being present at the periphery (Figure 4.6). The concentration o f cells was extremely 
low, when considering the number seeded into the original construct. Around cells, there 
appears to be a cleared area where fibrin was stretched or degraded by the cell.
♦
50 jxm
Figure 4.6 Images o f histological sections o f oB M SC s embedded in fib rin  glue and 
cultured fo r 2 weeks. Photos w ere taken at lOx m agnification. oB M SC s can be seen 
along the periphery  o f the fib rin , indicated by arrow s. H aem otoxylin  (p u rp le ) stains cell 
nuclei, and eosin (p in k ) is the counterstain (p robab ly  fib rin  glue). A ro u n d  cells, the 
fib rin  appears to be stretched or degraded.
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4 . 3 . 3  T e s t i n g  t h e  e f f e c t  o f  t h r o m b i n  c o n c e n t r a t i o n  o n  o B M S C  a c t i v i t y  
u s i n g  t h e  A l a m a r  B l u e  a s s a y
Ovine BMSCs were metabolically active in the fibrin plugs for the 9-day period o f the
experiment. The mean absorption o f the ovine BMSCs at different thrombin concentrations at 
day 1 were: 41.80 ± 8.41 (standard error) with no thrombin dilution (500 IU2), 33.50 ± 5.91 
with at 250 IU2 (half thrombin dilution), and 27.94 ± 5.68 at 100 IU2 (a fifth dilution). On 
day 3, the readings were 46.53 ± 15.01 with no dilution, 40.72 ± 8.41 at 250 IU2, and 
30.45±5.86 at 100 IU2. On day 9, the mean absorption were 48.71 ± 14.88 in the plugs with 
undiluted thrombin, 54.73 ± 11.89 at 250 IU2 o f thrombin, and 39.18 ± 10.52 at a fifth 
dilution. Figure 4.7 illustrates these results in a bar graph.
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Figure 4.7 G rap h  indicating o B M S C  metabolic activ ity  when suspended in d ifferen t 
concentrations o f fib rin , which was achieved by varying  the th rom bin  concentration. 
Although at a lower density o f fib rin  (w ith  the lowest th rom bin  concentration), the 
A la m a r Blue™  absorption is low er than the other groups at day 1, 3 and 9. This  
difference was not statistically significant.
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Comparing the different dilutions o f thrombin using one-way ANOVA, there was no 
significant difference in the proliferation o f the cells in the plugs (day 1, p=0.38; day 3, 
p=0.30; day 9, p=0.69). Cells were observed to migrate out o f the fibrin onto the tissue 
culture plastic, and although there appeared to be no difference in the migration between 
groups, this was not quantified. W ithin each group, there were no significant differences 
between time points (p>0.05 in all cases).
4.4 Discussion:
This chapter has shown that after the spraying o f oBMSCs in fibrin glue at 1 Atm o f pressure, 
cells are still viable, active and proliferative. There was no significant difference observed in 
the spraying o f fibrin glue at 0.5, 1.0 or 1.5 Atm o f pressure, although there was a difference 
in proliferation at 48 and 72 hours, in cells that were sprayed compared to those that were not 
sprayed. However, the results show that, overall, 1.0 Atm is the lowest pressure at which a 
well-distributed coating o f fibrin glue can be achieved and so is the best pressure to be used.
Fibrin is a natural component o f the wound healing system. The enzyme, thrombin, which in 
the presence o f Ca2+ ions catalyses the fibrinogen precursor to fibrin molecules, which then 
assemble into a gel, affects the density o f fibrin fibres in the 3D matrix. Although ovine 
BMSCs appear to proliferate in fibrin (at the commercial concentration) for 14 days, there 
was a possibility that different densities o f gel would be more beneficial to cell growth than 
others. However, in this study no differences were found in cell proliferation with cells 
grown in fibrin w ith no diluted thrombin or in fibrin with thrombin diluted by a ha lf or by a 
fifth. This is similar to results found by Catelas, Sese and Helgerson (2004), which showed 
that the concentration o f thrombin did not effect the proliferation o f hBMSCs to the same 
extent as the fibrinogen concentration. This is despite the fact that a lower thrombin
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concentration results in a fibrin mesh structure with fibrils o f a larger diameter and larger 
pore size (>5 pm at a 5 IU thrombin), and that Tisseel™ contains significantly more 
fibrinogen than human plasma (75-115 mg/mL versus 2-4 mg/mL in plasma; Exner et al. 
1979). The thrombin concentrations used in this experiment was at the commercial 
concentration o f 500 IU, where the mesh structure would develop with thinner fibrils and 
smaller pores (<1 pm, (Baxter Tissue Engineering Guide). This is in contrast to a study by 
Bensaid et al. (2003), which found that a thrombin concentration o f 100 pm was more 
optimal that a concentration o f 500 pm. This experiment also found that fibrin, in vitro, was 
optimal for hMSC growth at 20% o f the normal fibrinogen levels used commercially. 
However, it should be noted that a much smaller concentration o f cells was used in this study 
(5x l04 cells/mL) when compared to our study ( lx lO 6 cells/mL).
Cells were observed to migrate out o f the fibrin  glue scaffold at all thrombin concentrations 
and when samples had been sprayed as well. Promoting cell proliferation and migration is an 
observed property o f fibrin glue (Becker, Domschke and Pohle 2004; Cox, Cole and Tawil 
2004; Brown 1993). However, from the thymidine-H3 incorporation assay results, it appeared 
that proliferation in both fibrin groups was lower than in the group that was grown directly on 
tissue culture plastic. The effects o f nutrient gradients, from the supplemented media, and 
oxygen diffusion through the gel could have influenced the results, as sprayed fibrin applied 
as a thinner finely applied layer, may differ in these properties from cells grown in a 
monolayer, or those cells applied to the cell surface in fibrin using a cannula. Migration o f 
cells, as well as differences in proliferation may have resulted. Despite the differences in 
proliferation, however, the cells were always metabolically active in fibrin glue, according to 
my Alamar Blue* data, and the activity levels were not shown to greatly increase over 7 
days. The unaccounted cell proliferation in the thymidine assay, as discussed in Chapter 2,
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due to S-phase cells already being present when the thymidine-H3 had been added to cell 
culture media, may also have affected the results. In addition, cell number was not accounted 
for in the Alamar Blue* assays, meaning that the results, which were reported in this chapter 
to reflect cell metabolism, may have been confounded by the increase in cell numbers over 
time, as the cells proliferated (see Chapter 2 Discussion).
A quantitative measure o f cell migration out o f gels from these various groups (different 
concentrations o f thrombin, sprayed fibrin) could be visualised using time-lapse video 
microscopy (Knapp, Helou and Tranquillo 1999). This migration is the likely explanation for 
the lack o f cells viewed in the histological specimens. Modifying the fibrin w ith integrin- 
binding molecules such as ROD peptides could possibly modify cell migration from the gels 
(Meinhart 2005; Yang et al. 2004). In future, scanning electron microscopy (SEM) o f 
oBMSCs in varying fibrin densities may also give a visual perspective on cell survival, 
spreading, and morphology.
In future experiments, it would be interesting to grow oBMSCs in fibrin glue on non-treated 
tissue culture plastic, or tissue culture plastic that has been specially treated such as Ultra 
Low Attachment coated polystyrene, produced by Coming, Coming, N.Y., U.S.A.), which is 
coated with a hydrogel layer that prevents cell attachment. Using the Alamar Blue assay, we 
have shown that the spraying o f BMSCs does not affect its viability or proliferation. One 
dermal tissue engineering study using this system with epidermal cells had similar Trypan 
Blue results (Cohen, Bahoric and Clarke 2001). However they did not attempt a viability 
assay within fibrin glue itself (their spray technique was tested on cells in culture media).
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In order to make more detailed observations o f the effects and viability o f BMSCs suspended 
and sprayed in fibrin, it would be useful to look at the histology o f the cells in fibrin, sprayed 
or unsprayed, as well as electron microscopy, 1) in itia lly after spraying the cells in fibrin 
glue, as well as 2) making more macroscopic observations o f the different plugs after culture, 
at different thrombin concentrations, and after being sprayed at different concentrations. Lee 
et al. (2005) showed that rat BMSCs were viable and healthy in morphology after being 
suspended in fibrin glue, using histology, scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM); however such work has not been repeated using 
ovine BMSCs.
Whether or not the shear stress and flu id flow experienced by the cells in fibrin instigates an 
effect on the cells differentiation or programmed cell death (apoptotic) pathways is not 
known. Shear stress has been shown to induce osteocalcin expression in rat BMSCs (Kreke 
and Goldstein 2005) and may aid in the osteogenic differentiation o f cells. In the Live/Dead 
experiment presented in this chapter, some cells appeared to undergo cell death minutes after 
spraying, having first reacted with the “ live”  cell marker calcein AM  to produce fluorescent 
calcein molecules. Whether or not this is apoptosis or necrosis due to irreversible cell damage 
could be determined by using apoptosis assays such as the terminal transferase dUTP nick 
end labelling (TUNEL) assay, which detects the DNA degradation step in apoptotic cells 
(Gavrieli, Sherman, and Ben-Sasson 1992), or protein detection methods like 
immunohistochemical staining or western blotting for apoptotic markers such as Annexin V, 
Bax or p53 (Loewe et al. 2006; Basu and Haidar 1998). Also, as cell death due to apoptosis 
often takes longer than 1 hour to initiate and progress, the 1 hour time point for the 
Live/Dead assay might not have been sensitive enough to detect apoptosing cells. Therefore, 
there may have been unrecorded cell loss after spraying, which should be taken into account
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in the future. However, those oBMSCs that do survive actively metabolise and proliferate, as 
shown using Alamar Blue and Thymidine-H3 incorporation. Spraying did affect cell 
metabolism after the first 24 hours post-spraying (Results- 4.3.2.3), but cells appear to have 
recovered by Day 2 o f the experiment. To look at the effects o f spraying in fibrin glue on 
oBMSC osteogenic differentiation, one could perform RT-PCR detection o f early 
osteoblastic genes such as cbfa-1 or osterix.
Currie et al. (2003) found no significant difference between spraying keratinocytes onto 
freshly debrided porcine wound sites in fibrin glue or without (cells suspended in culture 
medium) on the epithelial areas after three weeks in vivo.
In conclusion, oBMSCs were viable and were able to metabolise and proliferate in fibrin 
glue. Spraying at 1.0 Atm gave the best result in terms o f control and even distribution o f 
fibrin onto surfaces, and did not significantly affect cell viability or metabolism. In the next 
two chapters, the oBMSC-fibrin spray system described in this chapter is used in an attempt 
to encourage new bone formation around orthopaedic implants in vivo , by spraying oBMSCs 
onto implant surfaces.
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CHAPTER FIVE
AUGMENTING THE FIXATION OF MASSIVE 
IMPLANTS USING BONE MARROW STROMAL
CELLS
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5.1 Introduction
For treatment o f bone tumours o f the extremities, endoprosthetic replacements are a viable 
alternative to amputation and the preferable option in modem surgery. As described in 
Chapter l , bone tumour replacements have a significantly lower survival rate when compared 
to total hip replacements (Blunn et al. 2000). The main cause o f this high failure is aseptic 
loosening. In the case o f massive bone tumour implants fixed within the femoral cavity using 
cemented intramedullary stems, excessive bending and torsion within the fixation causes 
loosening and failure o f the implant (Unwin et al. 1996; Roberts et al. 1991). Revisions are 
not as successful as a primary replacement and sometimes an amputation is required.
Previous chapters o f my thesis showed that cultured oBMSCs can be isolated from ovine 
bone marrow and are viable and proliferate w ithin fibrin glue, with or without spraying at 1 
atm. Earlier work has showed that rat BMSCs, when implanted in vivo, can significantly 
increase bone formation within a femoral defect in chemotherapy-treated and non­
chemotherapy-treated rats. The aim o f this chapter is to investigate whether or not spraying 
oBMSCs in fibrin glue w ill increase bone formation and attachment to the HA-coated collars 
o f a massive bone tumour replacement in an ovine model.
157
The hypotheses of this chapter are that:
1) By applying BMSCs to the surface of massive implant HA-coated collars, bone 
growth and bone-implant contact will be increased, compared to untreated and fibrin 
glue-treated controls.
2) Increasing the number of BMSCs will result in greater new bone formation around 
the collars.
The aims and objectives o f this chapter are to:
1. Spray oBMSCs at two different concentrations (2 x 106 cells and 10 x 106 cells) in 
fibrin glue onto the HA-coated collars o f tibial midshaft replacements in an ovine in 
vivo model;
2. Measure the area o f new bone growth around the implants using radiography, and 
compare these results to untreated implant controls and those implants treated with 
fibrin glue only;
3. Observe and measure the area o f bone growth around the centre o f each implant collar 
using histological techniques;
4. Measure the bone-implant contact at the centre o f each implant collar;
5. Measure the percentage porosity o f the new bone growth adjacent to implant collars 
as an indicator o f bone loading; and
6. Measure the amount o f fibrous tissue adjacent to the implant collars.
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5.2 Materials and Methods 
5.2.1 oBMSC Isolation and Expansion
OBMSCs were isolated as previously described (See Chapter 2 Materials and Methods). 
Cells were expanded to passages 3 and 4 for use in this study.
5.2.2 Preparation of BMSCs in Fibrin Glue
The fibrin glue used was Tisseel® fibrin glue (Baxter Health Care Ltd., Newbury, Berkshire,
(ft)UK). This glue consisted o f four components, a vapour-heated Tisseel powder component 
(100-130 mg protein, o f which approximately 75-115 mg is fibrinogen); a bovine aprotinin 
solution; a vapour-heated thrombin powder (45-55 mg protein containing about 500 IU2 
active thrombin), and a calcium chloride solution (see Chapter 1 for a detailed description 
about fib rin ’s properties). The Tisseel® fibrinogen component was reconstituted in the 
aprotinin solution after a 10-minute incubation at 37°C in a heater manufactured by Baxter 
Health Care (Fibrinotherm®, Baxter Health Care Ltd., Newbury, Berkshire, UK). Pre- 
operatively, for cell-loaded implants, 2 x 106 or 10 x 106 oBMSCs were centrifuged at 2000 
rpm for 5 minutes. The supernatant was discarded and the pellet at the bottom o f the 
universal was re-suspended in the 1 mL o f reconstituted thrombin and injected back into the 
manufacturer’s vial for transport to the operating theatre.
5.2.3 Implant Design and Manufacture
The implant used was a mid-shaft tibial replacement, which was a design that had previously 
been used in a goat in vivo study by Coathup et al. (2000). Implants were made from titanium 
alloy (Ti6A14V). The implant shaft was 50 mm long and 10 mm in diameter. HA-coated 
collars were used at each transection site. HA coatings were highly crystalline and were
159
around 50 jam thick (Plasma Biotal, Tideswell, North Derbyshire, UK). The collars were 15 
mm in length, with 1 mm grooves (Figure 5.1). The implant consisted o f proximal and distal 
parts that were joined together during surgery by two juxtapositioned screws. Each stem was 
fixed within the intramedullary canal using cement. A long groove was present along each 
stem to promote the interlocking o f cement.
Distal stem Proximal stem
HA-coated collar
Screw. Distal stem
HA-coated collar
Proximal stem 
1
< 50 mm
<--------- Midshaft
-------------50 mm
Figure 5.1 a) Photo o f an ovine mid-shaft tib ia l replacement. The implants were made of 
titanium  alloy and were comprised o f two components, each o f which had a grooved, 
HA-coated collar at the transection site, and an intram edullary stem. The two pieces 
were fixed in the centre w ith screws, b) shows a schematic diagram o f the implant, 
showing the dimensions of the im plant and the division between the two components, as 
well as the location o f the thread holes.
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5.2.4 Experimental Groups
There were four experimental groups, with six animals randomly assigned to each:
Group 1: Untreated implants (n=6);
Group 2: Implants sprayed with 2 mL fibrin glue/collar (n=3);
Group 3: Implants sprayed with 2 x 106 autologous oBMSCs/collar in 2 mL fibrin glue 
(n=6);
Group 4: Implants sprayed with 5 x 106 autologous oBMSCs/collar in 2 mL fibrin glue 
(n-2).
5.2.5 Surgical Procedure
A ll animals were handled and cared for as described in Chapter 2 (Materials and Methods) 
and the site o f surgery was prepared as previously described. Approximately six weeks prior 
to surgery, bone marrow aspirates were taken from skeletally mature mule ewes, from the 
appropriate experimental animals and oBMSCs isolated as outlined in Chapter 2 o f this 
thesis. Tibiae were first clipped to expose the skin, after which the area was washed with an 
iodine solution (as described in Chapter 2). The operation was carried out under sterile 
conditions. The animal’s right leg was draped to expose the medial anterior aspect o f the 
right tibia. This area was rinsed with a chlorhexidine solution and then a proximal-distal 
incision 60 mm in length was made, starting 50 mm distal to the tibial tuberosity. A  50 mm 
section o f the tibial midshaft was excised 60 mm from the tibial tuberosity using an air-saw 
(Figure 5.2a). The periosteum from this section was removed intact (Figure 5.2b).
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Figure 5.2 a) A fte r resection o f soft tissue from  the tib ia  50 mm from  the tib ia l 
tuberosity, an in itia l cut was made to the tib ia ; b) A 50 mm tib ia l segment w ith  an intact 
periosteum, which was replaced w ith  a massive im plant.
The intramedullary canals were prepared for implantation by first removing the bone marrow, 
then by repeated washing with saline (a sterile, 0.9% sodium chloride solution). Where 
necessary, canal diameters were increased to ensure a minimum cement mantle thickness o f 
approximately 1.5 - 2.0 mm. In experimental group animals, 2 mL o f autologous oBMSCs in 
fibrin glue was sprayed onto the HA-coated surface o f the implant collars (proximal and 
distal) at 1.0 atm o f pressure. To do this, the fibrinogen and thrombin components o f the 
fibrin glue were transported to the operating theatre w ith or without oBMSCs (see 4.2.1) and 
maintained at 37° C in a Baxter Fibrinotherm* device (Baxter Health Care Ltd., Newbury, 
Berkshire, U K) until used. Each component was loaded into a 1.0 mL syringe (included in 
the Tisseel' package) and snapped into a dual-syringe holder w ith attached plunger device. 
To spray the fibrin  glue using this system, a Duploject' (Baxter Health Care Ltd., Newbury, 
Berkshire, UK) spray set was used, which consisted o f sterile plastic tubing which connected 
to a dual-syringe tip, which allowed air to come into contact w ith the fibrin  components as 
they came out o f the syringe. The other end o f the tubing was connected to a FibrijeL 
(Micromedics, Inc., St. Paul, Minnesota, USA) pressure gauge, which was connected to a 
pressure pump (see 4.2.2). The Fibrijet was set to 1 atm and the plungers o f the fibrin  system
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pressed to allow release o f aerolised fibrin onto the surface o f the HA-coated implant collars. 
The implants were slowly turned as the fibrin was applied, to allow an even distribution o f 
fibrin around the collar (Figure 5.3). Either two million or ten m illion cells were applied to 
each collar (proximal and distal) o f every implant in the oBMSC group.
Figure 5.3 HA-coated collar on distal segment of implant being spray-coated with 
oBMSCs suspended in fib rin  glue, pre-implantation.
Control animals recieved fibrin glue only or no treatment to the collar at all. Implants were 
cemented in place using Palacos R with Gentamicin (Biomet Europe, South Wales, UK, 
Figure 5.4a). The two halves o f the prosthesis were joined centrally (Figure 5.4b), and the 
surrounding fasica, muscle and skin were closed.
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Figure 5.4 a) Distal implant (from untreated control group) component being cemented 
into intramedullary canal; b) Implant assembled in centre with screws, w ith oBMSCs in 
fib rin  glue on HA-coated collars.
A spray bandage (OpSite®, Smith &  Nephew, Gallows H ill, Warwick, UK) was applied prior 
to recovery. Animals were allowed immediate postoperative mobilisation and weight-bearing 
as tolerated. Antibiotic and analgesic prophylaxis was administered daily with subcutaneous 
injections o f Exenel™ (ceftiofur hydrochloride, 1 mL/50 kg, Pfizer Animal Health, 
Tadworth, Surrey, UK) and IM injections o f Vetergesic™ (buprenorpine, 0.6 mg/animal, 
Reckitt and Colman Products Ltd., Hull, UK) for three days post-operatively. Animals were 
kept in individual pens until fu lly weight-bearing and were then grouped together in large 
pens.
Animals were euthanised 6 months post-operatively by an intravenous overdose o f 0.7 mg/kg 
pentabarbitone (20%, J.M. Loveridge Ltd., Southampton, UK).
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5.2.6 Radiography and Radiographic Analysis
Medio-lateral (M L) radiographs o f the right tibiae were taken at two and three months post- 
operatively for the control (untreated) and 2.0 x 106 oBMSC groups, using an MX4 X-ray 
machine (PLH Medical Ltd., Watford, UK). For the fibrin-only and 2.0 x 107 oBMSC 
groups, radiographs were taken at six months only, as part o f two pilot groups. A t six months, 
both M L and anterior-posterior (AP) radiographs were taken after animal sacrifice and 
removal o f the right tibia, in all four groups. For analysis o f new bone formation, digital 
images o f the radiographs were captured using an JVC KY  F55B Colour Video Camera using 
Zeiss KS300 software (Imaging Associates, Thame, UK). The radiographed area adjacent to 
the implants was divided into eight regions o f equal size, and labelled from A-H (Figure 5.6). 
Images were captured using a JVC KY  F55B Colour Video Camera along with Zeiss KS300 
software (Imaging Associates, Thame, UK). Bone area in these regions was then quantified 
using the KS300 image analysis software.
The osseointegration o f the pedical bone was measured by determining the length o f 
radiolucent lines found between the pedicle o f bone and the implant surface (see Figure 5.5), 
using image analysis software. The lengths o f the radiolucent lines were expressed as a 
percentage o f the length o f pedicle-implant interface, as measured using image analysis 
software.
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Figure 5.5 Sample radiograph (2\106 BMSCs/collar, M L  view) divided into eight 
regions (A-H) for quantitative analysis o f new bone formation adjacent to implants. The 
pedicle of bone grown along the length o f the implant shaft is indicated w ith a white 
arrow. A radiolucent line between the pedicle of bone and the implant is shown with a 
black arrow.
5.2.7 Undecalcified Hard Resin H isto logy and A na lys is
Following sacrifice, all right tibiae were prepared for histology by stripping excess soft tissue
and fixing in 10% neutral buffered formalin (NBF) for a minimum period o f one week. 
Specimens were dehydrated in increasing concentrations o f industrial methylated spirit 
(IMS). Samples were de-fatted in chloroform and immersed in a 50% IMS, 50% resin 
mixture (LR White Resin, London Resin Company Ltd., Reading, Berkshire, UK), followed 
by immersion in 100% resin. Samples were then cast using a polymerisation accelerator (LR 
White Accelerator, London Resin Company Ltd., Reading, Berkshire, UK). Specimen blocks 
were sectioned at four sites, using a water-cooled band saw with a diamond-edged blade 
(Exact saw, Germany). One section was made through the centre o f the proximal collar and 
one through the centre o f the distal collar. Thin sections (approximately 80 pm thick) were 
prepared (Exact grinding machine, Germany; and Exact Polishing machine, Germany) and 
stained with Toludine Blue (Bancroft and Stevens 1986) and Paragon (Tanzer et al. 2003) to 
stain soft tissue and bone, respectively. Stained slides were then viewed under an Olympus
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BH2 light microscope and images digitally captured using a JVC KY  F55B Colour Video 
Camera. Bone area and bone-implant contact was quantified using image analysis software 
(Zeiss KS300 software, Imaging Associates, Thame, UK).
5.2.7.1 Bone Area
To measure bone area using image analysis software, the area o f bone was ‘encircled’ using 
freeform polygons and the area w ithin it calculated by the software in mm (see Figure 5.14 
and Figure 5.15 for sample photographs o f sections).
5.2.7.2 Bone-implant Contact
To measure bone-implant contact, 48 equi-distant points spanning the entire surface o f the 
implant collar were analysed at 2.5x magnification for the presence o f bone-implant contact. 
The results were recorded as yes or no (0 or 1) at all points and the percentage o f contact 
calculated out o f 48.
5.2.7.3 Bone Porosity Measurement
To measure bone porosity around the centre o f each implant collar, photographs were taken 
at 2.5x magnification around the implant collar. A  17x13 line grid was then overlaid onto 
these photographs, with lines approximately 1.0 cm apart from one another (Figure 5.6). At 
each intersection point w ithin an area o f bone, the number o f porous regions was quantified. 
To calculate a percentage, the number o f intersections with pores was totalled and divided by 
the total number o f intersections w ithin the bone area adjacent to the implant collars. The 
same grid was used for all photographs.
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Figure 5.6 An example of a photograph of bone adjacent to a control group distal collar 
with adjacent bone growth, onto which a grid has been overlaid for the quantification of 
bone porosity. Evaluation of porosity was made at each grid intersection point.
5.2.7A  Fibrous Tissue Measurement
The percentage o f fibrous tissue adjacent to implant collars was quantified at 48 points along 
the implant surface, at 2.5x magnification. The width o f the layer was quantified from its 
contact with the implant outwards, within a 2.0 mm distance. The percentage o f fibrous tissue 
within this distance was then calculated and results analysed using the Mann Whitney U non- 
parametric comparison o f means.
5.2.8 S ta tis tics
To test the normality o f the distribution o f the data, the Kolmogorov-Smirnov test was used, 
using SPSS 11.0 for Mac OSX. Parametric data was analysed using an independent-samples 
T test; non-parametric data was analysed using the Mann-Whitney U test. Where there were 
more than two groups (radiographic analysis) being analysed, the non-parametric Kruskal- 
Wallis test was used. Bivariate (Pearson’s) and partial correlations were used to analyse any 
correlations between the percentage porosity o f bone adjacent to implant collars (Point 00)
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and bone-implant contact (Point 0) to observe i f  bone-implant contact affected the porosity 
o f the bone observed. Results were considered significant when p < 0.05.
5.3 Results
Sheep fu lly recovered within a few days post-operatively and were weight-bearing on all four 
limbs for the duration o f the experiment.
5.3.1 Radiography
There were distinct patterns o f growth observed around the implants. The largest amount o f 
bone was observed posteriorly and medially along the implants. A  greater amount o f bone 
growth adjacent to the implants was observed at the proximal transection site than distally. 
Figure 5.7 and Figure 5.8 show typical radiographs for all 4 groups. A  greater amount o f new 
bone formation could be seen in the two BMSC-treated groups (2 x l0 6 and lOxlO6 
BMSCs/collar) than in the control (untreated and fibrin glue-treated) groups, as well as a 
lower frequency o f radiolucent lines between the implant and bone pedicles.
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Figure 5.7 Radiographs of control (untreated and fibrin-glued treated) implants, (a-d) 
are radiographs from one untreated control animal, w ith M L  radiographs taken at 2 
(a), 3 (b) and 6 (c) months, and an AP radiograph taken at 6 months (d). Bone growth is 
marked (B), as well as radiolucent lines, which are demarcated with arrows. Photos are 
shown here at 0.9x of the actual size.
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Figure 5.8 Radiographs of BMSC-treated implants (0.9x magnification), (a-d) are 
radiographs taken of the same animal treated with 2xl06 BMSC/coIlar at 2 (a), 3 (b), 
and 6 (c and d) months, with (a-c) being taken in the M L view and (d) taken in the AP 
view, (e) and (f) are the M L and AP radiographs of another lower-BMSC dose animal, 
taken at 6 months. A larger cuff of new bone growing over the implants from the 
transection sites can be seen in these radiographs than with the controls seen in Figure 
5.7. An even larger amount of bone can be seen proximally and distally in (g) and (h), 
which are the M L  and AP views of an implant treated with lOxlO6 BMSCs/collar. New 
bone is marked with a “ B,”  and radiolucent lines are indicated with arrows.
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5.3.1.1 Bone Area
Analysis o f new bone adjacent to tibial implants using M L radiographs showed that at each 
o f the time points investigated, there was a significant increase in bone formation around 
those implants treated with 2 m illion autologous oBMSCs in fibrin glue (24.07 ± 5.988 mm2 
at 2 months, 51.01 ± 26.13 mm2 at 3 months and 79.74 ± 17.25 mm2 at 6 months, when 
compared to control animals (2 months-5.24 ± 3.09 mm2, p=0.053; 3 months-12.37 ± 9.87 
mm2, p=0.083; and 6 months-30.13 ± 6.72 mm2, p=0.017, (Figure 5.9a). A t 6 months, there 
was also a significant increase in bone growth in the AP aspect o f the 2 million-oBMSC 
group radiographs when compared to controls (90.34 ± 8.66 mm and 57.38 ± 9.04 mm 
respectively, p=0.05, see Figure 5.9b). A t 6 months, although there was an increase in the 
area o f bone measured adjacent to implants treated with 10 m illion BMSCs/collar, there was 
no significant difference when it was compared to the 2 m illion BMSC group in the AP view 
(112.29 ± 33.03 mm2 in the 10 m illion group, p=0.44) or M L view (138.74 ± 9.30 mm2, 
p=0.18). Also, there was no significant difference between the 10 m illion BMSC group and 
the other two groups in the AP view (p = 0.06 between the 10 m illion and control groups and 
p=0.08 between the 10 m illion and fibrin group) and between the 10 m illion and fibrin 
groups in the M L view (p=0.08). When the two oBMSC groups were combined and 
compared to non-treated and fibrin-only controls, there was a significant difference in the 
amount o f bone observed in the AP and M L views (p < 0.01, Figure 5.10). W ithin each 
group, there were statistical significant differences observed between 2 and 6 months in the 
control and low-dose oBMSC groups (p=0.05 and p=0.01, respectively).
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5.3.1.2 Pedicle Gap Lengths
Radiolucent pedicle gap lengths were found to be longest in the control group, with a mean 
percentage gap length o f 76.65 ± 10.19 % in the AP view, and 52.67 ± 14.97 % in the ML 
view. The smallest percentage gap lengths were found in the high-dose BMSC group (1.0 x 
107 cells/collar) in the AP view (25.02 ± 18.9 %), and the fibrin glue-only group in the ML 
view, with a 23.05 ± 11.23 % pedicle gap length (Figure 5.11). A Kruskal-Wallis non- 
parametric test for multiple groups found a significant difference between all four groups in 
the length o f pedicle gaps adjacent to distal collars in the AP view (p=0.03). Comparing the 
control (untreated) group and the low-dose BMSC group (2.0 x 106 cells/collar) using the 
Mann Whitney U test, a significant difference was found (p=0.01).
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Figure 5.9 a) Results of radiological analysis over 2, 3, and 6 months, in the M L  aspect. 
A t each time point, there was a significant increase in the area o f bone adjacent to the 
implants in the oBMSC-treated group, when compared to the control group, b) 
Comparison of bone area adjacent to implants in the M L  and AP aspects at 6 months, 
in all four experimental groups. There was an increase in the amount o f bone in the AP 
aspect when 5 times the number o f oBMSCs were applied to the surface o f implant 
collars.
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Figure 5.10 Radiographic bone area results from the combined oBMSC-treated groups 
compared to the combined results o f the two control (untreated and fib rin -on ly) groups.
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Figure 5.11 Graphs showing the percentage of bone pedicle along implants with gaps 
(seen as radiolucent lines) between the implant and bone, a) shows the results of 
analysis in the AP view, and b) shows results o f the M L  view analysis.
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5.3.2 Histological Analysis
5.3.2.1 Bone Area
Woven and lamellar bone was observed in and around the collars in all groups, as seen in 
Figure 5.12, Figure 5.13, Figure 5.14, Figure 5.15 and Figure 5.16, which are examples o f 
collars from the different groups. Haversian systems were also seen in both groups, although 
they were more prominent in the BMSC-treated groups than in the control groups (Figure 
5.17). The layer o f new bone growth around implant collars was also observed to be thicker 
in the cell-treated group (Figure 5.14) than in the control group (Figure 5.15), which had a 
combination o f fibrous tissue and bone adjacent to the HA-coated collars (Figure 5.18). 
Resorption along the outer edge o f this bony layer was also observed in both control and low- 
dose BMSC samples (Figure 5.19), as the bone surface appeared ‘scalloped’ following recent 
osteoclast activity.
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Figure 5.12 Midsection through the proximal (a, c) and distal (b, d) HA-coated collars 
of control group specimens, stained w ith Toluidine Blue and Paragon. Bone formation 
(B) adjacent to the implant collars can be seen, along with fibrous tissue (F). A fibrous 
tissue layer was often found between the implant and new bone formation.
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Figure 5.13 (a-d). Photos of thin, undecalcified, sections from 2.0xl06 BMSC-treated 
group stained with Toludine Blue and Paragon. Bone formation was observed around 
implant collars (distal and proximal). A larger, thicker, cuff of bone was found adjacent 
to the collars of BMSC-treated implants than in the control groups. Although a fibrous 
tissue layer was seen around some implant collars, between the bony layer and implant, 
this was seen less frequently than around control implants.
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Figure 5.14 Lamellar bone (B) grown adjacent to a proximal HA-coated (HA) implant 
collar (I), which was treated w ith BMSCs in fib r in  glue (2 x 106 BMSCs/collar). 
Haversian systems can be seen, as well as bone growth into the grooves o f the collar and 
bone-implant contact (4x magnification).
Figure 5.15 Bone formation (B) around a control (untreated) im plant collar (I). This 
layer of bone is thinner than that often observed w ith the BMSC-treated implants and is 
not in contact w ith the HA-coated im plant surface. The HA-coating can be seen as a 
grey layer as indicated (HA, 4x magnification).
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Figure 5.16 Bone growth into a BMSC-treated collar (2x l06 BMSCs/collar, lOx 
magnification). Contact can be seen between the new bone and HA-coating o f the 
implant collar. Haversian systems (H) can be seen surrounding the canals (black spots 
in photo- see encircled region).
Figure 5.17 BMSC-treated collar seen in Figure 5.16, at 40x magnification. Bone 
formation can be seen in contact w ith the HA-coating o f the im plant collar. In  this 
photo, there is ingrowth o f bone to the HA-coating (HA) and Haversian systems can be 
seen (H-white circled area).
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Figure 5.18 Porous bone adjacent to implant collar, separated by a fibrous tissue layer. 
This photograph was taken at 5x magnification and is of a distal collar from the 
untreated control group.
Figure 5.19 Resorption pits along the outer edge of a low-BMSC dose treated proximal 
collar, taken at lOx magnification. Osteoclasts are prominent multinuclear cells, which 
are indicated with black arrows.
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A significantly greater amount o f fibrous tissue was quantified adjacent to the untreated, 
control collars when compared to the cell-treated groups. As seen in Figure 5.20, 
significantly increased bone area was demonstrated adjacent to the mid-point o f the collars in 
the oBMSC groups when compared with the control implants (mean 46.50 ± 8.35 mm2 in the 
low dose group, 127.63 ± 36.94 mm2 in the high dose group and 21.07 ± 7.03 mm2 in the 
untreated control group; p=0.02 between the low-dose group and controls, p=0.01 between 
the high-dose group and controls and p=0.05 between the high and low oBMSC doses). The 
fibrin glue-only group had a higher amount o f new bone formation around implant collars 
than the low-oBMSC dose group (64.49 ± 23.59 mm2), although this difference was not 
significantly different when compared to each o f 4 the other three groups. Looking at the 
proximal and distal collars separately (Figure 5.21), there was no significant difference 
between all groups, except between the distal collars in the control and high-oBMSC group 
(15.93 ± 8.90 mm2 and 220.16 ± 58.60 mm2, p=0.05), and low-oBMSC group and high 
oBMSC group (35.60 ± 12.62 mm2 and 220.16 ± 58.60 mm2, p=0.044). Although there was 
more bone observed around the proximal collars in the control and low-dose oBMSC groups 
(control group 27.49 ± 11.83 mm2; fibrin-only group 53.94 ± 37.68 mm2, low-dose oBMSC 
group 50.27 ± 12.00 mm2, high-dose BMSC group 81.36 ± 26.43) than the distal collars 
(control group 15.93 ± 8.90, fibrin-only group 71.52 ± 36.33 mm2; low-dose oBMSC group 
35.61 ± 12.62 mm2, high-dose oBMSC group 220.16 ± 58.60), this was the opposite in the 
other two groups, and these differences were not statistically significant.
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Figure 5.20 Comparison o f bone area around the centre o f im plant collars, as measured 
using histological analysis.
N=6 (all groups)
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Figure 5.21 A comparison o f histological results, comparing proxim al and distal collars 
between groups.
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5.3.2.2 H istology: Bone - Im plant Contact
Mean bone-implant contact was increased in the fibrin glue, low-dose oBMSC group (21.35 
± 9.84%) and high-dose oBMSC group (47.66 ± 14.01 %), when compared to the control 
group (10.88 ± 10.12 %, Figure 5.22). However, this difference was not found to be 
statistically significant (p=0.936 and p=0.05, respectively).
Only two out o f twelve implant collars in the control group had bone-implant contact 
(16.67%), whereas three out o f six collars in the fibrin glue group (50%), five out o f twelve 
in the low-dose oBMSC-treated group (41.67%) and four out o f four collars in the high-dose 
oBMSC group (100%) had bone-implant contact. Bone-implant contact was observed at both 
proximal and distal collars.
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Figure 5.22 B one-im plant contact around im p lan t collars in the untreated  control, 
fib rin -on ly , low -concentration o B M S C  group, and high-concentration o B M S C  group.
N=6 (all groups)
Untreated Control Fibrin Glue Only 2.0 x 10e6 BMSCs/mL 1.0 x 10e7 BMSCs/mL
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5.3.2.3 Bone Porosity Measurement
Looking at bone porosity in the bone adjacent to implant collars in the four groups, the 
control group had the highest mean percentage porosity (24.37 ± 4.13%), followed by the 
fibrin-only group (17.41 ± 4.11%), the low-dose oBMSC group (14.91 ± 1.80%) and the 
high-dose oBMSC group (11.76 ± 1.68%), with the lowest mean porosity. The difference 
between the untreated control group and the high-dose oBMSC group was significant 
(p=0.018) and although the untreated control group had almost double the mean percentage 
porosity compared to the low-dose oBMSC-treated group, the difference was not statistically 
significant (p=0.064). Figure 5.23 summarises these results in a bar graph. Implants with no 
bone present adjacent to the implant collars were excluded from the above analysis.
When bivariate correlations were made between the percentage bone porosity and percentage 
bone-implant contact across all four groups, the correlation coefficient was statistically 
significant (Pearson’s coe ffic ien ts .377, p=0.05). When data was categorised into the four 
experimental groups and then analysed for correlation between mean percentage porosity and 
bone-implant contact, there was also a statistically significant correlation (Partial 
coefficient=0.478, p=0.013). A  positive correlation indicates that with increased bone- 
implant contact, an increase in bone porosity can also be observed.
185
N=6 (all groups)
Untreated Control Fibrin Glue Only 2.0 x 10e6 BMSCs/mL 1.0 x 10e7 BMSCs/mL
Group
Figure 5.23 Bar graph showing the mean percentage bone porosities in the four 
experimental groups.
5.3.3 Percentage o f F ib rous T issue A d jacent To Im plant Collars
Measurement o f fibrous tissue layers adjacent to implant collars within 2 mm o f the implant 
found a mean fibrous tissue percentage o f 70.72 ± 10.23% in the control group, 42.63 ± 
17.70% in the fibrin-only group, 64.30 ± 10.18% in the low-dose oBMSC group and 32.90 ± 
11.14% in the high-dose oBMSC group. There was a significant difference between the 
untreated control group and the high-dose oBMSC group (p=0.048). Figure 5.24 shows these 
results graphically.
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Figure 5.24 Bar graph illustrating mean fibrous tissue lengths adjacent to implant 
collars.
5.4 Discussion
The study described in this chapter demonstrated that BMSCs, when sprayed onto the surface 
o f HA-coated implant collars, significantly increased bone formation around the collars and 
improved bone-implant contact to massive segmental bone tumour implants when compared 
to untreated implants with HA-coated collars. By promoting the growth o f a “ bony bridge”  
across the transection site from the host bone to the implant collar, load transfer to the 
implant at the transection site may be improved. This in turn, may improve the failure rates 
experienced by massive endoprostheses. Further radiographic analysis looking at the effects 
o f applying BMSCs in fibrin glue onto HA collars o f the massive implants on radiolucent line 
formation around the stem would be useful, as this is the mode o f aseptic loosening o f these 
implants in humans. In this PhD, the focus was to determine whether or not applying BMSCs 
to orthopaedic implants would augment bone growth adjacent to the implants and improve 
bone-implant contact. Therefore, analysis o f radiolucent lines and loosening around the stem 
was not investigated. Radiolucent line formation and progression, which is considered to be
N=6 (all groups)
Untreated Control Fibrin Glue Only 2.0 x 10e6 BMSCs/mL 1.0 x 10e7 BMSCs/mL
Group
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evidence o f loosening, is not generally seen around massive implants until after the first 
year’s duration. This is a comparatively short-term study in animals and therefore radiolucent 
line formation and progression were d ifficu lt to study.
This study has a relevant clinical application as it utilises BMSCs to augment the 
effectiveness o f an implant already widely used for massive endoprosthetic reconstruction 
and/or replacement. This is in contrast to other studies that have only shown the effectiveness 
o f BMSCs in rats when combined w ith a gel carrier (Lee OK 2005), or when seeded in an 
osteoconductive surface such as p-tricalcium phosphate or HA, in conjunction with an 
internal plate (Arinzeh et al. 2003), external distraction (Richards et al. 1999) or external 
fixation (Lee et al. 2005). Although these models have clinical relevance in demonstrating 
bone tissue engineering with BMSCs, the model I used is also immediately weight bearing 
and was tested in sheep, which have been shown to have loading patterns running through 
their hind limbs as compared to humans (Bergmann et al. 1984). Fibrin glue is a convenient 
vector for BMSCs as it is commercially available and simple to reconstitute and assemble. 
This fibrin-oBMSC system has been shown in this study to significantly augment bone 
regeneration. Fibrin glue is already widely used in many different areas o f surgery and is 
familiar to surgeons worldwide. It is possible that osteoinduction could be further encouraged 
by using a scaffold that promotes the proliferation o f cells and their differentiation into 
osteoblasts, as well as retaining them in the structure. An example o f this could be fibrin 
combined with BMPs, HA or P-tri-calcium phosphate, or all o f these combined (Hong et al. 
2006; Han et al. 2005; Schmoekel et al. 2005). One potentially negative aspect to using 
autologous BMSCs in patients who have bone tumour replacements is the possibility o f 
metastatic cells in the bone marrow that may be isolated with autologous BMSCs (Wakasugi
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et al. 2002; Bruland et al. 2005), which may justify the use o f allogeneic cells in these 
patients (see General Discussion - Chapter 7).
Radiographic analysis o f bone growth in all groups indicated a similar pattern, whereby there 
was more new bone formation medially and posteriorly around the implants and less new 
bone formation laterally and anteriorly. This pattern is similar to that observed in the clinical 
scenario o f femoral endoprosthetic replacements, where a medial and posterior increase in 
bone mineral density (BMD) was found, as well as a BMD decrease laterally and anteriorly 
(Inglis and Walker 1991). This reflects the pattern o f stress and strain around proximal 
femoral replacements measured telemetrically (Taylor et al. 1997) and a study using 
photoelastic coatings to measure shear strain (Hua and Walker 1992), where the strain 
measured medially was 53% o f normal on the medial side, but only 35% on the lateral side o f 
the implant.
The purpose o f quantifying bone porosity o f bone adjacent to implant collars was to observe 
any difference in bone quality between groups. Bone is known to be responsive to load, 
therefore, it was thought that, i f  BMSCs were promoting fixation o f the massive implants in 
this model, one might see, in addition to an increase in bone area and bone-implant contact, a 
lower porosity o f bone. Also, it was thought that, with the addition o f osteoblast precursor 
cells, the quality or type o f bone observed may be different to bone found adjacent to control 
group implants. There was a significant difference between the porosity o f the untreated 
control group and that o f the high-dose oBMSC-treated group, although the N-number o f the 
latter group was only 2, as opposed to 6 in the former. It must also be noted that there was an 
increase in the amount o f bone-implant contact in all treated groups when compared to the 
control group, although this difference was only statistically significant between the control
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group and the high-dose oBMSC group. Although the bone-implant contact in the fibrin-only 
group is comparatively high compared to the control group, the N-number is ha lf o f the 
control group and therefore the results may change when the other samples are taken into 
account.
Interestingly, when percentage bone porosity was correlated with bone-implant contact over 
both control and low-dose BMSC groups, there was a positive correlation, indicating that 
with increased bone-implant contact, there is increased bone porosity. This result is 
contradictory to W o lffs  law (W o lff 1892), which states that bone responds to load. A  greater 
degree o f bone-implant contact would indicate a higher amount o f load being transmitted 
from the implant to the surrounding bone, requiring a denser bone formation. However, with 
increased bone-implant contact there is less o f a fibrous tissue layer between bone pedicles 
and implants. This fibrous tissue layer could possibly have a role in transmitting load from 
connecting soft tissue (such as muscle) to the bone, thus causing denser bone formation, and 
without such a force, the bone could be more porous (Blunn 2007). Current outcomes o f HA- 
coated collars show that, while in some patients there is bone growth over the implant collars 
and along the shaft o f the prosthesis (70% o f cases, Unwin, Walker and Blunn 1995), others 
have little or no bone growth (30% o f cases). This result can be unpredictable. However, with 
the application o f BMSCs in fibrin glue to the implant collar, there may be a more predictable 
outcome with regards to bone growth over HA-coated collars, with an increase in bone- 
implant contact and corresponding bone quality. The results o f the radiographic bone pedicle 
gap analysis support this claim, as there was a significant decrease in the pedicle gap found 
between bone adjacent to implants in the high-dose BMSC-treated group when compared to 
control groups. The fibrin glue group also had a positive outcome, although it must be noted 
that the N-number for this group and group 4 was half o f groups 1 and 3 (n=3).
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The study by Unwin, Walker, and Blunn (2005) found that when plasma-sprayed, HA collars 
were used in massive implants in human patients, there was a qualitative difference observed 
in the radiolucent lines (pedicle gap) found between new bone growth and the implant, when 
compared to untreated and bead-coated collars. It may be possible that the use o f BMSCs 
furthers this effect.
My analysis o f percentage fibrous tissue adjacent to implant collars found statistically 
significant differences between the untreated control and high-dose oBMSC group, and 
between the low-dose oBMSC group and high-dose oBMSC group. These results indicate 
that treating implant collars with a high concentration (1.0 x 107/mL) o f BMSCs in fibrin 
glue reduced the percentage o f fibrous tissue adjacent to the implant, which may reduce 
loosening in the longer term. It may be interesting to investigate how such a fibrous tissue 
layer between implant and bone may affect loading o f bone, and i f  fibrous tissue lengths 
differ over a larger sample size. Demarcating implant orientation (anterior, posterior, medial, 
and lateral) when processing histological specimens may also show trends with regards to 
fibrous tissue lengths, bone porosity and bone area around implant collars. The data reported 
in this chapter showed a substantial difference in the bone area found adjacent to proximal 
collars, when compared to distal collars (over twice the amount o f bone), however, no 
observable difference in bone morphology (porosity, type o f bone) was seen between the 
proximal and distal collars. Therefore the difference in bone area between the two collars 
may be attributable to differential loading o f the proximal and distal collars in ovine tibiae, 
influencing different levels o f bone growth according to W o lffs  law (W o lff 1892). Although 
fibrin glue increased new bone formation and bone-implant contact around implants, its 
influence is not as substantial as when oBMSCs were applied. Fibrin glue does appear to 
have some effect on bone formation. Once again, it should be noted that the fibrin-only and
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high-dose oBMSC groups had a much lower sample size (N=3 and N=2, respectively), when 
compared to the other two groups.
Fibrin has a natural role in the wound-healing pathway. It is one o f the first matrix molecules 
present at wound sites, providing a physical barrier and temporary strength to the wound site. 
As discussed in the introduction to this thesis (Chapter 1), fibrin glue has been shown to 
encourage osteoconduction when applied with HA (Abiraman et al. 2002). However it has 
also been shown to induce significantly less bone growth in vivo when compared to fibrin 
glue combined with BMSCs with or without a ceramic scaffold (Lee et al. 2005; Yamada et 
al. 2003). A  study by Kadiyala et al showed an increase in bone formation when the p-TCP 
scaffold was impregnated with fibronectin before cells were seeded onto the scaffold (Bruder 
et al. 1998; Arinzeh et al. 2003). One study by Roy et al. (1993) actually showed a decrease 
in new bone formation around a titanium femoral endoprosthesis in canines when fibrin glue 
was used to pack bone graft around the implant, when compared to fibrin-free implants. An 
in vivo study in rats by Lee et al. in 2005 showed that there was no significant difference 
between untreated femoral gaps and those treated with fibrin glue only. However, bone 
growth was significantly increased with the addition o f allogenic BMSCs, up to 20% more 
bone. This effect was even more pronounced in those rats treated with chemotherapy. Those 
rats treated with fibrin and BMSCs compared to those with chemotherapy only, had a 220% 
increase in bone formation.
It has been suggested that fibrin glue can have a pro-angiogenic effect, which may promote 
new bone growth or repair (Kania et al. 1998). Based on experimental results presented in the 
literature, it is unlikely that the fibrin glue is completely responsible for the observed increase
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in bone growth when compared to implants with untreated, HA-only collars. Increasing the 
sample size may alter the pilot results presented in this chapter.
HA has already been well documented in the literature as being osteoconductive (Blunn et al. 
2000; Coathup et al. 2000; D ’Antonio, Capello and Jaffe 1992; Geesink 1993). Possible 
mechanisms o f this bone-promoting effect have been suggested. One theory is that as HA 
slowly degrades in the body, the degradation products released from the implant surface, such 
as calcium and phosphate, or the change in pH (Ozawa and Kasugai 1996; Kurioka et al. 
1999), may promote differentiation o f the BMSCs to osteoblasts, or even improve bone 
formation by host osteoblasts which have migrated to the implant site, or the BMSC-derived 
osteoblasts (Datta et al. 2006). Kilpadi, Chang and Beilis (2001) have also shown that HA 
has the capacity to bind proteins such as important integrins (for example a5(31 and avp3), as 
well as fibronectin, vitronectin and osteoblast precursor cells, when compared to metals.
Another question that my chapter aimed to answer was the question o f cell dosages. In the 
radiographical results, there was no significant difference found between the groups with 10 
x 107 BMSCs/collar, and all other groups. This is probably due in part to the small sample 
size, which may have contributed to the high standard error (almost equivalent to a third o f 
the measured new bone area). In the histological results, the high dose o f oBMSCs resulted in 
a significantly higher bone area, bone-implant contact and lower percentages o f fibrous tissue 
and bone porosity adjacent to the collars. O f course, increasing the N-number could 
potentially make the addition o f more cells to the collars significant. However, this group was 
essentially a small pilot group and cell dosages w ill be investigated in more detail in future 
projects, with the right number o f specimens to produce a result w ith the appropriate 
statistical power. This sort o f work has not previously been published in the literature for in
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vivo bone tissue engineering. It is possible that cell dosage does not affect the amount o f new 
bone formation around collars. This may be possible i f  there is some sort o f threshold or 
upper lim it on the effects o f cells, so that beyond a certain number o f cells there is possibly 
no difference in the results. A clinical study by Gu, Zhang and Qi (2006) looking at the 
treatment o f lower limb ischemia with autologous BMSCs found that the BMSC dosage (1 x 
105 cells versus 1 x 108 cells) significantly affected the outcome, which was the development 
o f collateral blood vessels and a decrease in amputation rates. This group found that for an
Q
effective dosage, one must use a minimum o f 1 x 10 cells. However, cell dosages may have 
a different effect in cases o f hard (bone) tissue engineering, and result in different amounts o f 
trophic factors being released into the environment by implanted BMSCs, which may 
indirectly facilitate bone growth (Caplan and Dennis 2006).
5.5 Conclusion
BMSCs can be used in a fibrin glue spray system to augment bone growth around massive 
implants. Bone growth around BMSC-treated implants was significantly increased when 
compared to controls. Bone-implant contact was also improved and the length o f radiolucent 
gaps between the new bone and implants was reduced. The quality o f bone (porosity) was 
also observed to be different between untreated and BMSC-treated implants. Fibrin-treated 
implants also showed a similar effect, although much lower than when a high concentration 
o f BMSCs was applied to implant collars. The enhancement o f bone growth and quality 
observed when BMSCs in fibrin glue are applied to HA-coated collars may improve the 
fixation o f massive implants. This could potentially reduce incidences o f aseptic loosening.
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CHAPTER SIX
THE EFFECT OF BMSC DOSAGES AND GUIDED 
BONE REGENERATION ON THE FIXATION OF 
REVISION IMPLANTS.
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6.1 Introduction
The previous chapter showed that the application o f autologous BMSCs to massive implants 
resulted in improved new bone formation and bone-implant contact. However, in that 
experiment, only two cell dosages (2.0 x 106 and 10.0 x 106 BMSCs) were investigated. Two 
important questions that arose from that study were: 1) Whether or not a higher or lower 
concentration would result in more or less new bone formation; and 2) Whether allogeneic 
BMSCs w ill stimulate equal or increased amounts o f bone when compared with autologous 
BMSCs.
The use o f autologous BMSCs is advantageous, as it uses the patients’ own cells at the site o f 
implantation, reducing the risk o f disease transmission. Bone marrow aspiration, which is 
required for the isolation o f BMSCs, is an invasive procedure. In contrast, i f  allogeneic cells 
were to be used, an immediately available product could be made possible. Allogeneic cells 
have been shown to produce bone in many in vivo models (Arinzeh et al. 2003; De Kok et al. 
2003; Tsuchida et al. 2003).
Guided bone regeneration using an e-polytetrofluoroethylene (e-PTFE, Gore-Tex™) 
membrane promotes new bone formation by sealing the defect site from the surrounding 
tissue (Bhumbra et al. 1998). E-PTFE is a biocompatible, non-resorbable, synthetic 
membrane that has previously been used in guided bone regeneration. Its inner layer, which 
has 1 mm pores, prevents the ingrowth o f cellular material such as fibrous tissue, whereas 
water and various macromolecules and growth factors can pass through freely. In a small 
rabbit tibial defect model, e-PTFE was shown to significantly improve new bone formation 
compared to uncovered controls (Bhumbra et al. 1998). E-PTFE has also been shown, in a 
large animal model, to effectively prevent wear-particle induced osteolysis at the acetabular
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cup implant-bone interface created by total hip replacements, significantly reducing the 
aseptic loosening o f these implants (Bhumbra et al. 2000). Guided bone regeneration 
techniques have previously been applied to bone tissue engineering techniques, where a non- 
porous poly-DL-lactide chamber was used in combination with BMSCs and demineralised 
bone matrix (DBM) to promote new bone formation in rabbit radii (Giardino et al. 2002). 
However, use o f PTFE to cover orthotopic defects or implants treated with BMSCs has not 
been previously investigated. The use o f a membrane in this model may prevent the 
migration o f cells out o f the defects into the surrounding tissues or from one site to another, 
as well as promote new bone formation.
The hypothesis of this chapter is that a larger cell dosage would result in greater new 
bone formation in cortical defects and improve bone-implant contact in an in vivo 
revision implant model, when compared to lower cell dosages. Also, allogeneic BMSCs 
would be as effective as healing a bone defect as autologous BMSCs.
The aims and objectives o f this chapter were:
1. To use an ovine tibial transcortical pin model to investigate the effects o f varying cell 
dosage (1.0 x 105, 1.0 x 106, and 1.0 x 107 BMSCs/mL), as well as fibrin alone, on the 
amount o f new bone formation, w ithin a 1.5 mm ‘gap’ defect, in an in vivo ovine model.
2. To investigate the effect o f using allogeneic cells on the amount o f new bone formation in 
the same model.
3. To evaluate new bone density in the gaps created in this model using radiological 
techniques.
4. To prepare histological sections and measure the amount o f new bone formation adjacent 
to the implants and within the gaps.
5. To quantify the amount o f bone-implant contact.
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6.2 Materials and Methods
6.2.1 oBMSC Iso la tion  and Expansion
Ovine BMSCs were isolated as previously described (See Chapter 2, Materials and Methods). 
Cells were expanded to passages 3 and 4 for use in this study.
6.2.2 Im plant Design and M anufacture
The implants were small partially-threaded transcortical screws similar to that used by 
Bhumbra et al. (1998) and manufactured from titanium alloy (Ti6A14V, Figure 6.1). The 
screws were 25 mm in length, and the distal M5 threaded region was 5.0 mm in diameter. A 
cutting flute was located at the bottom, for ease o f insertion into the cortical bone. The top 
half o f the screw was 3.0 mm in diameter and was plasma sprayed with a highly crystalline, 
thin (<50 pm thick) HA-coating (Plasma Biotal, Tideswell, North Derbyshire, UK).
Figure 6.1 Example o f a transcortical screw used in study. The top segment was H A- 
coated and either left untreated, sprayed w ith fib rin  glue-only, or a combination o f 
fib rin  glue and varying concentrations o f BMSCs (1.0xl05-1.0xl07 cells/mL).
6.2.3 Cell Dosages
Three implants were inserted into the left and right tibia o f each sheep, w ith a total o f six 
implant groups per sheep.
• Threaded segment 
Cutting flute
HA-coated, 
unthreaded segment
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Table 6.1 outlines the treatment and position o f the six groups investigated, which were 
rotated clockwise in each successive animal. Cells were administered via incorporation 
within fibrin glue and sprayed onto the surface o f the unthreaded, HA-coated segment o f the 
implant at 1.0 atm o f pressure.
1. No treatment 4. 1 x 10 autologous oBMSCs/mL in fibrin
2. Fibrin only 5. 1 x 10 autologous oBMSCs/mL in fibrin
3. 1 x 105 autologous oBMSCs/mL in fibrin 6. 1 x 106 allogeneic oBMSCs/mL in fibrin
Table 6.1 Groups used in experiment, in the order they were placed in the first sheep.
6.2.4 Preparation of BMSCs in Fibrin Glue
Tisseel® fibrin glue (Baxter Health Care Ltd., Newbury, Berkshire, UK) was reconstituted at 
37°C as described in Chapter 4. Pre-operatively, for cell-loaded implants, 5.0 x 104, 5.0 x 105, 
or 5.0 x 106 oBMSCs were counted and put into a universal container and spun in a 
centrifuge at 2000 rpm for 5 minutes. The supernatant was discarded and the pellet at the 
bottom o f the universal resuspended into 0.25 mL o f reconstituted thrombin. This was mixed 
with 0.25 o f the Tisseel® fibrinogen component preoperatively when the fibrin-cell mixture 
was sprayed onto the implants. The fibrin control group consisted o f fibrin glue only, without 
cells.
6.2.5 Surgical Procedure
A ll animals were handled and cared for as described in Chapter 2 (Materials and Methods), 
and the site o f surgery prepared as previously described. Six skeletally mature mule ewes 
were used in this experiment. A ll methods were completed under sterile conditions.
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Approximately six weeks prior to surgery, bone marrow aspirates were taken from sheep in 
the BMSC group and oBMSCs isolated as outlined in Chapter 2 o f this thesis. The animal 
was draped to expose the medial anterior aspect o f the right tibia. This area was rinsed with a 
chlorhexidine solution and a small (10.0 mm) incision was made 30.0 mm distal to the tibial 
tuberosity. The tibia was exposed by blunt dissection. A  small section o f the periosteum was 
scraped at the approximate vertical centre o f the bone. A 6.0 mm hole was then drilled into 
the near cortex. A drill guide was inserted to centralise drilling. A  4.0 mm hole was drilled 
through the far cortex and tapped with an M5 tap and corresponding tap guide. The site was 
then washed with saline. A t this point, implants in the treated groups were sprayed with fibrin 
with or without oBMSCs, according to the experimental group, onto the HA coated section o f 
the implant with 1.0 atm o f pressurised air. The implant was then inserted into the tibia, and 
the threaded section screwed into the far cortex. As the implant was only 3.0 mm in diameter 
at the near cortex, there was a 1.5 mm gap between the implant and bone, which was bridged 
by fibrin in groups 2-6. The top o f the implant at the near cortex was then sealed with a 
square piece o f e-polytetrafluoroethylene membrane (e-PTFE, Gore-Tex®, Gore, Flagstaff, 
Arizona, USA) measuring approximately 5.0 mm x 5.0 mm, and glued onto the bone using 
butyl-cyanoacrylate glue (Figure 6.2a, Vetbond™, National Veterinary Supplies, Talke Pits, 
Stoke-on-Trent, UK), after which, the fascia, muscle, and skin were sutured. Two more 
implants were similarly inserted in each tibia, with each implant 30 mm apart (see Figure 
6.2b).
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Figure 6.2 a) Diagram illustra ting  insertion o f transcortical screw in bone, b) Distance 
of holes from tib ia l tuberosity (see top o f diagram).
A spray bandage (OpSite, Smith &  Nephew, Gallows H ill, Warwick, UK) was applied,
after which they were sacrificed, by intravenous injection o f 0.7 mg/kg pentabarbitone (20%, 
J.M. Loveridge Ltd., Southampton, UK). Both tibiae were harevested immediately and fixed 
in 10% neutral buffered formalin (NBF) and processed for histology.
6.2.6 R adiography and R ad iograph ic  A na lys is
Medio-lateral (M L) radiographs o f each tibia were taken using an MX4 X-ray machine (PLH 
Medical Ltd., Watford, UK) at 66 kV  and 50 mA, for 0.6 seconds, at 0.8 m from the 
specimen. Images o f the radiographs were captured using a JVC KY F55B Colour Video 
Camera, and the density within the defects were analysed using Zeiss KS300 software 
(Imaging Associates, Thame, UK). Results were normalised for each sheep according to the 
mean bone density o f surrounding cortical bone.
before the animal was brought out o f anaesthesia. Animals were kept for a period o f 6 weeks,
2 0 1
6.2.7 Undecalcified Hard Resin Histology and Analysis
Tibiae were prepared for histology as described in Chapter 4. A  band saw was used to cut out
approximately 20 mm sections o f bone around each screw site from the tibiae, to facilitate 
processing and sectioning. Thin sections were prepared as previously described and bone area 
within the defect and bone-implant contact quantified using image analysis techniques.
6.2.8 Statistics
The sample size was calculated to a power o f 80% with a p-value o f 0.05 using data from 
Chapter 4. This resulted in a sample size o f 6.
To test the normality o f the distribution o f the data, the Kolmogorov-Smirnov test was used, 
using SPSS 11.0 for Mac OSX. Non-parametric data was analysed using an analysis o f 
variance (Friedman’s test) for non-parametric related samples. Data from the different groups 
were compared in pairs using the Mann Whitney U test. Results were considered significant 
when p < 0.05.
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6.3 Results
Sheep fu lly recovered within a few days post-operatively, and were weight-bearing on all 
four limbs.
6.3.1 Radiographic Analysis
Mean density values were calculated for bone within cortical defects (Table 6.2, Figure 6.3). 
The highest mean density was found in the group with the highest concentration o f BMSCs in 
fibrin (1 x 107 BMSCs/mL, 136.2 ± 3.31) and the lowest mean density in the group with the 
lowest concentration o f BMSCs (1.0 x 105 BMSCs/mL, 132.96 ± 5.51). Using Friedman’s 
paired non-parametric test for multiple groups, there was no statistical difference in the mean 
bone density between groups, (p = 0.86). When all groups were compared to one another 
using the Wilcoxon test to compare two paired groups, there was no significant difference 
between groups (p > 0.05 for all pairings, see Table 6.3).
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Number G roup Mean Density
1 Control (No Treatment) 132.96 ±5.51
2 F ib rin  Glue Control 133.9 ± 4.51
3 1.0x10s auto BMSCs/mL 134.19 ± 4.88
4 l.OxlO6 auto BMSCs/mL 133.02 ±3.99
5 l.OxlO7 auto BMSCs/mL 136.2 ±3.31
6 l.OxlO6 alio BMSCs/mL 135.73 ±4.75
Table 6.2 Mean density in cortical defect, as observed radiographically. Percentage 
density indicates the mean density o f defect divided by the mean cortical density o f the 
surrounding bone.
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Figure 6.3 Graph showing normalised bone density in the gaps between the top ha lf o f 
the screws and the surrounding bone. The density was normalised based on the means 
of the surrounding cortical bone.
N=6 (all groups)
Screw Only Fibrin Glue Only Ix l0e5 oBMSCs Ix l0e6 oBMSCs Ix l0e7 oBMSCs Ix l0e6 Allogeneic
oBMSCs
Group
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Paired G roup P-valuc
Screw Only -  Fibrin Glue Only 0.88
Screw Only -  lx lO 5 auto oBMSCs 0.70
Screw Only -  lx lO 6 auto oBMSCs 0.94
Screw Only -  lx lO 7 auto oBMSCs 0.88
Screw Only -  lx lO 6 alio oBMSCs 0.88
Fibrin Glue Only -  lx lO 5 auto oBMSCs 0.81
i
Fibrin Glue Only -  lx lO 6 auto oBMSCs 0.75
Fibrin Glue Only -  lx lO 7 auto oBMSCs 0.43
Fibrin Glue Only -  lx lO 6 alio oBMSCs 0.64
1x10s auto oBMSCs -  lx lO 6 auto oBMSCs 0.94
lx lO 5 auto oBMSCs -  lx lO 7 auto oBMSCs 0.70
lx lO 5 auto oBMSCs -  lx lO 6 alio oBMSCs 0.35
lx lO 6 auto oBMSCs -  lx lO 7 auto oBMSCs 0.18
1 x 106 auto oBMSCs -  1 x 106 alio oBMSCs 0.48
1 x 107 auto oBMSCs -  1 x 106 alio oBMSCs 0.81
Table 6.3 p-values from the Wilcoxon non-parametric paired statistical test. 
Auto=autologous; allo=al(ogeneic.
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6 . 3 . 2  H i s t o l o g y
6.3.2.1 New Bone Form ation
New bone in the defects was continuous with the surrounding cortical bone when observed, 
in all groups, and was often separated from the implant and PTFE membrane by a fibrous 
tissue layer (Figure 6.4). The threaded portion o f the implants was in contact with the 
surrounding cortical bone (Figure 6.5). The highest average new bone formation was found in 
the untreated control group (67.33 ±6.83 mm') and the least in the BMSC group with the 
lowest concentration o f cells (1.0 x 10  ^ BMSCs/mL, 39.24 ± 1.28 m rrf, mean new bone 
formation).
Figure 6.4 Photographs showing typ ica l histological sections through the centre o f the 
partly -th readed  screws, taken  at 4x m agnification , a) shows a sample fro m  an im p lan t- 
only group specimen; b) shows a specimen from  the fib rin -o n ly  group; c) shows some 
new bone fo rm ation  around an im p la n t treated  w ith  1.0 x 106 cells/m L in f ib r in  glue; 
and d) shows a sample fro m  the 10 x 107 cells/m L in fib rin  glue. O ld  bone (present p re - 
operatively) is m arked  w ith  an ‘ O ’ , new bone w ith  an ‘N ’ , fibrous tissue w ith  an 4F% 
and H A  w ith  ‘H A . ’
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a)
b)
Figure 6.5 Images o f histological sections around the implants, a), c), d) and e) show 
new bone formation (N) which is continuous w ith the older cortical bone (O), but 
separated from  the im plant (I) by fibrous tissue layer (F). The threaded portion o f the 
implant seen in b) shows contact w ith the surrounding older cortical bone.
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When all fibrin and BMSC-treated groups were compared (see Table 6.4 and Figure 6.6), no 
significant differences were demonstrated (p=0.25). However, a significant difference was 
found between the autologous and allogeneic BMSC-fibrin-treated groups and the untreated 
control group (p = 0.03).
Control 67.33 ±6.83
Fibrin Only 40.53 ± 1.28
1.0 x 10'^  autologous BMSCs/mL 39.2419.95
1.0 x 106 autolgous BMSCs/mL 48.03 ± 10.90
1.0 x 107 autolgous BMSCs/mL 43.69 ± 10.70
1.0 x 106 allogeneic BMSCs/mL 43.93 19.98
Table 6.4 Results of new bone formation, measured using histology and image analysis, 
in all six groups.
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Figure 6.6 G rap h  outlin ing  the result new bone fo rm atio n  m easurem ent in all six 
groups. The e rro r bars represent standard e rro r.
6.3.2.2 Bone-lm plant Contact
Woven bone was found along both the endosteal and periosteal surfaces o f the tibial defects, 
in contact with the surrounding cortical bone. However, in all samples bone-implant contact 
was observed on only two occasions in the untreated control group. In these two specimens, 
the percentage bone-implant contact was 37.85% and 20.50% each. In all other cases, there 
was fibrous tissue filling  the space and in contact with the implant.
N=6 (all groups)
Control Fibrin Only 1 x 10e5 1 x 10e6 1 x 10e7 1 x 10e6
autologous autolgous autolgous allogeneic
BMSCs/mL BMSCs/mL BMSCs/mL BMSCs/mL
Group Num ber
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6.4 Discussion
In this experiment, HA-coated, partially threaded trans-cortical screws were treated with 
fibrin or with a combination o f autologous or allogeneic BMSCs in fibrin glue and implanted 
into 1.5 mm tibial defects. In contrast to Chapter 4, when autologous BMSCs suspended in 
fibrin and sprayed onto HA-coated implant collars enhanced new bone formation in an in 
vivo model, this same system for applying BMSCs to implants did not result in an increase in 
new bone formation, or in bone-implant contact. Interestingly, in this model, those samples 
with no treatment demonstrated significantly more bone area within defects than with either 
fibrin or BMSCs. It is thought that BMSCs have the ability to augment new bone formation 
when implanted into a model o f bone repair either a) by differentiating into bone-forming 
osteoblasts or b) via the recruitment o f cells favourable to bone repair and ossification, either 
by direct cell-cell interactions or by the secretion o f growth factors and/or cytokines, either 
locally or systemically (See 5.4). As the cells in this model were not marked, it is impossible 
to make any conclusions as to whether or not the cells had a direct effect on new bone 
formation in the defects created in the model used in this chapter. It is possible that the use o f 
a semi-occlusive e-PTFE membrane, with possible side effects o f using fibrin glue within a 
sealed bone cavity, may have had a deleterious effect on new bone formation.
It is possible that mechanical factors played a role in the lack o f new bone formation in this 
model. Studies such as those by Nagatomi et al. (2003), Hamilton, Maul and Vorp (2004) and 
Ignatius et al. (2005) have shown the sensitivity o f BMSCs to mechanical forces and that 
while an application o f compressive forces can cause osteoblastic differentiation o f BMSCs, 
shear forces can cause cells to differentiate into mature vascular endothelial cells. Whereas 
low stress and strain are conducive to intramembranous bone formation, compressive stresses 
have been shown to induce a chondrogenic response in BMSCs. Ignatius et al. (2005)
211
demonstrated increasing expression o f the master osteoblastic gene CBFA-1 after mechanical 
stretching o f a human osteoblast precursor cell line (hFOB 1.19). It has been proposed that 
this mechanical effect is regulated by the MAP kinase (MAPK) signalling pathway, using 
extracellular signal-regulated kinase 1/2 (ERK 1/2) (Simmons et al. 2003). What was 
interesting about the BMSC group in Chapter 4 was that even with the addition o f BMSCs, 
patterns o f bone growth medio-laterally and anterior-posteriorly around mid-shaft tibial 
replacements were similar to that observed clinically, which has been shown to correlate with 
patterns o f stress and strain (Blunn and Wait 1991; Taylor et al. 1997). It may be the case that 
in this particular model, strain was not transmitted to the BMSCs as effectively as in the 
ovine model used in chapter 4. Thus the cells may not have differentiated into osteoblasts or 
may have differentiated into another cell type such as a fibroblast phenotype. A  notable 
difference between this study and previous studies, that may have affected the contribution o f 
cell dosage to bone growth, is that they used models where the cell construct is mechanically 
loaded. Petite et al inserted a coral implant loaded with autologous BMSCs in an ovine 
model, where the defect was stabilised with a rigid plate. Lengthening plates were also used 
by Arinzeh et al. (2003) to stabilise a canine defect into which a ceramic cylinder loaded with 
BMSCs was implanted. Perhaps without this stable fixation (Zhim et al. 2005) the implants 
underwent micromotion in relation to the near cortex, which caused the formation o f a 
fibrous tissue layer. Jasty et al. (1997) implanted porous-coated, cylindrical implants into the 
distal femoral metaphases o f dogs and exposed them to various micrometers o f oscillary 
motion for six weeks. In the groups with lower levels o f micromotion (0-40 pm), bone, 
fibrocartilage and fibrous tissue was found, whereas at the higher level o f motion (150 pm), a 
dense fibrous tissue layer was found surrounding the implants. It may be useful to measure 
the forces transmitted to the defects, possibly using telemetric analysis (Taylor et al. 1997). 
Although it may be useful investigate the effects o f more rigid fixation on the tibia, Bhumbra
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et al. (1998) showed new bone formation in a rabbit femoral model with a 500 (im defect 
around trans-cortical screws.
In other models o f bone tissue engineering, it is possible that cells may have migrated out o f 
the bony site and into the surrounding soft tissues, influencing bone formation from the 
musculature and vasculature. Marking cells, as well as retrieving bone samples togehter with 
surrounding soft tissue, would allow an analysis o f MSC migration from the site. Cell fusion 
has been observed in cases where cells have fused in kidney tissue with host cells (Terada et 
al. 2002) such as hepatocytes (Wang et al. 2003), causing transdifferentiation or stimulation 
o f new bone formation based on cell fusion and perhaps higher gene expression based on the 
aneuploidy o f the system or the development o f chimeric cells with the gene expression and 
chromosomal organisation o f both cell types (Medvinsky and Smith 2003). I f  such is the case 
with the osteogenic contribution o f BMSCs, a PTFE membrane may have interfered. It is also 
possible that e-PTFE membrane played a role in the failure o f fibrin or BMSCs and fibrin to 
induce greater amounts o f bone formation than the untreated group. It has also been shown 
that PTFE affects cell cytokine expression (Wakabayashi et al. 1997). Takata, Wang and 
Miyauchi (2001) showed that cells from an osteoblastic cell line (MC3T3-E1) did not readily 
attach and proliferate on e-PTFE. Alpar et al. (2000) found downregulated mitochondrial 
activity in those HPLF and SAOS-2 cultures grown on e-PTFE. It would also be useful to 
compare the effects o f e-PTFE to no e-PTFE with fibrin or BMSCs in a similar large animal 
model.
Haematoma formation in this model may have resulted in cytotoxic levels o f potassium ions. 
Street et al. (2005) demonstrated that haematoma supernatant prevented endothelial cell 
proliferation and microtubule formation in v itro  and that that haematomas contain high levels
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o f VEGF, which give it the potential to form new blood vessels when transplanted 
subcutaneously in mice. However this occurs only once the haematoma has been resorbed 
and its inhibitory effect diminished. I f  the large numbers o f dead cells or fibrin glue kept in 
the space by e-PTFE triggered a macrophage response, this may have resulted in cells being 
phagocytosed, as well as possibly triggering osteoclastic activity. This is in contrast to the 
normal situation in which guided bone generation using a semi-occlusive barrier is normally 
applied, as in other situations the number o f BMSCs/osteoprogenitors migrating from the 
marrow to the defect site is significantly lower. The percentage o f BMSCs in the bone 
marrow has been estimated as being approximately 0.001 %-0.0001 % o f all bone marrow 
cells (Pittenger et al. 1999).
It is also possible that fibrin itself may have impeded new bone formation in this particular 
model. This may be in part due to the e-PTFE membrane preventing degradation o f BMSCs 
by migrating cells or due to the attraction o f fibroblasts to the site by the fibrin. Fibrin has 
previously been shown to be conducive to cell proliferation and migration (Becker, 
Domschke and Pohle 2004). Tisseel® contains factor XHIa, and fibronectin, which 
encourages cell migration (Cox, Cole and Tawil 2004; Brown 1993), in addition to increasing 
levels o f the angiogenic factor VEGF in vivo (Hojo et al. 2003). Lennon et al. (2000) showed 
that in subcutaneously implanted cell-seeded ceramic cubes, BMSCs were able to produce 
bone in vivo when diluted with dermal fibroblasts, up to a ratio o f 50:50, providing evidence 
that fibroblasts have differential effects on new bone formation in vivo.
Also, as fibrin is conducive to fibroblast and vascular smooth-muscle cell migration, it is 
possible that the fibrin glue encouraged migration o f BMSCs from the defect site into the 
marrow. Although work by many authors has shown that BMSCs can proliferate and
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differentiate in fibrin glue (Boo et al. 2002; Lee et al. 2005), as well as ovine BMSCs as 
shown in Chapter 3 o f this thesis, fibrin and fibrin and BMSCs have not previously been 
tested in this kind o f model. Fibrin alone has not been shown in the literature to be 
osteoinductive unless combined with osteoprogenitor cells, such as BMSCs or an 
osteoconductive scaffold such as hydroxyapatite (Abiraman et al. 2002; Lee et al. 2005; 
Yamada et al. 2003). The fibrin glue layer was allowed to set for 3 minutes, after which fibrin 
may have set around the screw, but not necessarily directly attached to the bone surface. It is 
a possibility that shear stresses between the fibrin and bone surfaces within the gap caused 
osteocytes apoptosis via a flu id flow effect (Van der Vis et al. 1998).
One technique that could be used to improve bone is pre-operative osteogenic stimulation o f 
BMSCs. As discussed in Chapter 4, studies have shown an increased angiogenic response o f 
BMSCs after 7 days’ treatment with standard osteogenic supplements. It would be interesting 
to test whether or not osteogenic BMSCs, or fibrin with added growth factors, would show 
any difference in results.
Regarding the radiological results, the use o f radiography in an attempt to measure 
differences in bone mineral density between groups in this experiment was not a sensitive 
enough method. Also, the far cortex in most o f the radiographs obscured visualisation o f the 
defect. Genant (1998) reported, for example, that radiographs showed bone loss only when 
the bone mineral density had reduced by 30-50%. A more precise method would be to use 
dual energy X-ray absorptiometry (DEXA), which can digitally monitor and quantify bone 
density.
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In conclusion, autologous and allogeneic BMSCs were suspended in fibrin glue at different 
concentrations and sprayed onto HA-coated partially fixed trans-cortical screws within 1.5 
mm defects, and compared to fibrin only or untreated controls in an ovine model. It was 
found that there was no significant effect o f varying cell dosage on the amount o f new bone 
formation or bone-implant contact. Thus the proposed hypothesis is invalid. W ith PTFE, 
there did not seem to be any benefit in preventing fibrous tissue growth. There was 
significantly more bone formation in the group with no treatment when compared to all other 
groups. It may be possible that BMSC-based bone tissue engineering is not beneficial to 
every clinical scenario and/or in combination with guided bone regeneration.
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CHAPTER SEVEN 
GENERAL DISCUSSION
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The overall hypothesis o f my thesis was that bone marrow stromal cells (BMSCs) could be 
applied to orthopaedic implants using a fibrin glue-spray system, in order to increase 
bone growth adjacent to these implants and improve bone-implant contact.
Experimentation to examine this hypothesis has been reported in this thesis (Figure 7.1).
Firstly, in Chapter 2, bone marrow stromal cells were isolated from the iliac crest o f sheep 
and expanded in culture. These cells were characterised by differentiating them down 
different cell lineages (osteoblastic and adipogenic), using chemical cues. For example, 
oBMSCs treated with osteogenic supplements had increased ALP activity after 7 to 14 days 
and were positive for calcium phosphate deposition. Cells treated with adipogenic reagents 
showed increased lipid content. However, when other cell lines that were not derived from a 
stromal cell lineage were tested for their osteogenic potential after treatment w ith the same 
reagents, they were found to react similarly. These results indicate that these tests are not 
specific for oBMSCs. Nevertheless, isolated oBMSCs did show an ability to produce a 
mineralised matrix, indicating that they may also form mineralised tissue i f  implanted in vivo. 
The rigorous controls used in this chapter have not generally been used by other groups when 
using osteogenic differentiation to characterise BMSCs (Bruder, Jaiswal and Haynesworth 
1997; Declercq et al. 2005; Janssen et al. 2006; Gorustovich, Rosenbusch and Guglielmotti 
2002), and this brings into question these commonly - used techniques. There is also a 
possibility that these cultured cell lines are de-differentiating in culture conditions causing 
phenotypic instability (Real et al. 2006) and/or trans-differentiating when certain cues are 
present, or when in contact w ith other mature cell types. Examples o f these are the 
transdifferentiation o f mesenchymal stem cells down the hepatic
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lineage when serum-deprived and then treated with supplements, or co-cultured with liver 
cells, as well as the differentiation o f BMSCs into neurons using the signalling molecule 
Sonic hedgehog (Shh) and retinoic acid (Talens-Visconti et al. 2007; Lange et al. 2005; 
Kondo et al. 2005).
In order to fu lly characterise the oBMSCs used in this study and identify them as being the 
multipotent cells described in the literature (Haynesworth et al. 1992; Jaiswal et al. 1997), 
more in v itro  work needs to be done, looking at gene expression after stimulation with 
supplements for differentiation. Also, surface marker analysis or “ gene chip”  analysis needs 
to be done, with a panel o f antigens that are known to positively or negatively react with 
BMSCs, using a FACS or MACS system (Pittenger et al. 1999). “ Gene chips”  may also 
provide useful information (Bourne et al. 2004; Hishikawa et al. 2004). As always, a 
thorough, correct statistical analysis o f the results is required. Results from Jiang et al. 
(2002a; 2002b) have recently been challenged, due to flaws in the analysis o f surface marker 
expression o f their special multipotent adult progenitor cells, or MAPCs, as well as the 
mislabelling and use o f their results in more than one ‘original’ publication (Verfaille and 
Jiang 2006; Jiang et al. 2007).
BMSCs are thought to undergo osteogenic differentiation via a MAP kinase-mediated 
mechanism (Jaiswal et al. 2000). Pre-differentiation o f these cells into osteoblast precursor 
cells or osteoblasts may help expedite the bone healing process by skipping stages o f 
differentiation, or the requirement for certain environmental/mechanical cues in order to 
differentiate and, once integrated into the repair site, could begin bone matrix and matrix 
mineralisation without delay. Additionally, the applied cells could be genetically modified 
first to express osteogenic growth factors and cytokines .
The peripheral blood was tested as another source for stromal cells in Chapter 3. Ovine 
peripheral blood stromal-like cells (oPBSCs) were isolated, expanded and characterised. The 
aim o f pursuing an alternative to BMSCs was to obtain a similar cell population without 
painful bone marrow aspiration procedures, which usually require a general anaesthetic. In an 
attempt to increase the BMSC numbers in the blood, and thus the number o f cells isolated 
from the blood, two techniques were tested: 1) pre-induced blood loss and 2) the 
administration o f granulocyte-colony stimulating factor (G-CSF). Whereas blood loss did not 
appear to have a noticeable effect on the number o f oPBSCs isolated from sheep, G-CSF 
administration resulted in a significant increase in oPBSC number in the blood stream two 
weeks post-treatment. When expanded in culture and then characterised by differentiation 
down three cell lineages (osteogenic, chondrogenic, and adipogenic), the oPBSCs showed a 
response similar to oBMSCs, indicating cell plasticity and the ability to produce calcium 
phosphate nodules in v itro , even without stimulation using osteogenic reagents. Other groups 
have also demonstrated the in v itro  osteogenic capacity o f PBSCs isolated from circulating 
peripheral blood (Rochefort et al. 2006, Kassis et al. 2006). There may be some resulting 
concern that these cells could ossify in the body and contribute towards heterotopic 
ossification. However, nodule production only occurred after the cells had been grown in 
static culture for 28 days. It is a possibility that the cells do not have this capacity when being 
circulated in the peripheral blood. It may also be possible that these cells home to specific 
tissues and that their appearance in the bloodstream is only transitory (Devine et al. 2001). 
The mobilisation o f HSCs and BMSCs after G-CSF administration may be a result o f 
changes and/or modifications to the niche environment within the bone marrow. It is known 
that BMSCs and HSCs interact w ith each other via cell surface molecules such as VCAM-1 
(on BMSCs), VLA-4 and CXCL12 (on HSCs), as well as cytokines such as stromal-derived 
factor-1 (SDF-1), (Kronenwett, Martin and Haas 2000; Kucia et al. 2004; Levesque et al.
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2001), and that both cell types can influence each other in terms o f cell proliferation (Baksh, 
Davies and Zandstra 2005). Further work is required into the niche environment o f the bone 
marrow, including HSC-BMSC interactions, and changes that may induce BMSC 
mobilisation.
G-CSF has so far been shown to be useful in stimulating the mobilisation o f BMSCs from the 
bone marrow, in order to isolate them from the blood. Besides the potential o f these cells for 
localised application o f BMSCs, G-CSF may have other applications. Alternatively, G-CSF 
has shown some potential for amplifying natural healing responses by mobilising BMSCs for 
fracture healing (Bozlar et al. 2005), or by mobilising endothelial progenitor cells to promote 
the repair o f cardiac ischemia (Minamino et al. 2005). Also, further study into changes in the 
microenvironment and HSC-BMSC relationship after cytokine therapy and cell mobilisation 
may facilitate the application o f these techniques in the future.
After two stromal-like cell types were investigated for their potential use in augmenting bone 
growth adjacent to orthopaedic implants in an in vivo model, Chapter 4 investigated oBMSC 
viability, proliferation, and morphology in v itro  after being sprayed at 1 atm w ith fibrin glue. 
The ultimate goal o f such as system was to apply oBMSCs to the surface o f orthopaedic 
implants, in order to increase bone formation at the site o f application. The use o f such a 
system would be a much more convenient and translatable method, as the cells are cultured 
separately and then combined with fibrin per-operatively rather than pre-culture o f the cells 
onto the implant. Both methods have been shown to produce the same amount o f new bone in 
vivo when seeded onto ceramic cubes and implanted ectopically (Kruyt et al. 2004). A ll o f 
the assays showed that oBMSCs were not affected by spraying at 1 atm. Specifically, cell 
viability was preserved post-spraying, similar to unsprayed samples, and proliferation was
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maintained in v itro  as measured up to 72 hours post-spraying. This chapter provided evidence 
that oBMSCs, with osteogenic potential, could survive after spraying at 1 atm in a fibrin glue 
carrier. The next step in my thesis was to test whether oBMSCs applied using this system 
could improve bone formation and contact adjacent to orthopaedic implants, in an in vivo 
model.
Chapter 5 investigated the ability o f oBMSCs to augment new bone formation adjacent to 
massive orthopaedic implants in an ovine model. OBMSCs suspended in fibrin glue, at two 
different densities (2x l06 cells/collar and lOxlO6 cells/collar), were sprayed onto the 
hydroxyapatite-coated collars o f massive implants and implanted into the midshaft o f sheep 
tibiae, and compared to untreated implants. The area o f bone adjacent to the implants and to 
the implant collars was increased when implants were treated with low and high doses o f 
oBMSCs in fibrin glue when compared to untreated implants. When fibrin glue was applied 
to the collars alone, new bone formation was increased around collars when compared to 
untreated implants, however levels were not as high as when cells were used. It must be 
noted, however, that the fibrin-only and high-BMSC dose had a lower number o f samples 
than the other two groups. This w ill be investigated further in future work. Those implants 
treated with a higher density o f cells showed an increase in new bone formation when 
compared to those treated with the lower number o f cells, although this difference was not 
statistically significant. Bone-implant contact was also improved and although this result was 
not statistically significant, more than twice the number o f BMSC-treated collars had bone- 
implant contact when compared to untreated implants. When the presence o f radiolucent lines 
between the new pedicle o f bone and implant was evaluated radiographically, there was a 
significant decrease in the length o f these lines in both BMSC-treated groups, when 
compared to control specimens.
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The percentage o f fibrous tissue adjacent to implants was found to be significantly reduced 
when oBMSCs were applied to implant collars when compared to untreated implants (low 
dose p=0.02; high dose p=0.01), as measured using histological specimens. The higher dose 
o f oBMSCs also resulted in a significant reduction in fibrous tissue when compared to the 
lower dose group. Additionally, radiolucent lines between pedicle bone and the implants 
were reduced in BMSC-treated groups. Regarding bone porosity, bone adjacent to collars in 
the high-dose BMSC group had ha lf the porosity o f the untreated control groups samples 
(p=0.018), and the low-BMSC group about 39% less, although there was no significant 
difference (p>0.05). The reduction in porosity found in the BMSC-treated groups correlates 
with bone-implant contact and may be related to load transfer from the implant to host bone 
when BMSCs are applied. Additionally, statistically significant positive correlations were 
found between bone porosity and bone-implant contact in all groups. Increased extra-cortical 
bone formation and in-growth fixation to the implant surface w ill increase implant fixation, 
improve stress transfer across the bone-prosthesis junction and improve fixation o f the 
prosthesis, thereby improving fixation. The above results showed that BMSCs significantly 
enhance new bone formation when applied in fibrin glue onto the HA-coated collars o f 
massive implants, improving bone-implant contact.
The autologous oBMSCs isolated and expanded were shown to have beneficial results on 
new bone formation around massive implants, as shown in Chapter 5. The next steps in this 
research are: 1) an optimization o f the system, looking mainly at cell dosages, and 2) the 
application o f this method in a clinical setting. Patients undergoing bone tumour replacement 
could have their BMSCs harvested in advance, isolated, expanded, and applied to the HA-
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coated collars o f their implants, using a fibrin glue spray system. This research w ill be carried 
out w ithin the next few years.
One must consider that when using the autologous BMSCs o f a bone cancer patient, the 
theoretical risk o f undetected metastatic tumour cells being isolated from the bone marrow in 
addition to BMSCs. I f  this is the case, use o f donor-derived, allogeneic BMSCs may also be 
useful (Horwitz et al. 1999). However, one must also consider that all BMSCs, autologous or 
allogenic, are immunosuppressive and express VEGF, which is essential to tumour growth 
(Aggarwal and Pittenger 2005; Ferrara and Davis-Smyth 1997). These effects may have 
negative consequences for tumourogenesis in any patient (Djouad et al. 2003).
Future research looking into the use o f BMSCs in conjunction with massive implants could 
also investigate the use o f implant materials with a lower Young’s modulus. The use o f such 
a material, w ith a modulus closer to that o f bone, would further promote load transfer from 
the implant to the host bone. An increased compressive load promote more bone growth, as 
developed from W o lffs  law (W o lff 1892), and BMSCs may also be responsive to such 
forces (Ignatius et al. 2005), and may also further increase bone formation and bone-implant 
contact when applied to these implants. Whether a different polymer, metal, or a porous 
material was used, increased load transfer via this mechanism may be an effective solution.
In future work, cells should be tracked to try and identify their contribuation to new bone 
formation in in vivo models. This could be done by genetically modifying the cells to express 
a gene, such as lacZ, which encodes the bacterial enzyme p-galactosidase, green fluorescent 
protein (GFP) and Flue, which encodes fire fly  luciferase (Zhou et al. 2005).
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A further strategy to improve bone formation around the implants could be to incorporate 
growth factors into the fibrin-cell mixture that is sprayed onto the HA collars. Inclusion o f 
growth factors such as BMP-2 or BMP-7, well documented osteogenic factors, could further 
increase bone formation, by influencing the differentiation o f the cells. Alternatively, these 
factors could be supplied using a cell therapy approach, where genetically modified BMSCs, 
expressing BMPs or other relevant genes, could be implanted at the repair site (Tsuchida et 
al. 2002; Lieberman et al. 1999; Edwards et al. 2004; M istry and Mikos 2005). Growth 
factors targeting neo-angiogenesis and revascularisation could also play an important role, 
such as VEGF (Geiger et al. 2005; Peng et al. 2005) and SDF-1.
Following from the results o f Chapter 5, another large animal in  vivo  model was used in order 
to establish i f  cell dosage effects bone formation. The purpose o f Chapter 6 was to find the 
optimal dosage when BMSCs were implanted peri-operatively, for use in future bone tissue 
engineering models. Six groups were compared: 1) no treatment; 2) fibrin glue-only; 3) lx l  O' 
autologous oBMSCsmL; 4) lx l  06 autologous oBMSCs/mL; 5) lx lO 7 autologous 
oBMSCs/mL; and 6) lx lO 6 allogeneic oBMSCs/mL. Six HA-coated transcortical screws 
were coated with one o f the six treatments (or not coated, in the case o f the untreated 
control), and implanted into 1.5mm tibial gaps in the mid-shaft o f sheep. After a period o f six 
months, bone formation, and bone-implant contact was assessed radiographically and 
histologically. Radiographically, there was no significant difference in new bone formation 
between the six groups. When specimens from all six groups were compared histologically, 
no significant difference was found. Further investigation into altering this model and 
understanding why oBMSCs were not effective in this part o f my thesis, as opposed to the 
one described in Chapter 5, is required.
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7.1 Future Work
The BMSC-fibrin glue spray technique could also be applied to total hip arthroplasty 
(THAs). Despite the success o f cemented and uncemented THAs, they still incur a high 
revision rate when compared to knee replacements (Kurtz et al. 2005). Approximately 50,000 
THAs are performed in the UK every year ( l m illion per year worldwide; Department o f 
Health 2006). Failures are most often a result o f aseptic loosening o f the components due to 
wear debris-associated osteolysis, and revision surgery is costly.
As discussed by Bhumbra et al. (2000) and Coathup et al. (2005), it may be possible to 
prevent the loosening o f implants through this mechanism by improving the fixation between 
the bone and implant, or promoting the formation o f a biological bony seal around the 
component, in order to prevent the influx o f wear particles or pressurised jo in t fluid. Current 
in vivo work in a goat THA model w ill hopefully be able to show whether or not BMSCs do 
improve bone formation and bone-implant contact o f uncemented acetabular cups to host 
bone.
BMSCs were used in the in vivo models in this study, rather than PBSCs. BMSCs have been 
used in other models previously, but there is only one previously described study in the 
literature utilising PBSCs (Wan, He and Li 2006). Most literature on PBSCs (Rochefort et al. 
2006; Mansilla et al. 2006; Khosla and Eghbali-Fatourechi 2006; Kassis et al. 2006) have 
been published relatively recently, although they show a similar potential for use in bone 
tissue engineering applications as BMSCs (Wan, He and Li 2006). One example o f this, 
shown in Chapter 3 o f this thesis, is their ability to produce nodules o f calcium phosphate 
even without stimulation with osteogenic supplements. Further in vivo studies are required 
using PBSCs, to test their osteogenic potential in situ.
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In conclusion, the work described in this thesis has successfully proved the hypothesis, which 
was that viable BMSCs could be applied to orthopaedic implants using a fibrin glue- 
spray system, and increase bone formation adjacent to the implants and improve bone- 
implant contact. The successful application o f BMSCs in bone tissue engineering has thus 
been demonstrated. This small step towards understanding which cells facilitate the 
regeneration o f tissues, and in which situations in v ivo , w ill hopefully contribute towards 
directly improving patients’ quality o f life and reduce implant morbidity, with the clinical 
application o f a BMSC-fibrin spray system; and indirectly, by stimulating the further 
development o f new and innovative approaches to bone tissue engineering and regeneration.
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